Peptide mimics of the thrombospondin C-terminal binding domain: Analysis of their therapeutic potential to trigger immunogenic death of cancer cells targeting the TSP1-CD47 axis by Gómez Morales, Luis
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Cancer account for the death of millions of people worldwide each year. This 
heterogeneous group of diseases are a result of both cell intrinsic and immunological 
processes that allow certain aberrant cell populations to grow uncontrolledly and escape 
from antitumor immune responses, among other characteristics. The increasing 
understanding of these processes has highlighted the limitations of classical therapies 
aiming to induce regulated cell death of cancer cells, but it has also pointed out their 
previously unidentified strengths while opening new avenues for overcoming resistance 
and novel therapies with less secondary effects. 
During my thesis, I was involved in a collaborative project between Sorbonne 
University (LBM UMR 7206 – DRUG Lab/Kaybiotix) and the UANL (Laboratorio de 
Immunología y Virología–FCB) aimed to develop and evaluate the potency of peptide 
mimics of thrombospondin-1 (TSP1), a matricellular protein, high-affinity ligand of the 
cell receptor CD47. This receptor has attracted considerable interest as a therapeutic target 
in recent years, as its interaction with other of its ligands, SIRPα, represents an immune 
checkpoint susceptible of being targeted by blocking monoclonal antibodies. However, 
CD47 engagement by TSP1 controls signaling pathways relevant for therapeutic targeting, 
including the induction of regulated cell death. In this context, our group has developed 
peptide mimics of TSP1 with the implementation of a structure-activity relationship 
studies. 
If small molecules have dominated the pharmaceutical world throughout the 20th 
century, the progress made over the past two decades in the field of peptides (syntheses 
on solid support, stability improvement, structure optimization, formulation, etc.) has 
made it possible to consider them as promising therapeutic tools. Indeed, overcoming the 
intrinsic problems of peptides has brought these molecules back to the forefront of 
research and discovery, determining the new generation of therapeutic molecules. These 
advances have enabled peptides to enter the pharmaceutical industry market. 
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In the following chapters, I will briefly describe the biology of cancer and its target 
opportunities, focusing regulated cell death induction, CD47 and TSP1. I will then define 
the objectives of my thesis around the evaluation of the potency of the first peptide mimic 
of TSP1 (i.e., PKHB1) to induce regulated cell death and awake antitumor immune 
responses against T cell acute lymphoblastic leukemia and breast cancer. Finally, I will 
describe a homotrimerization strategy used in a TSP1 peptide-mimic that significantly 
improved the cell binding and cell death-inducing ability of monomeric peptides. 
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Cell death and cancer 
_____________________________________________________ 
Cancer 
Cancer is a group of diseases that account for the death of millions of people 
worldwide. It can occur in both sexes, in all ages, and despite advances achieved across 
the last years, to date, 50% of the people diagnosed with cancer die from it (Globocan, 
2020). In 2020, 19.3 million people were diagnosed with cancer, and cancer was the cause 
of death of at least 10.0 million people the same year, being breast cancer the most 
diagnosed, and lung cancer the most lethal (Figure 1) (Globocan, 2020). 
 
Figure 1. Worldwide cancer incidence and mortality in 2020. (Extracted from Globocan, 2020) 
 
Hanahan and Weinberg summarized ten hallmarks that are common between the 
different types of cancer (Figure 2) (Hanahan and Weinberg, 2000, 2011). These qualities 
largely define cell intrinsic and immune processes that permit cancer development, 
survival and spreading, and therefore, they also represent target opportunities to combat 
the disease. One of them that is centrally related to this project, is their ability to resist cell 
death induction, as cell death induction is currently the main strategy to treat cancer this 
will be discussed in depth in the chapter dedicated to cell death. 
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Figure 2. The hallmarks of cancer. (Adapted from Hanahan and Weinberg 2011) 
 
The acceleration of angiogenesis and the invasion of other tissues by metastases also 
play key roles in cancer progression. Evidently, this anarchic cell reproduction is possible 
thanks to an energy metabolism adapted to their functioning but also thanks to the 
participation of the tumor microenvironment which will communicate with the cells to 
meet their energy needs while protecting them from current therapies. Among the other 
characteristics described by Hanahan and Weinberg, the lack of efficient recognition of 
tumor cells by the immune system present in the tumor microenvironment will lead to 
genomic instability and chronic inflammation participating in the initiation and 
progression of cancer. 
Among the root causes of uncontrolled cell proliferation, mutations in tumor 
suppressor genes, also known as anti-oncogenes, prevent their function of inhibiting cell 
proliferation that negatively regulates the cell cycle or induces regulated cell death. The 
mutation or deletion of these genes leads to the loss or alteration of their function, giving 
these cells aberrant capacities that modulate their behavior. For example, the TP53 gene, 
known as “the guardian of the genome”, is mutated in many cancers, and has functions 
that affect cell itself and its microenvironment (Amelio et al., 2018). 
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The tumor microenvironment includes cellular and non-cellular components. 
Stromal cells of the microenvironment represent angiogenic vascular cells, immune cells 
and cancer associated fibroblasts (CAFs) while non-cellular components form the 
extracellular matrix (ECM). This includes the interstitial matrix and the basement 
membrane including secreted factors and matrix proteins such as collagen, proteoglycans, 
glycoproteins (Spaw, Anant and Thomas, 2017). The tumor microenvironment plays a 
key role in resistance to different therapies. Indeed, the environmental factors of the tumor 
are considered to be the main reasons for treatment failure and targeting the macrophages 
associated with cancer, CAFs or the signals they induce, may prove to be an effective 
strategy (Hirata and Sahai, 2017). 
Likewise, cells of the innate and adaptive immune system present in tumors are 
therapeutic targets of interest and have become the main protagonists of new treatments 
based on immuno-oncology. Indeed, one of the most important challenges of 
tumorigenesis is to overcome a process called immune surveillance of tumors 
(Grivennikov, Greten and Karin, 2010). This process represents the ability of the immune 
system to recognize cancer cells as abnormal and to kill them by the action of 
lymphocytes. One of the anti-tumor therapeutic strategies then consists of stimulating the 
lymphocytes by removing checkpoints, responsible for their ineffectiveness. Targeting 
these checkpoints, including the CTLA-4 protein and the PD-1 / PD-L1 axis, is proving 
to be a powerful anti-tumor strategy that won scientists James Allison and Takusu Honjo 
the Nobel Prize in medicine in 2018 (James P. Allison – Facts – 2018 - NobelPrize.org, 
no date). 
Cells of the innate immune system are the most abundant in tumors, particularly 
macrophages. They are generally associated with a high resistance to treatment and 
therefore a poor prognosis of survival, which makes them targets of choice for the 
immunotherapeutic treatment of cancer. Macrophages, have a dual role in cancer: they are 
important mediators of phagocytosis of aged, damaged and cancer cells, but they can also 
promote tumor growth and metastasis helping the tumor escape immunosurveillance 
(Jaiswal et al., 2010). The CD47 receptor is known to be one major source of tumor 
escape, by providing the anti-phagocytic “don’t eat me” signal to macrophages. Therefore, 
 7 
it represents a new checkpoint of the innate immune system and offers the way for a new 
generation of checkpoint inhibitors (Matlung et al., 2017). Nevertheless, CD47 plays 
crucial roles in the immune system as well, which widens its importance as a therapeutic 
target. This will be addressed later in the manuscript. 
The main strategy to eliminate cancer cells from the body after tumor resection 
(when possible), consists in killing cancer cells. However, the development of compounds 
capable of effectively and selectively restoring cancer cell death is a major challenge in 
anticancer therapies. This issue becomes a real challenge when the approach aims to 
identify compounds capable of activating immunogenic death, which enables the 
destruction of tumors by the immune system and promote the long-term immune memory 





Certainly, scientific definition of biological life is at least complicated, especially 
considering the evolutionary origin of life on earth from prebiotic chemistry, RNA, and 
viruses (Lazcano and Miller, 1996). Indeed, although viruses are major biological entities, 
whether a virus is or not alive is an ongoing debate that does not seem to have a measurable 
scientific answer (Koonin and Starokadomskyy, 2016). In that sense, and despite the 
apparent simpleness of the task, scientific definition of “death” and its implications is not 
less complicated, as it is inexorably connected to life and its definition. 
Keeping evident differences from viruses, it has been posited that the cell is the basic 
unit of life. Therefore, the cell membrane can constitute one of these limits. Having 
established this, it is possible to raise scientific questions around cell life and its death for 
practical means. In this way, cell death can be defined as the permanent ending of the 
cellular processes, which can be observed in cell traits and actions susceptible to being 
measured in vitro or in vivo. The Nomenclature Committee on Cell Death (NCCD) 
proposes that these attributes are met when (i) the integrity of the cell membrane has been 
lost, (ii) the cell or its nucleus have fragmented, and/or (iii) it has been phagocyted by 
adjacent cells (Kroemer et al., 2005). 
 
Types of cell death 
Cells can die by accident or in a regulated fashion (Figure 3 left). Sudden changes 
alien to the cell, which nature can be mechanical (e.g., smearing), chemical (e.g., pH), or 
physical (e.g., temperature), can directly break the cell membrane and/or nucleus, without 
the need of any further cellular component, causing an accidental cell death (ACD), where 
the cell is incapable to adapt to these stimuli, and therefore, genetic, or pharmacologic 
interventions cannot prevent it. On the other hand, cells have evolved to sense less abrupt 
environmental changes that can be detrimental for the system they conform, and trigger 
regulated cell death (RCD; Figure 3 right) using their own molecular machinery (Galluzzi 
et al., 2014). As these processes require the availability of molecular sensors, second 
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messengers, and executioners which expression is internally modulated by the cell, 
genetic interventions or pharmacologic agents can affect the lethal outcome, whether by 
interfering with the signaling of certain components of the machinery, or with the ability 
of the cell to adapt to stress. In this way, RCD is necessary for life adaptation, species 
preservation, and evolution (Ameisen, 2002), and, playing crucial roles to contain local 
perturbations, and to recycle, remodel and repair tissues, RCD is necessary to maintain 
the hallmarks of health (López-Otín and Kroemer, 2021). 
Many examples exist in which it has been demonstrated that RCD processes are 
“scheduled” since the cell’s birth. Such types of RCD processes are generally referred to 
as programmed cell death (PCD) (Galluzzi et al., 2014). PCD is crucial during 
multicellular animal development to sculpt or delete structures, and in adulthood to 
moderate cell number during maintenance of tissues (Fuchs and Steller, 2011). 
 
 
Figure 3. Types of cell death. Left. Different to accidental cell death (ACD), regulated cell death (RCD) 
uses the molecular machinery of the cell. Programmed cell death (PCD) refers to the types of RCD 
programmed since the birth of the cell to modulate the number of certain cell populations. Right. 
Generally, microenvironmental perturbations induce cell stress and promoting and inhibitory signals of 
RCD. If the cell does not achieve to adapt to stress, it can become engaged into an RCD process 
(Extracted from Galluzzi, et al. 2014). 
 
RCD mechanism 
RCD commence with inner or outer stimuli that activate an initiator mechanism. 
This in turn leads to the activation of mediator molecules and the production of modulable 
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second messengers in the cell that lead to activation of executioner mechanisms (Vanden 
Berghe et al., 2014; Galluzzi et al., 2018). All of these signaling cascades can be inhibited 
by negative regulators of RCD at different steps, until surpassing certain boundaries after 
which death is imminent. These borders separating life-to-death decisions have been 
termed “points of no return” and are illustrated by the massive enhancement of molecular 
processes like caspase activation, mitochondrial outer membrane permeabilization 
(MOMP) and loss of its transmembrane potential (∆ψm), and exposure of 
phosphatidylserine (PS) residues to the outer face of the cell membrane as “eat me” signals 
for adjacent phagocytes (Kroemer et al., 2005). Nevertheless, none of these processes 
have a unique irreversible lethal role by themselves, thus, only the observation of two or 
more of these criteria reassures that a cell is committed to die. 
Therefore, only recently it has become clear that RCD is an interconnected circuitry 
of sensors and reactors with physiological roles (many of which are not directly related to 
death) that can gradually transition trough points of no return. Thus, although several RCD 
subroutines with specific biochemical characteristics have been described, they all occur 
in precise circumstances, variables including the cell itself and the molecular machinery 
that they express, or are able to express, and the extracellular matrix and its components. 
In this way, all RCD subroutines are susceptible to the interference of other cellular 
pathways occurring concomitantly in varying circumstances (Figure 4). 
Playing RCD decisive roles in the pathophysiology of a wide variety of diseases, 
identification of their characteristic biochemical criteria in particular cases has taken 
pivotal pharmacological relevance, as the evaluation of common points of no return help 
to identify in a first step discrete initiator or executioner mechanisms responsible of their 
delivery, and in a second step, the mediators and second messengers modulating the lethal 
response, all of which can be pharmacologically or genetically targeted or evaded. Such 
biochemical standards have replaced the traditional approaches classifying cell death as 
type I, II and III to refer to apoptotic, autophagic, and necrotic-like morphologies, 
respectively (Clarke, 1990). Indeed, diverse RCD products render a gradient of 
morphologies similar to these, and morphological classification is still used (Green and 
Llambi, 2015). However, substantial, clinically relevant biochemical differences conceal 
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within similar morphological outcomes (e.g., MPT-driven necrosis versus pyroptosis), 
and equally pertinent similarities may lay between two different ones (e.g., intrinsic versus 
extrinsic apoptosis). For this reason, the morphological classification should not be taken 
as anything but complementary to a biochemical definition. 
 
 
Figure 4. Known cell death subroutines. RCD implicate the participation of biochemical 
hallmarks that define certain types of cell death subroutines (indicated in different colors) in different cell 
types. These molecular actors will shape morphological features in the dying cell that will result in a 
varying range from fully apoptotic to fully necrotic morphology. As an interconnected network, the 
molecular actors of RCD may overlap in different situations. MPT, mitochondrial permeability transition; 
ICD, immunogenic cell death; ADCD, autophagy-dependent cell death; LDCD, lysosome-dependent cell 
death; NET, neutrophil extracellular traps (Adapted from Galluzzi et al., 2018). 
 
Apoptosis is a cell death program characterized by the broad participation of a type of 
cysteine proteases called caspases, which regulate an extremely controlled set of events that 
result in characteristic morphological features. Being the participation of caspases the main 
biochemical hallmark of apoptosis, for convenience of the present thesis I will subclassify 
RCD in two: a) apoptosis, as a canonical form of caspase-dependent RCD, and b) 
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regulated necrosis, as the exemplification of the interconnection between caspase-
dependent and -independent RCD circuitry. Moreover, autophagy and immunogenicity of 
RCD will be mentioned as well, as examples (also convenient for the present thesis) of 
death-related cell adaptation to stress. 
 
Apoptosis: two canonical caspase-dependent cell death modalities 
Apoptosis can be triggered by intrinsic or extrinsic signals that lead to activation of 
different initiator mechanisms, being therefore considered two different RCD subroutines 
sharing some biochemical hallmarks and a characteristic morphology. While intrinsic 
apoptosis is triggered after inner sensing of a microenvironmental disturbance (e.g., DNA 
damage, ER stress, growth factor removal), extrinsic apoptosis is generally triggered after 
engagement of a death receptor with an agonistic ligand (e.g., a member of the TNFR 
family and a TNF). In both cases, the different triggering mechanisms will generally 
provoke the activation of initiator caspases (e.g., caspase 8 in extrinsic apoptosis) and 
other signaling cascades that normally implicate the production and recruitment of 
proapoptotic BCL-2 family members, including BAX and BAK, that will mediate pore 
formation in the mitochondrial membrane, resulting in MOMP, ∆ψm dissipation, and 
release of intra-mitochondrial proapoptotic proteins like SMAC and cytochrome C. The 
activation of executioner caspases (e.g., caspase 3 and caspase 7), which will accelerate 
cell-demolishing mechanisms that will shape higher degrees of their characteristic cell 
morphology (Figure 5) including pseudopod retraction, cell rounding, volume reduction, 
and membrane blebbing, chromatin condensation and nuclear fragmentation, irrelevant or 
null ultrastructural organelle modifications, and an intact plasma membrane until terminal 




Figure 5. Extrinsic and intrinsic apoptosis circuitry. (Extracted from Koren and Fuchs, 2021) 
 
The study of apoptosis laid bare the complexity of RCD mechanisms that can be 
triggered physiologically, in pathological processes, and the therapeutical opportunities to 
trigger or inhibit them. Indeed, although caspases characterize this type of RCD, they, can 
also trigger non-apoptotic RCD subroutines like necroptosis and pyroptosis (Vanden 
Berghe et al., 2014; Galluzzi et al., 2018), or even activities apparently unrelated to death, 
such as autophagy (Tsapras and Nezis, 2017), inflammation (Martinon and Tschopp, 
2004; Van Opdenbosch and Lamkanfi, 2019) and cell differentiation (Lamkanfi et al., 
2007; Bell and Megeney, 2017). In the same way, several forms of RCD modalities do 
not rely on caspases, but on a large variety of initiators and executioners that have been 
described only recently and are subject of intense research currently (Vanden Berghe et 






The word necrosis comes from the Greek “νεκρóς” (nekrós), which means “death”. 
The term is generally used to refer to the death of animal tissues, and in cell biology to 
allude to type of cell death morphology characterized by rapid plasma membrane 
permeabilization, granulation of the cytosol and oncosis (swelling of organelles). Such 
morphological features of cell death can be observed in many types of RCD and in ACD. 
Therefore, an adequate differentiation between ACD and regulated forms of necrosis is 
imperative to study the implications in cell physiology of cell death modalities rendering 
such morphological attributes. In this way, regulated necrosis is defined as the different 
types of cell death subroutines that, under a genetically encoded cellular machinery, lead 
to a substantial necrotic morphology (Vanden Berghe et al., 2014). 
Some types of regulated necrosis subroutines have been described in depth, many 
of these cell type-specific. Such subroutines include necroptosis, pyroptosis, pyronecrosis, 
ferroptosis, ETosis, NETosis, oxytosis, and parthanatos. Though, the list is not over, as 
more inductors and executioners that trigger RCD modalities that do not meet the 
biochemical criteria of the mentioned subroutines continue to be reported. 
Interestingly, several components of the regulated necrosis machinery overlap at 
several points among different regulated necrosis subroutines and with those of apoptosis, 
advising the interconnection between both networks, and the possibility to activate similar 
executioners. Indeed, all types of regulated necrosis described to date share the 
participation of actors of the bioenergetic and redox metabolism. These weaponry control 
MOMP, lysosomal membrane permeability, oncosis, and plasma membrane permeability, 
classic in different types of regulated necrosis (Figure 6). 
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Figure 6. An integrated view of the emerging modes of regulated necrosis. (Extracted from Vanden 
Berghe et al., 2014). 
 
Role of Ca2+ signaling in cell death: link between extracellular and intracellular Ca2+  
a) Plasma membrane 
The cell plasma membrane actively participates in RCD control. Plasma membrane 
is a semi-permeable phospholipid bilayer with embedded proteins that physically contains 
components necessary for cellular function and an adequate concentration of vital ions 
and organic molecules. This way, the permanent loss of its integrity is a sign of cell death 
(Kroemer et al., 2005). Moreover, together with its selective permeability, expression of 
ion channels differentially controls the flux and inner concentration of certain organic 
molecules, sodium, potassium, and calcium ions, which directly regulate several 
executioner mechanisms of RCD (Cooper, 2000; Vanden Berghe et al., 2014; Liu and 
Levine, 2015). As it is the contact site of the cell with its outer environment, through it 
travel biochemical signals from the outside to the inside of the cell, and vice-versa. Thus, 
in the tissue context, different components of the plasma membrane send direct signals 
that regulate phagocytic consumption, such as the expression of CD47 as “don’t eat me” 
signal (Jaiswal et al., 2009) and calreticulin and phosphatidylserine exposure as “eat me” 
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signals (Gardai et al., 2005; Kroemer et al., 2005). Plasma membrane can also initiate 
RCD by sensing signals from the outside (e.g., TNFa or TSP1) via cell receptors (e.g., 
TNFa receptor, toll-like receptors or CD47 in certain scenarios) and associated complexes 
able transduce further signals that can be lethal in the adequate context. This can be 
dynamically regulated by cellular mechanisms that permit these receptors or their 
associated molecules to expose or internalize, or to undergo significant conformational 
changes that modulate their lethal signaling. 
b) Cytosolic calcium control by the endoplasmic reticulum 
Inside the cell, other membrane-enclosed structures modulate cell death. This is the 
case of the endoplasmic reticulum (ER), which control cellular processes of survival and 
responses to stress. Lipid biosynthesis, protein folding and transportation, as well as 
mitochondrial biogenesis occur at the ER. Being the major intracellular depository of 
calcium ions (Ca2+), it also participates in important cellular activities like cell 
proliferation, differentiation, motility, and death where intracellular Ca2+ signaling is 
crucial (Brini et al., 2013; Plattner and Verkhratsky, 2016; Castillo, Chen and Jacobs, 
2021). Cytosolic Ca2+ flux is extremely regulated. At physiological concentrations, it 
fluctuates around 0.1 µM and can increase with ER Ca2+ release or via extracellular Ca2+ 
influx, where Ca2+ concentrations are higher (around 500 µM and 1200 µM respectively) 
(Berridge, Lipp and Bootman, 2000; Berridge, 2002; Plattner and Verkhratsky, 2016). 
Ca2+ is an exceptionally multifaceted ubiquitous second messenger, which roles variate 
depending on the intensity of cytosolic and intra-reticular fluctuations. As expected, 
cytosolic Ca2+ overload and intra-reticular Ca2+ exhaustion is detrimental for the cell and 
can be induced to provoke cell death, as evidenced by its participation in different RCD 
subroutines. 
Intracellular flux of Ca2+ can be regulated by extracellular or intracellular 
mechanisms (Figure 7) (Martínez-Torres, 2013). Some extracellular agonist ligands can 
activate cognate membrane receptors (e.g., G-protein-coupled receptors), which will, by 
different means, induce phospholipase C (PLC) phosphorylation and the consequent 
conversion of membrane phosphatidyl-inositol diphosphate (PIP2) to inositol triphosphate 
(IP3), a soluble second messenger that activates the IP3 receptor (IP3R) calcium channels 
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at the ER. The activation of this channel moderately augments cytosolic Ca2+ 
concentration, which in turn activates a calcium-induced calcium release (CICR) 
mechanism. CICR activates more Ca2+ channels at the ER, principally the ryanodine 
receptors (RyR), which consequently increase the cytosolic Ca2+ concentration, and, if the 
mechanism progression is not prevented, the depletion intra-reticular Ca2+ (Berridge, Lipp 
and Bootman, 2000; Berridge, 2002). 
 
Figure 7. Store-operated Ca2+ entry. (Extracted from Martínez-Torres, 2013) 
 
At this point, the intraluminal Ca2+-interacting trans-ER-membrane proteins stromal 
interaction molecule (STIM)-1 and/or STIM-2 sense Ca2+ store exhaustion at the ER 
lumen, undergoing conformational changes and associated oligomerization. This will also 
promote the oligomerized protein translocation to the contact sites of the ER with the 
plasma membrane, where the plasma membrane Ca2+ channel Orai (1, 2 and 3) proteins 
locate. Oligomerized STIMs Orai activation also activates other calcium release-activated 
calcium (CRAC) channels that mediate a massive cytosolic Ca2+ entry, and a 
physiologically relevant intracellular Ca2+ increase (Capiod, 2013; Pinto et al., 2015; Xu 
et al., 2015). 
The different mechanisms of Ca2+ influx mediate important physiological tasks and 
are functionally regulated according to the cell type and its spatiotemporal situation, and 
its deregulation has pathophysiological consequences. For example, kinases from Src and 
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Ras family, which have been historically related to cancer development, can amplify PLC 
signaling (Rusanescu et al., 1995; Bivona et al., 2003; Stith, 2015). Indeed, 
overexpression and rearrangement of Ca2+ channels, pumps, and exchangers, as well as 
intermediate molecules like PLC, have been found to lead to elevated Ca2+ levels in cancer 
cells (Monteith et al., 2007; Stewart, Yapa and Monteith, 2015), and these aberrations are 
generally associated with enhanced proliferation rates and treatment resistance (Orrenius, 
Zhivotovsky and Nicotera, 2003; Capiod et al., 2007). 
 
Caspase-independent, autophagy-dependent RCD 
Autophagy is a regulated, multi-step, machinery of cell adaptation to stress in which 
the cell degrades itself. It is usually carried out as a mechanism of self-maintenance used 
during starvation for energy saving, and for the elimination of misfolded or pathogenic 
proteins or damaged organelles. Canonically, autophagy starts with a stress stimulus, such 
as starvation or rapamycin treatment, that indirectly triggers Beclin 1 phosphorylation 
(Kang et al., 2011; Nazarko and Zhong, 2013) and the subsequent production of other 
products of the autophagy-related gene (Atg) family, which conjugate at the site of loose 
membranes to form double-membrane complexes called phagophores. This process can 
be mimicked by the cell-penetrating Beclin 1 peptide-mimic Tat-Beclin-1 (Shoji-Kawata 
et al., 2013) and the ATG3-FLIP inhibitor Tat-vFLIP α2 peptide (Lee et al., 2009), which 
also initiate phagophore formation. 
The phagophore maturates with the help of the microtubule-associated protein 
1A/1B-light chain 3 (LC3), capturing the intracellular entities while elongating until 
engulfing them in closed vesicles called autophagosomes. Normally, autophagosomes will 
fuse with cell-inner lysosomes to degrade their cargo, completing autophagy (Klionsky et 
al., 2016). However, fusion mechanisms can be prevented (e.g., by Rubicon recruitment) 
and autophagosomes be involved in functions that lead to non-canonical outcomes (e.g., 
LC3-associated phagocytosis, LAP) (Martinez et al., 2015; Wong, Sil and Martinez, 
2018). 
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Most often, autophagy is cytoprotective. However, the molecular components of 
autophagy have been convincingly linked to RCD processes (Glick, Barth and Macleod, 
2010; Nikoletopoulou et al., 2013; Galluzzi et al., 2014; Mariño et al., 2014). Autosis is 
probably currently the clearest example of a caspase-independent, autophagic machinery-
dependent RCD subroutine (Liu and Levine, 2015). Autosis can be triggered by Tat-
Beclin-1, starvation, and cerebral hypoxia-ischemia, causing cell death with characteristic 
morphological outcomes including enhanced adhesion of the cell to the substrate, focal 
ballooning of the perinuclear space, and endoplasmic reticulum dilation and fragmentation 
(Liu et al., 2013). Autosis is not prevented by common pharmacological inhibitors of 
apoptosis or necroptosis, but pharmacological inhibitors of autophagy, as well as with 
cardiac glycosides or by the genetic inactivation of the Na+/K+-ATPase inhibit cell death 
(Liu et al., 2013). Moreover, in these experiments, blockade of autophagosome/lysosome 
fusion did not prevent autosis of osteosarcoma cells, and recent studies provided genetic 
evidence in the same sense, showing that Rubicon upregulation promotes autosis during 
myocardial ischemia/reperfusion injury (Nah et al., 2020), and suggesting that autosis is 
a non-canonical autophagy-related process. 
 
Immunogenic cell death 
Among the different types of regulated cell death, immunogenic cell death (ICD) 
has the particularity of being capable to activate an adaptive immune response against 
antigens of cellular (e.g., cancer antigens) or pathogenic (e.g., viral) nature, associated 
with dying cells (Kroemer et al., 2013a; Galluzzi et al., 2016, 2018). ICD is characterized 
by the exposure or release of endogenous immunogenic biomolecules, namely the 
damage-associated molecular patterns (DAMPs), which are sequentially produced 
following a state of stress, injury, or cell death (e.g., during cancer treatment). These 
released DAMPs bind to receptors located on immune cells, especially dendritic cells. 
Among different DAMPs, calreticulin (CRT) and other endoplasmic reticulum (ER) 
proteins such as heat shock proteins 70 and 90 (HSP70 and HSP90, respectively), ATP 
secretion, and the high mobility group box of non-histone chromatin protein 1 (HMGB1) 
are widely described. Collectively, DAMPs will recruit antigen presenting cells to the site 
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of ICD induction and will stimulate uptake, processing, and cross-presentation of dead-
associated antigens, resulting in an adaptive immune response (Figure 8). 
 
Figure 8. Immunogenic cell death in cancer treatment. Adapted from Kroemer & al. 2013. 
 
With the aim of triggering immunogenic cell death, targeting the CD47-TSP-1 axis 
might represent a promising strategy. If the TSP-1-CD47 interaction has been reported to 
































The thrombospondin-1–CD47 axis 
_____________________________________________________ 
Thrombospondins 
Generalities of a matricellular protein 
The ability of a tissue to adapt to enduring environmental challenges largely depends 
on the potential of local cells to modify their surroundings accordingly. Indeed, the 
extracellular matrix is constituted by molecules that cells produce and secrete locally to 
provide the tissues they conform structural and biochemical support (Frantz, Stewart and 
Weaver, 2010). Among these molecules, an important subset of non-structural, secreted, 
multi-domain, multifunctional proteins termed “matricellular proteins” can directly 
influence cell signaling in changing circumstances (Bornstein and Sage, 2002). 
Thrombospondins (TSPs), the first matricellular proteins to be described, are calcium-
interacting matricellular glycoproteins that regulate a great variety of cellular functions 
during different stages of tissue remodeling events including development, aging and 
several pathophysiological processes (Adams and Lawler, 2011; Isenberg and Roberts, 
2020). 
Discovery of the thrombospondin protein superfamily 
TSPs were discovered in platelet alpha granules as thrombin-sensitive proteins 
necessary for platelet aggregation (Baenziger, Brodie and Majerus, 1971). This first 
isolated TSP, thrombospondin-1 (TSP1, encoded by THBS1) was described to be a 
homotrimeric, multi-modular, calcium-sensitive protein encoded by a single gene 
(Phillips, Jennings and Prasanna, 1980; Margossian, Lawler and Slayter, 1981; Jaffe et 
al., 1982). However, four more genes (THBS2-5) were later found to encode similar 
proteins in mammals (TSP2-5) (Bornstein et al., 1991; Oldberg et al., 1992; Vos et al., 
1992; Lawler et al., 1993). These proteins are generally sub-classified as class A and class 
B TSPs, according to their tendency to oligomerize as homotrimers (TSP1 and TSP2) or 
homopentamers (TSP3, TSP4 and TSP5), respectively (Figure 9). 
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Class A  Class B 





Figure 9. Classification of mammal’s thrombospondins. Class A thrombospondins refer to TSP1 and 
TSP2, which naturally assemble as homotrimers. Class B thrombospondins refer to TSP3, TSP4, and 
TSP5/COMP, which assemble as pentamers. (Rotary shadowed microscopy images were taken from 
Lawler et al., 1985, 1995 and illustrations from Carlson, Lawler and Mosher, 2008). 
TSPs have been found to be extensively conserved across evolution, having 
apparently surged early in the evolution of animal multicellularity (Bentley and Adams, 
2010; Adams and Lawler, 2011). Indeed, the emergence of a TSP superfamily at the origin 
of animal evolution has been recently proposed (Shoemark et al., 2019) (Figure 10). This 
TSP superfamily is defined by the highly conserved C-terminal domain, generally referred 
to as the “signature domain”, which is composed by a globular carboxy-terminus, Ca2+-
interacting tandem repeats, and endothelial growth factor (EGF)-like modules. In this 
sense, the molecular architectures of all TSPs and TSP superfamily members are similar 
at the signature domain, but substantially differ as they approximate the N-terminal side. 
These differences consist in diverse modules that may or not be included in different TSPs 
(Figure 10), giving them tissue specificity while keeping their ability to interact with 




Figure 10. Domain architectures of the TSP family in mammals. (Extracted from Shoemark et al., 
2019) 
 
Complexity of multi-modular interactions 
Human TSPs have been the most largely studied to date and several cellular 
receptors and extracellular matrix ligands have been identified for each of their domains, 
although not for every TSP (Figure 11). 
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Figure 11. Class A TSP modules and their cell surface receptors or extracellular ligands. Class A 
TSPs contain all modules human, yet class B TSPs do not include all of them. The N-terminal pentraxin-
like domain is not present in TSP5. The von Willerbrand factor C and the type 1 TSP repeats (TSR) are 
only present in class A TSPs. 
Together with their multi-ligand nature, their oligomerization ability supposes 
intricate interactions with cell receptor complexes in membranes of the same cell, but also 
with receptors in different cells and in different extracellular matrices. As a result of such 
complexity, there is not a unique role for a given TSP, in contrast, these vary in different 
tissues but even among cells according to their spatiotemporal circumstances, where 
different TSP receptors or ligands may or not be present (Figure 12). 
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Figure 12. Complexity of simultaneous interactions of one TSP with several cell receptors. A class A 
TSP (Carlson, Lawler and Mosher, 2008), CD36, alpha and beta integrins and CD47 were chosen for 
cartoon exemplification. 
 
TSPs and disease: the crucial role of the signature domain 
The previous suggests different mechanisms for regulating TSP expression, and that 
dysregulation of any of these could lead to disease. Indeed, the expression of the different 
human TSPs varies in a multi-level, cell-specific, tissue-specific fashion within different 
stages of development, aging and pathophysiological processes including, cancer, 
inflammation, viral infection, wound healing, arterial injury, ischemia and reperfusion, 
heart hypertrophy, pulmonary arterial hypertension, Alzheimer’s disease, diabetes and 
metabolic disorders, atherosclerosis, fibrosis, and skeletal and joints disorders (Stenina-
Adognravi, 2014). However, the understanding of the mechanisms regulating their 
expression is largely incomplete to date. 
Being TSP1 the first described TSP and playing determinant pathophysiological 
roles in the cancer microenvironment and during inflammation (Lopez-Dee, Pidcock and 
Gutierrez, 2011; Jeanne et al., 2015; Huang et al., 2017; Kaur et al., 2021), compared to 
the other TSPs, the regulation of its expression has been the most studied to date. TSP1 
expression is commonly associated to limiting cancer activities, as it is downregulated by 
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activated oncogenes and upregulated by various tumor suppressor genes (Insenberg and 
Roberts, 2020; Kaur et al., 2021). Nevertheless, increasing evidence conversely depicts 
how TSP1 overexpression in the tumor microenvironment can play pro-tumorigenic roles 
via interaction with its receptors (Jeanne et al., 2015; Huang et al., 2017). 
The opposing roles that TSP1 play in cancer illustrate the complex interplays that 
TSPs orchestrate during tissue remodeling, largely characterized by regulation of cell 
proliferation and death processes. Certainly, TSP1 deficiencies are also implicated in 
diseases associated to incorrect tissue development, remodeling, or repair, such as familial 
pulmonary artery hypertension, post-refractive surgery chronic ocular surface 
inflammation, familial premature myocardial infarction, and sickle cell disease (Insenberg 
and Roberts, 2020). Interestingly, ancient TSPs are also crucial for these processes in basal 
metazoan (e.g. TSP is crucial for hydra head regeneration) although they only share 
comparable signature domains with TSP1 (Shoemark et al., 2019; Figure 10). 
Moreover, many genetic alterations of other human TSPs that are associated to 
similar diseases occur within the signature domain (Adams & Lawler, 2008). Such is the 
case of THBS5 gene, for example, for which >100 mutations in the signature domain are 
associated with the hereditary diseases pseudo-achondroplasia and multiple epiphyseal 
dysplasia (Posey et al., 2004; Kennedy et al., 2005). Another example is the increased risk 
to suffer familial premature coronary artery disease of patients with nonsynonymous 
single-nucleotide polymorphisms in the regions of thbs1 and thbs4 genes (Topol et al., 
2001). This poses a clear interest for this protein domain and its ligands in the field of 
medicine and drug development against cancer and diseases involving inflammation-
related tissue remodeling processes. 
 
Structure of the thrombospondins’ signature domain 
The signature domain of TSPs is composed of three modules: a globular lectin-like 
sequence at its C-terminus, aspartate-rich tandem repeats prompt to interaction with Ca2+ 
and one or several EGF-like modules at the N-terminus (Figure 13A). The crystal 
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structures of soluble recombinant signature domains of TSP1, TSP2 and TSP5/COMP 
have been solved, yet not all of them included the same modules. The crystal of TSP1 
included the globular C-terminus and part of the calcium binding repeats (Kvansakul, 
Adams and Hohenester, 2004); the one of TSP2 comprised the globular C-terminus, all 
calcium binding repeats and the three EGF-like modules (Carlson et al., 2005); and that 
of TSP5/COMP consisted of the globular C-terminus, the calcium-binding repeats and the 
last EGF‐like repeats (Tan et al., 2009). As expected from their highly conserved sequence 
identity, the three of them show a similar conformation, consisting of a prototypic globe 
that is semi-wrapped by a Ca2+-binding wire and ends with an EGF-like stalk. (Figure 
13B). 


























   
      
Figure 13. The thrombospondin signature domain. Schematic representation (A) and representative 
crystal structure (B) of the thrombospondin signature domain. C-terminus in magenta; Calcium binding 
wire in blue; EGF3 in beige and EGF2 orange; calcium ions are red spheres; note that there are calcium 
ions in the bottom of the globe). (Carlson, et al. Nat Struct Mol Biol, 2005). 
 
The globular C-terminus: a ligand of CD47 
Among the TSP signature domain substructures, the C-terminal globe is the most 
highly conserved across evolution (Figure 14). The globular C-terminus of TSPs is 
composed of two beta sheets with seven beta strands each, spaced by a small alpha helix 
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and folded in a wrapped candy-like fashion (Kvansakul, Adams and Hohenester, 2004; 
Carlson et al., 2005; Tan et al., 2009). 
The transmembrane protein CD47 is the only known receptor for this domain (Gao 
et al., 1996), and two peptide sequences termed 4N1 (RFYVVMWK) and 7N3 
(FIRVVMYEGK), that constitute the last beta strands of each beta sheet, have been 
proposed to be responsible of the TSP1-CD47 interaction (Kosfeld and Frazier, 1993). 
Several lines of research have later provided immunoprecipitation and microscopical 
evidence of the TSP1–CD47 interaction (Kaur et al., 2011, 2021; Martinelli et al., 2013; 
Soto-Pantoja, Kaur and Roberts, 2015). However, long after its identification, a mystery 
prevails around its mechanics, as 4N1 and 7N3 strands are hidden within the three-
dimensional structure of the TSP globe (Kvansakul, Adams and Hohenester, 2004; 
Carlson et al., 2005; Tan et al., 2009), and no crystal structure of the interaction with 
CD47 or any other protein is available to date. TSP1 requires the extracellular domain of 
CD47 to induce cell signaling (Mateo et al., 2002), however surface plasmon resonance 
experiments using recombinant CD47 extracellular domain and TSP1 signature domain 
proteins did not reflect binding (Adams et al., 2008). However, it was later found that 
detergent-stable, high affinity binding, necessary for immunoprecipitation of CD47 with 
TSP1, only occurs in a CD47 isoform containing an o-glycosaminoglycan modification in 





Figure 14. CLUSTAL W alignment of thrombospondins C-terminus. The alignment was prepared in 
CLUSTALW, and the 50% identity consensus is shown below the aligned sequences. Black highlighting 
indicates identical residues, grey indicates conserved similar residues and white background indicates 
unrelated amino acids. Cysteines are in green, with Cys 974 of TSP-1 indicated with an asterisk. KGD 
motifs in olive, the protease-binding motifs from TSP-1 in aquamarine, the collagen-IX binding motif 
from TSP-5 in blue and the CD47-binding motifs identified from TSP-1 peptides are in mauve. 






(Continues) Figure 14. CLUSTAL W alignment of thrombospondins C-terminus. Ag, Anopheles 
gambiae; Bt, Bos taurus; Ci, Ciona intestinalis; Dm, Drosophila melanogaster; Ec, Equus callibrus; Gg, 
Gallus gallus; Hs, Homo sapiens; Mm, Mus muscularis; Pm, Penaeus monodon; Rn, Rattus norvegicus; 
Xl, Xenopus laevis. (Continued in next page). 
 
Unidentified protein folding mechanisms might explain TSP1 interaction with 
CD47. Molecular modeling studies have suggested that TSP1 globe undergoes discreet 
conformational changes when in close contact with the cell membrane, which allows 
exposure of the 4N1 peptide to the solvent (Figure 15) (Floquet et al., 2008). Moreover, 
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higher content of beta sheets and solvent-accessible surface in the globe of a putative TSP1 
signature domain in the absence of calcium were also predicted in another molecular 
modelling (Gupta et al., 2017). 
 
 
Figure 15. 4N1 cleft opening and exposure to the solvent. (Floquet et al. 2008) 
 
Although these changes have not been measured experimentally, they provide an 
overview of this interaction (Figure 16), which accounting to its molecular complexity 
has not yet been crystallized. 
 
Figure 16. Putative TSP1-CD47 interaction regions. Two different regions of CD47 (1 and 2) proposed 
to interact with the 4N1 peptide (extracted from Floquet et al., 2008). 
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Of note, although CD47 is not an evolutionarily ancient receptor of TSPs (Bentley 
and Adams, 2010), except for the arginine residue, the 4N1 sequence is extremely 
conserved across evolution (Figure 14). This is not the case of 7N3, which is only present 
in TSP1 (Figure 14). TSP1 is a better cell signal inducer than TSP2 and TSP4, yet all of 
them induce signaling (Jeff S Isenberg et al., 2009), suggesting that 7N3 is important, yet 
dispensable for TSP binding to its receptor. Using structure-activity relationship (SAR) 
studies, our team recently identified that the highly conserved amino acid sequence part 
of 4N1 is necessary for efficient membrane binding and consequent cell death activity of 
4N1-based peptide-mimics (Denèfle et al., 2016). Similar studies have not been reported 
for 7N3. Moreover, recent studies using super-resolution fluorescence microscopy have 
evidenced co-localization of a 4N1-derived peptide construct with CD47 in membrane 
clusters (Wang et al., 2020). 
A DDD motif that is also highly conserved from basal metazoans to mammals 
(Figure 14) contains the only calcium ions that bind to the globe, and it is exposed to the 
surface of the crystal structures of TSP1 (Kvansakul, Adams and Hohenester, 2004), TSP2 
(Carlson et al., 2005) and TSP5/COMP (Tan et al., 2009). Interestingly, this motif directly 





TSP1 TSP2 TSP5 
Figure 17. DDD-4N1 interaction. Crystal structures of the three TSP C-terminal domain available 
to date (TSP1, TSP2 and TSP5) show that a highly conserved DDD motif interacts with the 4N1 peptide 
within its three-dimensional structure. DDD motif and Ca2+ ions are shown in phosphorescent green; 
amino acids that conform the 4N1 beta strand are shown with white letters; the Asp residue responsible for 
the interaction is shown in pink. 
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The team of Dr. Adams, has suggested that this motif is involved in RGD-
independent and CD47-independent cell attachment (Adams et al., 2008). To assess this, 
they used a recombinant protein (termed Type35-7GCT) that incorporates the TSP1 globe 
and three last tandem repeats of the wire (thus, including both the DDD and an RGD 
motif), as well as VGD/RGD and AAA/DDD mutants of this protein with overall similar 
secondary structures to evaluate their attachment to cells coming from murine skeletal 
myoblasts (C2C12), human arterial smooth muscle, and murine dermal fibroblasts from 
wild-type and CD47 deficient (Cd47tm1Fpl) mice. Cell attachment was drastically reduced 
in all cases where the plates were coated with the VGD/RGD or the AAA/DDD mutants, 
suggesting that the DDD motif is directly implicated in cell attachment. previous 
Altogether, the previous evidence suggests the existence of a misunderstood, 
probably complex, protein folding mechanism in one or both proteins that surged during 
the evolution of vertebrates and enabled the TSP1 signature domain to interact with CD47, 
and therefore, probably with other unidentified transmembrane proteins evolutionarily 
related to this receptor, such as presenilins and immunoglobulins. However, as CD47 is 
the only known receptor and signal transducer of the TSP C-terminal domain, in the 
following pages, the known functions of CD47 will be described. Yet, similar to TSPs, 
which play diverse roles that are CD47-independent, CD47 has pharmacologically 
relevant, TSP1-independent functions that TSP1 regulate when competing for binding. 




Generalities of its interactions 
CD47 is a transmembrane glycoprotein member of the immunoglobulin superfamily 
that is expressed ubiquitously and plays several roles in the immune system of mammals. 
It is the only known cell receptor of the TSP1 C-terminal domain, and a counter-receptor 
of the signal-regulatory protein alpha (SIRPα) (Matozaki et al., 2009). CD47 controls 
signaling pathways that modulate cell responses to stress and cell differentiation, as well 
as cellular functions including cell adhesion (e.g., platelet activation) and motility (e.g., 
leukocyte migration), principally through its interaction with TSP1 (Soto-Pantoja, Kaur 
and Roberts, 2015). 
CD47 is composed of an extracellular immunoglobulin variable (IgV)-like N-
terminus, five membrane-spanning domains with important presenilin homology, and an 
intracellular C-terminus where alternative splicing occurs, leading to four isoforms 
(Roberts et al., 2012). Based its cloned sequence, it was predicted that the extracellular 
domain of CD47 contains seven N-glycosylation sites, and two functionally conserved 
disulfide bridges maintain the three-dimensional structure of the CD47 extracellular 
domain. One of these bonds locates near the N-terminus and links the extracellular domain 
with the extracellular part of the last (C-terminal) membrane-spanning domain (Figure 18 
left) (Brown and Frazier, 2001). Functional CD47–SIRPα interaction and mediated CD47 
signaling in T cells depends on this bond (Rebres et al., 2001). When the crystal structure 
of the CD47–SIRPα interaction was solved (Hatherley et al., 2008), it was shown that the 
second bridge, which links Cys23 of the second C-terminal-most beta strand with the 
Cys96 of the rest of the domain, is important for correct folding of the contact site, and 
hence necessary for interaction with SIRPα (Figure 18 right). Whether this long-distance 
disulfide bridge is necessary for TSP1 was not reported. 
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Figure 18. Ligands of CD47. Left. CD47 cartoon showing glycosylation sites (pink), disulfide bridges 
(yellow), and alternative splicing forms at the intracellular C-terminal domain. Right. In mammalian cells, 
CD47 can interact with the C-terminal domain of TSP1 (blue) and send “outside-in” signals. CD47 also 
serves as a counter-receptor for SIRPα. SIRPα is a transmembrane receptor mainly expressed in 
monocytes and macrophages, although it is also present at a lesser extent in dendritic and bone marrow 
progenitor cells, and in neurons, principally within the sites of synapsis (Barclay and Van den Berg, 2014). 
It consists of three connected extracellular domains and a unique transmembrane domain that links them 
to the intracellular domain. The extracellular domain that is most distal to the plasma membrane is of an 
IgV-type, and the remaining two that are closer to cell membrane are of an Ig constant-type. The 
intracellular domain of SIRPα contains four inhibitory motifs that are susceptible to interacting with 
phosphotyrosine phosphatases (dephosphorylation phosphoproteins) after extracellular stimulus by CD47 
or anti-SIRPα antibodies that bind to the IgV-like domain. These stimuli regulate intracellular inhibition of 
phagocytosis cascade and is known as the “don’t eat me” signal (Barclay and Van den Berg, 2014). 
 
Based on the contact sites of the CD47–SIRPα structure and the posttranslational 
modification of CD47 at Ser64, required for its immunoprecipitation TSP1 (Kaur et al., 
2011), it is predicted that the binding site of CD47 with TSP1 locates far from that of 
SIRPα. However, in Jurkat (and in CD47-defective JinB8) T cells, the whole TSP1 and 
the TSP1 signature domain, compete for binding with a recombinant SIRPα protein 
containing its three extracellular domains, and with the B6H12 anti-CD47 antibody 
(Isenberg et al., 2009). Initial studies using full length CD47 in nanodisc membrane 
platforms have recently claimed to reach a 40 nM affinity with TSP1, for which cryo-EM 
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structure analysis is being pursued, yet no evidence is currently available to the public 
(Young et al., 2020). 
Interestingly, crystallization of CD47 IgV alone rendered CD47–CD47 complexes 
stabilized by a “strand swap” between two different molecules (Hatherley et al., 2008). 
Before the interactions of this crystal was known, it had been proposed that CD47 from 
two different cells could interact homotypically (Rebres, Kajihara and Brown, 2005). 
Although CD47 IgV dimerization was considered to be artificial of the technique, a similar 
complex has been observed in crystals of CTLA-4, which is also a member of the 
immunoglobulin superfamily (Sonnen et al., 2010). Moreover, it has been suggested that 
CD47 could undergo conformational changes that leads to differential interaction and 
signaling in erythrocytes (Burger et al., 2012). An exciting speculation is that CD47 could 
undergo conformational changes when clustering, and that this could affect its interaction 
with TSP1, SIRPα, or even leading to interactions with other unknown ligands. However, 
this has not been sufficiently explored. 
 
A therapeutic target in cancer 
Role of CD47 as a “don’t eat me” signal sender 
Although CD47 regulates outside-in signaling regulating several cellular functions 
in the cell that expresses it, it is most known for its passive role as an extracellular sender 
of “don’t eat me” signals when it interacts with SIRPα in the membranes of phagocytes 
(including, but not limited to macrophages and dendritic cells). This signal withholds 
phagocytosis and is largely regulated by differences in CD47 and SIRPα expression, 
which modulate the intensity of the signal (Barclay and Van den Berg, 2014). The 
pathways that control CD47 expression, however, are not completely understood, but 
several cytokines (e.g., TNFα, IFNγ, IL-6), oncogenes (e.g., HIF-1, MYC, NFKB), micro 
RNAs (e.g., miR-708, miR-155, miR-200a), and enzymes (e.g., isoQC) can regulate CD47 
expression at different levels in cancer (Huang et al., 2020). 
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The “don’t eat me” signal is physiologically counter-regulated by the expression of 
“eat-me” signals, such as those sent by phosphatidylserine (PS) and calreticulin exposure. 
In erythrocytes, for example, high levels of CD47 are found in nascent and healthy, viable 
cells, but decreases with ageing and senescence; conversely, PS exposes with ageing, 
during infection, and in dying erythrocytes, enabling macrophages to recognize and 
eliminate them, dictating their lifespan (Arias and Arias, 2017). This also has 
pathophysiological implications in cancer. For example, circulating hematopoietic stem 
cells upregulate CD47 expression in their cell surface during their journeys through the 
bloodstream to avoid phagocytosis, and several types of leukemia do it as well, and CD47 
overexpression correlates with their progression (Jaiswal et al., 2009). Indeed, several 
types of solid and liquid cancers overexpress CD47, evading innate immune recognition, 
and clinically correlating with poor prognosis (Majeti et al., 2009; M. P. Chao et al., 2010; 
Chao, Weissman and Majeti, 2012; Willingham et al., 2012). In many of these cases, 
CD47 expression seems to be a counterbalance of calreticulin exposure (Mark P Chao et 
al., 2010). Therefore, it has been proposed that CD47 blockade with monoclonal 
antibodies can be a therapeutic strategy to disrupt this compensation and restore innate 
immune system-mediated phagocytosis of several types of cancers (Chao, Weissman and 
Majeti, 2012; Willingham et al., 2012). However, innate responses are not sufficient to 
explain the antitumor effects of these strategies, as targeting CD47 with monoclonal 
antibodies in immunocompetent mice improves the outcome compared to 
immunodeficient mice by triggering adaptive immune system-mediated tumor destruction 
(Tseng et al., 2013; Liu et al., 2015). Based on the previous, CD47 represents an immune 
checkpoint for tumor evasion (Figure 19). Currently, several phase I and phase II clinical 
trials evaluate humanized monoclonal antibodies that block the CD47–SIRPα axis to treat 
a variety of cancers (Jalil, Andrechak and Discher, 2020), and other approaches based on 
recombinant proteins, peptides (Hazama et al., 2020) and small molecules (Cabrales, 
2019; Oronsky et al., 2019, 2021; Lee et al., 2021; Yu et al., 2021) aiming to downregulate 
this interaction are also being assessed clinically and preclinically. 
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Figure 19. The CD47 immune checkpoint. CD47 blocking antibodies (1) and pro-phagocytic molecules 
such as calreticulin (2) cooperate to enhance tumor engulfment by APCs (3), enabling the processing and 
presentation of tumor antigens as peptides in the groove of MHC class I molecules (4) and the priming of 
CD8+ T cells specific for tumor antigens (5). MHC, major histocompatibility complex; TCR, T cell 
receptor. (Extracted from Vonderheide, 2015). 
 
CD47 outside-in signaling 
CD47 is more than a passive extracellular self-marker, and, although relevant in the 
cellular microenvironment, the sole differences in CD47 expression are largely 
insufficient to explain its pathophysiological roles. Indeed, CD47 controls a variety of 
intracellular signaling pathways that are activated by extracellular ligands. Some of these 
have been shown to be controlled by SIRPα, but the vast majority are largely governed by 
its interaction with TSP1 (Figure 18) and its lateral partners (Gardai et al., 2005; Sarfati 
et al., 2008; Murata et al., 2014; Soto-Pantoja, Kaur and Roberts, 2015). Interaction of 
CD47 with its lateral partners is essential for some CD47 activities or the function of its 
partner, which expands the number of CD47-dependent signaling pathways. 
Different to CD47, which is expressed ubiquitously, its lateral or intracellular 
binding partners are expressed differentially among cell types and particular 
spatiotemporal circumstances that regulate their expression and the expression of TSP1 in 
the microenvironment. This can directly regulate CD47 functions either by activating it or 
by perturbing its interactions with lateral partners and the signaling associated to them. I 
propose to call these CD47 “outside-in” signaling (as it is referred to integrin signaling 
after activation by ligands of the extracellular matrix) due to its functional similarities with 
integrin activation that regulate cell structural stability, motility, and responses to stress. 
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This has been previously proposed for G protein-coupled receptors (GPCRs) crosstalk 
with integrins (Shen, Delaney and Du, 2012), but, CD47 can regulate similar functions 
even in cells that do not express integrins, such as erythrocytes. In the following 
paragraphs a selection of signals with systemic implications will be presented. 
 
CD47 outside-in signaling in erythrocytes 
CD47 is necessary for correct erythrocyte physiology (Oldenborg, 2004, 2013; Kim 
et al., 2018), where it is part of the Rhesus (Rh) antigen complex (Lindberg et al., 1994). 
CD47 maintains erythrocyte stability within the band-3 based macrocomplex (Bruce et 
al., 2003) via the protein 4.2, which links this complex to the erythrocyte skeleton (Dahl 
et al., 2004). The stability of this complex is presumed to be regulated during 
erythropoiesis by the expression of different isoforms of the intracellular CD47 domain 
which will dictate their differentiation (Mordue et al., 2017). This suggests that CD47-
mediated intracellular signaling plays important roles in erythrocyte maturation. 
 
Figure 20. CD47 in the band 3 macrocomplex. (Adapted from Soto-Pantoja, Kaur and Roberts, 2015) 
The role of CD47 as a “don’t eat me” signal was first proposed in erythrocytes, 
where it plays crucial roles preventing SIRPα-mediated macrophage erythrophagocytosis 
(Oldenborg et al., 2000). However, it has been proposed that CD47 could undergo 
conformational changes during ageing that favor its interaction with TSP1, leading to 
converse, outside-in pro-phagocytic signals (Burger et al., 2012). Recent evidence using 
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super-resolution fluorescence microscopy indicates that CD47 cluster formation augments 
in aged erythrocytes, enabling stronger interaction with TSP1 and a TSP1 peptide-
construct based on 4N1K and provoking morphological changes in the erythrocyte (Wang 
et al., 2020). The authors suggest that these interactions may compete with SIRPα, 
impairing “don’t eat me” signals and enabling phagocytosis of aged erythrocytes. Finally, 
another recent report shows that TSP1-mediated CD47 activation in erythrocytes induces 
a Ca2+ and nitric oxide influx that leads to cell deformability (Bissinger et al., 2020). 




Figure 21. TSP1 peptide construct (4N1K-TAMARA) reveals CD47 cluster formation on aged 
erythrocytes. 
Integrin-associated CD47 outside-in signaling 
Unlike erythrocytes, which do not express integrins, CD47-mediated signaling 
pathways in different cell types are related to its lateral interaction with integrins, owing 
to this its historical recognition as an integrin-associated protein (Figure 22) (Brown and 
Frazier, 2001). Lateral associations of CD47 with integrins are necessary in various cell 
types to induce TSP1-mediated CD47 signals regulating cell-cell and cell-matrix 
interactions. Indeed, CD47 was first described after immunoprecipitated with αvβ3 
integrins, whose presence enhanced RGD-mediated neutrophil phagocytosis (Brown et 
al., 1990). Later, CD47 was found to be physically and functionally associated to other 
integrins, including αIIbβ3, which is usually in complex with FAK, Syk, and Src (Chung, 
Gao and Frazier, 1997), α2β1 (Wang and Frazier, 1998), and α4β1 (Li et al., 2002; Brittain 
et al., 2004). 
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CD47 physically associates with β3 integrins and heterotrimeric Gi proteins (Frazier 
et al., 1999) in various cell types. In lipid rafts, this association requires the 
transmembrane and the intracellular domains, which regulate cell attachment in a way 
dependent on Gi signaling; but outside rafts, only the extracellular domain associates with 
integrins, and CD47 engagement indirectly leads to integrin clustering and associated Lyn, 
Src and SHP2 activation (McDonald, Dimitry and Frazier, 2003). 
 
Figure 22. CD47: an integrin-associated protein. In many cell types, CD47 has been found to interact 
laterally with different integrins, which in turn may interact with CD36 (a complex containing the three 
receptors has not been directly reported, e.g., by immunoprecipitation, this uncertainty is denoted with a 
question mark), and intracellularly with PLIC-1/ubiquilin-1 and heterotrimeric G proteins. (Adapted from 
Soto-Pantoja, Kaur and Roberts, 2015) 
Ubiquilin-1, first described as a “protein linking IAP with the cytoskeleton” (PLIC-
1), directly interacts with the intracellular domain of CD47 in in this complex (Wu et al., 
1999). In Jurkat cells, exogenous overexpression of ubiquilin-1 inhibited CXCL12-
mediated PLC activation and CXCR4 internalization, as well as Gi coupled receptor-
mediated chemotaxis, and specific Gβγ-dependent intracellular Ca2+ influx, suggesting 
that ubiquilin-1 is a negative regulator of CD47 signaling (N’Diaye and Brown, 2003). 
Interestingly, a recent study demonstrated that CXCR4 ligation with CXCL12 controls 
CD47 turnover in mesothelioma and colon cancer (Mezzapelle et al., 2021). An 
interesting question raising from this is whether differences in ubiquilin-1 or its related 
molecular signaling could control CD47 turnover during cancer progression. 
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Cardiovascular functions of CD47 outside-in signaling 
Nitric oxide (NO) is central for correct control of vascular functions, hemostasis, 
muscle contractility regulation, tissue remodeling, and metabolism of cardiac and vascular 
tissue (Farah, Michel and Balligand, 2018). Therefore, deficiencies in NO signaling are 
associated to cardiac and vascular diseases such as coronary heart disease, coronary artery 
disease, myocardial infraction, erectile dysfunction, atherosclerosis, hypertension, 
cerebrovascular diseases and diabetic lesions (Cheng et al., 2014, 2020; Farah, Michel 
and Balligand, 2018; Kamm et al., 2019). On the contrary, a lack of regulation of NO 
signaling in vascular cells or neurons can lead to RCD by nitroxidative stress characteristic 
of Alzheimer’s disease (Malinski, 2007), or to tissue remodeling and vasorelaxation 
necessary for cancer metastasis and angiogenesis (Jeff S. Isenberg et al., 2009). 
CD47 controls cardiovascular functions via the regulation of nitric oxide (NO), 
principally by its interaction with TSP1. Initial studies identified TSP1 as a potent negative 
regulator of NO signaling in endothelial cells (Isenberg et al., 2005) and in vascular 
smooth muscle cells (Isenberg et al., 2007). As CD36 was a known receptor of TSPs  and 
a potent angiogenesis inhibitor with clear pharmaceutic interest (Silverstein et al., 1992; 
Dawson et al., 1997; Fortuna  Haviv et al., 2005) initial efforts focused in CD36 regulation 
of NO by TSP1. However, CD36 was soon found to be dispensable for TSP1-induced NO 
regulation, instead, CD47 dominant regulator of this process (Isenberg et al., 2006). 
NO is synthesized by three encoded NO synthases (NOS): inducible NOS (iNOS; 
produced during inflammatory conditions in leukocytes, endothelial cells, vascular 
smooth muscle cells, fibroblasts, nerve cells and cardiac myocytes), endothelial NOS 
(eNOS; produced by endothelial cells, cardiac myocytes, platelets, and erythrocytes) and 
neuronal NOS (nNOS; produced in autonomic cardiac neurons and ganglia, in cardiac 
myocytes and vascular smooth muscle cells) (Farah, Michel and Balligand, 2018). In 
endothelial cells, eNOS phosphorylation and activation is mediated by Akt, which activity 
is controlled by the vascular endothelial growth factor (VEGF) receptor-2 (VEGFR2). 
Canonically, the direct target of NO is soluble guanylyl cyclase (sGC), an enzyme that 
catalyzes guanosine-5’-triphosphate (GTP) conversion into cyclic guanosine 
monophosphate (cGMP), which, conjointly with hydrogen sulfide (H2S), generate 
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paracrine signals that regulate vascular tone, blood pressure, and tissue perfusion (Roberts 
et al., 2012; Farah, Michel and Balligand, 2018). CD47 redundantly inhibits this pathway 
at each step (Figure 23). 
 
Figure 23. Redundant regulation of nitric oxide signaling by the TSP1-CD47 axis. (Adapted from 
Soto-Pantoja, Kaur and Roberts, 2015) 
CD47 locates in close contact with VEGFR2 in endothelial (Kaur et al., 2010) and 
T cells (Kaur et al., 2014), and CD47 interaction with TSP1 displaces this complex and 
activates downstream VEGFR2 signaling. VEGFR2 signaling includes the activation of 
Src and Akt protein kinases (Kaur et al., 2010, 2014), which in turn regulate eNOS activity 
(Montagnani et al., 2001; Chen et al., 2012). Moreover, CD47 activation by TSP1 directly 
inhibits acetylcholine-stimulated eNOS phosphorylation and activation of PLCy and PI3K 
pathways, inducing intracellular Ca2+ increase (Bauer et al., 2010). TSP1 is a potent 
inhibitor of sGC in endothelial cells, vascular endothelial muscle cells, T cells, and 
platelets  (Isenberg et al., 2005, 2008; Isenberg, Wink and Roberts, 2006; Ramanathan et 
al., 2011). It has been suggested that TSP1-mediated CD47 signaling directly inhibits sGC 
(Miller, Isenberg and Roberts, 2010) via an increase of cytosolic Ca2+ influx that is also 
canonic of angiotensin II-mediated vasoconstriction pathway (Ramanathan et al., 2011). 
CD47 activation pathway also redounds in GTP, GTPase activation (Rebres, Kajihara and 
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Brown, 2005; Chang and Blackstone, 2007). Finally, CD47 activation by TSP1 inhibits 
hydrogen sulfide signaling in activation of T cells (Miller et al., 2013). 
 
CD47 outside-in signaling in T cells 
Together, the roles of CD47 as an extracellular sender of “don’t eat me” signals, a 
broad regulator of integrin functions, and a redundant director of vascular remodeling, 
make it a crucial participant for the correct functioning of the T cells, which implicate the 
entrance and exit of cells through the vasculature, and an adequate, safe cell motility 
throughout the long-distance travels. Indeed, CD47 is necessary for correct T cell trans-
endothelial migration and recruitment to the site of inflammation in vivo (Azcutia et al., 
2012, 2013). But besides this, CD47 also plays anti-inflammatory roles. Activation of the 
T cell receptor (TCR) increases TSP1 production and reduces CD47-regulated T-cell 
motility (Bergström et al., 2015). Conversely, TSP1 inhibits early T cell activation 
induced by ligation of the TCR with an anti-CD3 antibody in a way dependent on CD47, 
and this reduces CD47-induced pro-inflammatory interleukin (IL)-2 secretion and 
expression of the T cell activation marker CD69, while the 7N3 peptide impedes CD69 
expression (Li et al., 2001). Redundantly, SIRPα on the membrane of antigen presenting 
cells downregulate the expression of IL-12 receptor and reduces CD4+ and CD8+ cells 
responsiveness to IL-12 (Latour et al., 2001). CD47 also mediates immunosupressive 
activities via interaction with TSP1 and disruption of association with the VEGFR2 
receptor (Figure 24 left) (Kaur et al., 2014), as in endothelial cells (Figure 23). The 
inhibitory role of TSP1 in T-cells requires the presence of an isoform of CD47 with a 
heparan sulfate modification at Ser64 (Kaur et al., 2011). Finally, CD47 is also necessary 
for Fas-mediated apoptosis, where Fas ligation induces strong CD47 colocalization and 




Figure 24. Known lateral partners of CD47 different to integrins in T cells. (Adapted from Soto-
Pantoja, Kaur and Roberts, 2015) 
 
CD47 and autophagy 
CD47 has been proposed as a negative regulator of autophagy. Ionizing radiation 
was shown to induce autophagy in CD47-aberrant Jurkat (JinB8) cells but not in wild-
type Jurkat cells, as demonstrated by electron microscopy images, LC3 staining by 
fluorescent microscopy, increased protein expression of BECN1, ATG5, ATG7, reduced 
expression of SQSTM1/p62 (Soto-Pantoja et al., 2012). Consistently, genetic, or 
pharmacological blockade of CD47 in wild type Jurkat cells promotes cell survival, while 
exogenous induction of CD47 expression in JinB8 prevents autophagy. This is thought to 
be responsible of the systemic radioprotection that CD47 blockade provides to mice 
exposed to ionizing radiation (Soto-Pantoja et al., 2013). After this, other groups have 
also found that CD47 deficiency or therapeutic blockade confers protection against stress 
in the heart, kidney and during anticancer therapy, via activation of autophagy (Sharifi-
Sanjani et al., 2014; Feliz-Mosquea et al., 2018; El‐Rashid et al., 2019; Y. Li et al., 2020). 
However, the mechanisms of CD47 control of autophagy remain largely unknown. 
It has been suggested that CD47 activation by TSP1 can trigger autophagy in injured 
myocytes via a Ca2+-regulated induction of histone deacetylase-3, as the TSP1 peptide 
mimic 7N3 increased LC3, ATG5, and ATG7 protein levels, while an anti-CD47 antibody 
(miap301) decreased their expression (Sharifi-Sanjani et al., 2014). However, the 
autophagic flux was not measured. Others have drawn similar conclusions using the 4N1 
strand in a Ras-expressing but not in wild type murine cancer cell line (Kalas et al., 2013), 
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and in astrocytoma cells, but not in normal astrocytes (Sick et al., 2011), yet with similar 
methodological shortage. Thus, TSP1 activation of CD47-mediated autophagy remains 
inconclusive. 
Conversely, recent work reports that a recombinant SIRPα proteins (SIRPα-Fc, 
SIRPαD1-Fc, VEGFR1D2-SIRPαD1 bispecific fusion protein), together with 
pharmacological inhibition of autophagy potentiate the anticancer effects provided by 
CD47 blockade (Zhang et al., 2017; Zhang, Chen, et al., 2018; Zhang, Wang, et al., 2018). 
This was proved in human and murine non-small cell lung cancer and glioblastoma cell 
lines, where treatment with recombinant SIRPα proteins triggered a time-dependent 
increase of the autophagic flux and inactivation of the Akt/mTOR signaling pathway, and 
combination with chloroquine treatment enhanced tumor reduction (Zhang et al., 2017; 
Zhang, Chen, et al., 2018; Zhang, Wang, et al., 2018). 
Although the role of CD47 in autophagy prevention is widely misunderstood, the 
current knowledge suggests that CD47 activity regulates signaling pathways that inhibit 
autophagy initiation via a consistent pathway involving Akt and Ca2+ signaling, and that 
the outcome of the autophagic flux depends on the cell type (and its differentiation stage), 
the nature of the stress signal (e.g., radiation, genotoxicity, genomic instability), and the 
nature stimulus activated by the CD47 ligand (i.e., SIRPα blockade, or TSP1, or TSP 
peptide-mimics-driven activation). 
 
CD47 activation by TSP1 can trigger RCD 
CD47 signaling can induce cell death. This process has been observed in different 
cell types and is consistently related to cancer and immune cells in the resolution phases 
of inflammation. Initial experiments showed that CD47 ligation by immobilized anti-
CD47 antibodies (B6H12 and 2D3), TSP1 or TSP peptide-mimic 4N1K, induces caspase-
independent cell death of chronic lymphocytic leukemia (CLL) cells (Mateo et al., 1999). 
Later investigation confirmed these results and extended their observations to activated 
but not resting B cells, stem cells nor immature dendritic cells, and found that for cell 
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death to occur, CD47 crucially requires the correct expression of its transmembrane and 
extracellular domains (Mateo et al., 2002). 
A different group observed a similar outcome using soluble anti-CD47 antibodies 
(Ad22 and 1F7) in Jurkat cells, of T cell acute lymphoblastic leukemia (T-ALL), and in 
primary cells activated by an anti-CD3 antibody (OKT3), but not in resting T cells; while 
CD3-deficient Jurkat cells efficiently died after CD47 engagement (Pettersen et al., 1999). 
Also in activated T cells and in T-ALL, treatment with the TSP peptide-mimic 4N1K or 
with 1F7 induced a similar type of cell death, regulated by Giα proteins, which lowered 
intracellular cAMP levels, and reduced protein kinase A activity (Manna and Frazier, 
2003). Moreover, using a yeast two-hybrid system with CD47 as bait, another group 
described that the Bcl-2 homology 3 (BH3)-only protein 19 kDa interacting protein-3 
(BNIP3), a pro-apoptotic member of the Bcl-2 family, is a partner of CD47 that directly 
interacts with its intracellular domain to later induce mitochondrial damage and cell death 
of activated T cells (Lamy et al., 2003). 
In both CLL and T-ALL (and in activated T cells), it was observed that the cell death 
mechanism triggered by CD47 engagement is a caspase-independent process that induces 
a rapid phosphatidylserine exposure (2-6 h), with an almost simultaneous plasma 
membrane permeabilization. Later, consistent with the previous reports, it was 
demonstrated that CD47 engagement also induces the production of reactive oxygen 
species, and loss of ∆ψm, but without the release of proapoptotic proteins nor AIF (which 
is generally related to caspase-independent RCD processes), or the induction of chromatin 
condensation or DNA fragmentation (Roué et al., 2003). Similar traits were observed by 
different research groups in acute promyelocytic leukemia (NB4) cells after treatment 
with TSP1, the signature domain of TSP1, and 4N1K (Saumet et al., 2005), and in breast 
cancer cells, after treatment with the TSP peptide-mimic 4N1K or the soluble anti-CD47 
antibody 1F7, where, as in T-ALL, Giα proteins reduced intracellular cAMP levels, and 
protein kinase A activity (Manna and Frazier, 2004). More recently, it was further reported 
that another soluble anti-CD47 antibody (CC2C6) was also able to induce cell death in 
Jurkat cells via a CD47-dependent RCD mechanism involving the Mcl-NOXA pathway 
and calcium increase that was dispensable for cell death (Leclair et al., 2018). 
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Unfortunately, unlike for the previous reports, caspase dependence of cell death was not 
assessed, and it was only inferred from the absence of PARP-1 cleavage. 
The molecular machinery activated after CD47 engagement in these situations is 
largely consistent with the non-lethal signaling pathways induced by TSP1-mediated 
CD47 activation in different cell types. Indeed, in agreement with the regulating anti-
inflammatory effects of TSP1, mice deficient in CD47, TSP1 or TSP2 hold an inadequate 
resolution of pharmacologically induced inflammation (Lamy et al., 2007). Of note, 4N1K 
only triggers the death of activated T cells from wild-type but not from CD47-deficient 
mice (Lamy et al., 2007). Interestingly, for this type of RCD to occur, a “CD47-low” 
status (i.e., cells showing low antibody recognition by flow cytometry) on their cell 
surface is required (Van et al., 2012), suggesting that during resolution of inflammation, 
this would additionally facilitate phagocytosis of dying T cells. Taken together, this 
suggests that CD47-induced cell death could constitute an RCD mechanism in T cells 
activated during contraction phases of the immune response and in T cell acute 
lymphoblastic leukemia (T-ALL). Recent studies elegantly demonstrated that activation 
of the TCR signaling pathway induces cell death in T-ALL through a molecular 
mechanism resembling the physiological process of negative selection of T lymphocytes 
(Trinquand et al., 2016). An exciting question is whether CD47 is involved in such process 
of T cell development, and if alterations of CD47-mediated cell death pathways could 
have an impact in T-ALL development 
 
Triggering the TSP1-CD47 axis with therapeutic peptides 
Although targeting CD47 with TSP1-derived agonist peptide-mimics such as the 
4N1K showed to induce signaling with therapeutic potential many years ago (Mateo et 
al., 1999; Lamy et al., 2007), surprisingly, the potential of their applications were largely 
unexplored, probably because of the major drawbacks that used to be generally associated 
with their use as therapeutic tools, such as poor metabolic stability, poor selectivity, poor 
oral bioavailibility, immunogenicity and difficult syntheses (Danho et al., 2009). While 
peptides have long been considered only as biological tools by major pharmaceutical 
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industries, many recent solutions have been developed in academia to overcome these 
limitations (Erak et al., 2018). Indeed, as of 2017, 68 peptides had been approved in 
Europe, United States, and Japan, and 155 were under clinical investigation (Lau and 
Dunn, 2018), but by the time of writing, 75 are in the market, 160 in clinical trials. As the 
tendency keeps on raising, the therapeutic peptide market currently accounts for a well 
stablished market (Vlieghe et al., 2010; Fosgerau and Hoffmann, 2015), expected to soon 
overpass the USD 50 billion mark (Peptide Therapeutics Market To Reach USD 50.60 
Billion By, no date). 
Knowing the therapeutic potential of targeting CD47 with TSP1 peptide-mimics, 
our group revisited the chemical structure of 4N1, the beta strand of the TSP1 described 
to be essential to interact with CD47. The poor solubility of 4N1, together with its 
substandard serum stability, which is even worse in 4N1K, were rapidly identified as 
major drawbacks for their therapeutic use. Therefore, using structure-activity relationship 
studies, the behavior of this type of peptides in aqueous solutions was described, being 
able to generate soluble peptides that resisted degradation by serum proteins. Further 
analyses let our team identify its pharmacophores and generate a first product: PKHB1, 
the first peptide-mimic of the TSP C-terminal domain (Figure 25), suitable for therapeutic 
use in vivo (Denèfle et al., 2016). 
 
 
Figure 25. PKHB1 stability in serum. (Adapted from Denèfle et al. 2016) 
Using this first peptide, termed PKHB1, it was found that, similar to 4N1K, TSP1, 
and anti-CD47 antibodies, it induced RCD in CLL (Martinez-Torres et al., 2015). The cell 
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death mechanism triggered by PKHB1 in CLL also induces a rapid phosphatidylserine 
exposure and plasma membrane permeabilization independent of caspase activity, loss of 
mitochondrial membrane potential without the release of proapoptotic proteins nor AIF, 
induces the production reactive oxygen species, and does not induce chromatin 
condensation nor DNA fragmentation. Furthermore, it was found that the cell death 
mechanism induced by PKHB1 is regulated by an intracellular Ca2+ signaling controlled 
by PLCG1 activation (Figure 26), which overexpression was found to correlate with CLL 
progression, and which pharmacological or genetic inhibition in these cells prevent cell 
death (Martinez-Torres et al., 2015). 
 
Figure 26. Molecular mechanism of cell death induced by PKHB1 in CLL cells. When PKHB1 
engages to its target in CLL cell membranes, indirectly activates the overexpressed PLCG1, which cleaves 
PIP2 into IP3, a second messenger that opens calcium channels (IP3R) at the endoplasmic reticulum (ER). 
The sustained activation of PLCG1 in CLL, will lower levels of Ca2+ in the ER and result to the opening 
of further calcium channels (e.g., ryanodine receptors), which in turn will deplete Ca2+ stores from the ER 
and trigger the SOCE and CRAC mechanisms, leading to the entry of massive concentrations of Ca2+ into 
the cytosol that will activate serpases and induce mitochondrial damage (Extracted from Martinez-Torres 




















Cancer is a worldwide health problem, and many types of cancer are resistant to 
current therapies. Cancer therapy resistance and eventual relapse are in great part a result 
of cancer cell death evasion and immune escape, and therapy-induced immunogenic cell 
death is crucial for the long-lasting success of cancer therapies (Kroemer et al., 2013a). 
The TSP1-CD47 axis plays an important role in the immune system of mammals and in 
the tumor microenvironment (Soto-Pantoja, Kaur and Roberts, 2015; Kaur et al., 2021). 
The signaling activated by this axis, which in chronic lymphocytic leukemia induces cell 
death, can be reproduced by the TSP C-terminal domain peptide-mimic 4N1K (Mateo et 
al., 1999). Rational structural modifications of 4N1K gave rise to PKHB1, a serum stable 
TSP C-terminal domain peptide-mimic for which pharmacophore have been identified 
(Denèfle et al., 2016). Both PKHB1 and 4N1K trigger a particular type of caspase-
independent cell death modality in CLL that induces calreticulin exposure and is regulated 
by calcium signaling, leading to tumor growth decrease in immunodeficient mice 
(Martinez-Torres et al., 2015). Finally, first results from the laboratories hosting the 
present thesis work showed that PKHB1 kills cell lines from types of cancer besides CLL 
(Martínez-Torres, 2013; Denèfle et al., 2016; Gómez-Morales, 2017), and that it can 
induce the complete tumor regression of T-ALL tumors in immunocompetent mice 





















1. The RCD mechanism induced by PKHB1 is similar in different types of cancer 
 
2. PKHB1 can induce immunogenic cell death in liquid (T-ALL) and solid (breast) 
cancer cells 
 























The main goal of the present thesis was to evaluate the therapeutic potential of TSP 
C-terminal domain peptide-mimics that target the TSP1-CD47 axis in different types of 
cancer. 
Therefore, the specific aims of the present study were to: 
1) Study PKHB1-induced cell death mechanism in cells from different types of 
cancer 
2) Explore the implication of common actors of the anti-tumor immune 
response after PKHB1 treatment 























1. Study of the Mechanism of Immunogenic Cell Death induced 
by PKHB1 in T-cell leukemia 
The results in the present chapters gave rise to a patent: EP3650036A1, held by Sorbonne 
Université and Universidad Autónoma de Nuevo León. 
 
 
1.1. Article 1. CD47 agonist peptide PKHB1 induces immunogenic cell 
death in T-cell acute lymphoblastic leukemia cells 
 
1.2. Article 2. PKHB1 tumor cell lysate induces antitumor immune 
system stimulation and tumor regression in syngeneic mice 




Hematological malignancies, such as leukemia and lymphoma, are highly 
heterogeneous diseases that affect people of all ages and ethnicities and have long served 
as model diseases for cancer biology and treatment (Freireich, Wiernik and Steensma, 
2014). Thanks to this, a great improvement in cancer treatment has been achieved in the 
past decades. However, challenges still exist to treat, for example, T-ALL, a rare, 
aggressive, highly heterogeneous type of leukemia that under currently available therapies 
in developed countries has a 5-year survival rate of ~50% in adults and ~70% in younger 
patients, but of <10% in patients with relapse (Marks and Rowntree, 2017). This is largely 
explained by the fact that in these cases where treatment fails, effective options are limited. 
Therefore, more effective therapies are needed. 
Besides surgical resection, the main strategy to treat cancer has historically consisted 
in killing cancer cells (e.g., using radiotherapy or chemotherapies). With time, treatment 
effectiveness and specificity for these cells has improved with the understanding of cancer 
biology, which is now clear strongly depends on the development of aberrant capacities 
(e.g. neoantigens) that make some cancer cells incapable to correctly activate or execute 
cell death programs and/or to be recognized by the surveillant anti-tumor immune system, 
among other capacities (all of them famously reviewed by Hanahan and Weinberg, 2011). 
Although every cell has a plethora of genetically encoded apparatus that could lead 
aberrant cells to self-destruct (Galluzzi et al., 2018), many anticancer therapies induce 
apoptosis, a regulated cell death modality characterized by caspase dependency. However, 
activation of caspase-independent cell death mechanisms can be exploited as non-
redundant therapies for cancer treatment (Bröker, Kruyt and Giaccone, 2005). 
Based on the known implications of TSP1-CD47 axis in cell death of activated T-
cells (see introduction) and the similar traits observed for PKHB1-induced cell death in 
CLL (including fast process of almost simultaneous phosphatidylserine exposure and 
plasma membrane permeability, caspase-independence, regulation of calcium signaling, 
induces mitochondrial damage), it was hypothesized that PKHB1 could activate molecular 
pathways in T-ALL similar to those in CLL, which seem to differ to those used by other 
therapies and could be useful even in cases where conventional therapies fail. 
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Moreover, the role that the immune system plays in the context PKHB1-based 
anticancer therapy had not been assessed. In CLL, PKHB1 induced calreticulin exposure 
(Martinez-Torres et al., 2015), which leads cell death to awake immune responses (Obeid 
et al., 2007). However, in vivo experiments were performed in severely immunodeficient 
(NSG) mice; thus, although PKHB1 induced the reduction of tumor growth, this strictly 
reflected direct tumor cytotoxicity but not indirect anti-tumor immune responses 
(Martinez-Torres et al., 2015).
 68 
1.1. CD47 agonist peptide PKHB1 induces immunogenic cell death in T-
cell acute lymphoblastic leukemia cells 
 
Article published in “Cancer Science” on November 20th, 2018 (doi: 
10.1111/cas.13885). 
 
The data presented in this article were generated from a first hypothesis that PKHB1 
could trigger regulated cell death in T-ALL as it does in CLL. To assess this, PKHB1 was 
manually synthesized using solid support, purified by HPLC, and >99% pure lyophilized 
peptide fractions (confirmed by LC/MS analyses) were used to study the effects of this 
peptide in T-ALL cell lines (CEM and MOLT-4) and a murine model of tumorigenic T-
cell lymphoblasts (L5178Y-R), that was later used for experiments in vivo, using 
immunocompetent BALB/c mice. 
Cells were cultured in presence of PKHB1, and cell death was analyzed by flow 
cytometry, measuring phosphatidylserine exposure and plasma membrane permeability 
using annexin-V-APC (Ann-V-APC) and propidium iodide (PI), respectively. In all cases 
the percentage of Ann-V-APC+ and PI+ cells augmented in a dose-dependent manner. 
Pre-incubation of cells with a pan-caspase inhibitor did not prevent PKHB1-induced cell 
death in any case, but extracellular calcium chelation did in all cases. In addition, PKHB1 
induced the depolarization of the mitochondrial outer membrane, as observed by an 
increase of cells that lost staining with tetramethylrhodamine, ethyl, ester, measured by 
flow cytometry. Thus, PKHB1 triggered a caspase-independent cell death modality in T-
ALL cells which execution required calcium uptake and caused mitochondrial damage. 
In freshly isolated human and murine PBMCs, similar doses of PKHB1 did not 
change the proportion of cells stained with Ann-V-APC/PI, neither changed the proportion 
of CD4+ or CD8+ lymphocytes. PKHB1 did not reduce the viability (measured by MTT 
assays) of freshly isolated bone marrow, spleen, thymus, and lymph nodes cells neither, 
indicating a high selectivity to kill T-ALL cells but not other cells of the immune system. 
In immunocompetent mice bearing L5178Y-R tumors, PKHB1 induced tumor 
remission. Histopathological and immunohistochemical analyses of tumor samples taken 
from PKHB1-treated mice before remission revealed the presence of giant cells 
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(presumably phagocytes), CD4+ and CD8+ cells inside the tumor. Cell counts of bone 
marrow, spleen and thymus were higher and cell counts of lymph nodes were lower in 
PKHB1-treated mice compared to non-treated mice. Lymphocyte cell count was also 
higher in PKHB1-treated compared to untreated mice. Altogether, the previous suggested 
that, besides direct cytotoxicity of cancer cells, the immune system participated in the 
tumor eradication induced by PKHB1 treatment. 
We hypothesized that PKHB1-induced cell death was able to initiate immune 
responses against the tumor. As adjuvanticity is crucial for cell death immunogenicity, 
and DAMPs exposure largely provides such adjuvanticity, the ability of PKHB1 
cytotoxicity to induce DAMPs in these cells was assessed. One of these DAMPs that is 
exposed during cell death and is determinant for immunogenicity is the exposure of 
calreticulin to the cell membrane (Obeid, et al. Nat Med, 2007), and PKHB1 induced 
calreticulin exposure in CLL (Martínez-Torres, et al. Plos Med, 2015). Therefore, the 
ability of PKHB1 to induce calreticulin exposure in T-ALL was evaluated using a 
phycoerythrin-tagged anti-calreticulin antibody (CRT-PE) and an homologous antibody 
with an irrelevant target (MOPC-PE). Fluorescent signal was higher in untreated and 
PKHB1-treated CEM, MOLT-4 and L5178Y-R cells marked with CRT-PE when 
compared to MOPC-PE. However, PKHB1 treatment increased CRT-PE fluorescence 
compared to the untreated controls in the three cases; this was corroborated by fluorescent 
microscopy, suggesting that calreticulin exposed to the cell membrane after treatment with 
PKHB1. 
Besides calreticulin exposure, the release of other damage-associated molecular 
patterns (DAMPs) to the extracellular space such as ATP, HSP70, HSP90, and HMGB1 
are also determinant adjuvants of cell death immunogenicity (Galluzzi, et al. 2017). 
Therefore, whole protein expression of calreticulin, HSP70, HSP90 and HMGB1 was 
measured in cell lysates and lyophilized supernatants of CEM, MOLT-4 and L5178Y-R 
cells cultured with or without PKHB1 treatment using western blot. Different patterns 
were observed among cell lines but, compared with untreated controls, expression of  
these proteins was lower in PKHB1-treated cell lysates and higher in PKHB1-treated 
supernatants. HMGB1 release was corroborated by an enzyme-linked immunosorbent 
assay. ATP release was evaluated by measuring luciferin-oxyluciferin conversion in the 
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supernatants of both control and PKHB1-treated cells; higher luminescence in PKHB1-
treated cultures suggested ATP release. Altogether this indicates that PKHB1 treatment 
induced DAMPs exposure and release to the cell membrane and the extracellular space. 
Together, the in vivo behavior and DAMPs release suggest that PKHB1 could induce 
ICD with singular traits in T-ALL. Given the complexity of the cellular mechanisms that 
constitute anti-tumor immunity in vivo, the gold-standard to evaluate whether an 
anticancer treatment is able to induce ICD is the prophylactic vaccination of 
immunocompetent animals with cells killed by an ICD-inducer, which action would 
expose a variety of tumor antigens and generate adjuvants that initiate anti-tumor immune 
responses and generate immunological memory that is preventive of future tumor 
establishment. 
For this reason, mice were immunized with increasing number of L5178Y-R cells 
(0=naïve, 1.5, 3 or 5 x106 cells) killed by PKHB1. One week after, live L5178Y-R cells 
were inoculated in the naïve or immunized mice, and tumor growth was measured. While 
tumors grew normally in naïve animals, the number of immunized mice that did not 
develop the tumor augmented with the number of death cells that were immunized. Mice 
vaccinated with 5x106 cells did not develop the tumor. This had an impact in survival, 
which augmented in vaccinated animals. Moreover, to test whether PKHB1 treatment 
rendered long-term immunological memory, mice that had undergone complete remission 
after PKHB1 treatment or naïve mice of similar age were challenged with L5178Y-R cells. 
The tumor only established in one out of six PKHB1-treated mice, while all six naïve mice 
developed the tumor. 
Altogether, the data demonstrate that PKHB1 induces immunogenic cell death in T-
ALL and suggests that PKHB1 could be a useful therapeutic tool against T-ALL.
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Résumé de l’article 1 
 
La leucémie lymphoblastique aiguë à cellules T (T-ALL) a un mauvais pronostic 
dérivé de son hétérogénéité génétique, qui se traduit par une chimiorésistance élevée. 
Récemment, notre groupe de travail a conçu des peptides agonistes de CD47 dérivés de la 
thrombospondine-1 et a démontré leur capacité à induire la mort cellulaire dans la 
leucémie lymphoïde chronique. Encouragés par ces résultats prometteurs, nous avons 
évalué la mort cellulaire induite par PKHB1 (le premier peptide agoniste CD47 stable 
dans le sérum décrit) sur des lignées cellulaires humaines CEM et MOLT-4 (T-ALL) et 
sur une ligne cellulaire murine de lymphoblasts T tumorales (L5178Y-R), évaluant 
également la dépendance aux caspases et au calcium et le potentiel de membrane 
mitochondriale. De plus, nous avons évalué la sélectivité pour les lignées cellulaires 
cancéreuses en analysant la mort cellulaire et la viabilité des cellules non tumorales 
humaines et murines après l'activation de CD47. In vivo, nous avons déterminé que le 
traitement par PKHB1 de souris xenogreffées par la lignée tumorale L5178Y-R 
augmentait le nombre de cellules leucocytaires dans le sang périphérique et les organes 
lymphoïdes tout en recrutant des leucocytes sur le site tumoral. Pour analyser si 
l'activation de CD47 induisait la mort cellulaire immunogène (MCI), nous avons évalué 
l'exposition (calréticuline, CRT) et la libération (ATP, protéines de choc thermique 70 et 
90, boîte de groupe à haute mobilité 1, CRT) des motifs moléculaires associés aux 
dommages (DAMPs, traduit de l’anglais danger-associated molecular patterns), et nous 
avons vacciné en prophylaxie les souris xénogreffées par des lysats de cellules tumorales 
traités par le peptide PKHB1). Nous avons ensuite évalué  la mémoire immunologique. 
Nos données indiquent que PKHB1 induit une type de mort cellulaire indépendante des 
caspases et dépendante du calcium dans les cellules leucémiques, tout en épargnant les 
cellules non tumorales, murines et humaines. De plus, nos résultats montrent que PKHB1 
peut induire une MCI dans les cellules leucémiques car il induit l’exposition de la  CRT 
et la libération de DAMPs in vitro, et les vaccinations prophylactiques inhibent 
l'établissement de la tumeur in vivo. Ensemble, nos résultats améliorent la connaissance 
du potentiel des peptides agonistes de CD47 comme outils thérapeutiques pour traiter la 
leucémie lymphoblastique aiguë à cellules T.
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Resumen del artículo 1 
 
La leucemia linfoblástica aguda de células T (T-ALL) tiene un mal pronóstico 
debido a su heterogeneidad genética, lo que se traduce en una alta tase de 
quimiorresistencia. Recientemente, nuestro grupo de trabajo diseñó péptidos agonistas de 
CD47 derivados de  la trombospondina-1 y demostró su capacidad para inducir la muerte 
celular en leucemia linfocítica crónica. Alentados por estos prometedores resultados, 
evaluamos la muerte celular inducida por el PKHB1 (el primer péptido agonista de CD47 
estable en suero descrito) en líneas celulares de T-ALL humanas, CEM y MOLT-4 y en 
una línea celular de linfoblastos tumorales de células T murinos (L5178Y-R), evaluando 
la dependencia de caspasas, la dependencia de calcio y el potencial de la membrana 
mitocondrial. Además, evaluamos la selectividad para las líneas celulares cancerosas 
analizando la muerte celular y la viabilidad de las células no tumorales humanas y murinas 
después de la activación de CD47. In vivo, determinamos que el tratamiento con PKHB1 
de ratones que portaban tumores con la línea celular L5178Y-R aumentó el recuento de 
células leucocitarias en sangre periférica y órganos linfoides, al mismo tiempo que se 
reclutaban leucocitos en el sitio del tumor. Para analizar si la activación de CD47 indujo 
muerte celular inmunogénica (MCI), evaluamos la exposición (calreticulina, CRT) y 
liberación (ATP, proteínas de choque térmico 70 y 90, cuadro de grupo de alta movilidad 
1, CRT) de patrones moleculares asociados a daño (DAMPs, del inglés damage-
associated molecular patterns), y administramos una vacunación antitumoral profiláctica, 
que determina la memoria inmunológica. Nuestros datos indican que el PKHB1 induce 
muerte celular independiente de caspasas y dependiente de calcio en las células 
leucémicas y no en células humanas y murinas no tumorales. Además, nuestros resultados 
demuestran que PKHB1 puede inducir MCI en células leucémicas ya que induce la 
exposición de CRT y la liberación de DAMPs in vitro, y las vacunas profilácticas inhiben 
el establecimiento de tumores in vivo. En conjunto, nuestros resultados abonan al 
conocimiento del potencial que tienen los péptidos agonistas de CD47 como herramientas 
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T- cell acute lymphoblastic leukemia (T- ALL) has a poor prognosis derived from its 
genetic heterogeneity, which translates to a high chemoresistance. Recently, our 
workgroup designed thrombospondin- 1- derived CD47 agonist peptides and demon-
strated their ability to induce cell death in chronic lymphocytic leukemia. Encouraged 
by these promising results, we evaluated cell death induced by PKHB1 (the first- 
described serum- stable CD47- agonist peptide) on CEM and MOLT- 4 human cell lines 
(T- ALL) and on one T- murine tumor lymphoblast cell- line (L5178Y- R), also assessing 
caspase and calcium dependency and mitochondrial membrane potential. Additionally, 
we evaluated selectivity for cancer cell lines by analyzing cell death and viability of 
human and murine non- tumor cells after CD47 activation. In vivo, we determined 
that PKHB1- treatment in mice bearing the L5178Y- R cell line increased leukocyte cell 
count in peripheral blood and lymphoid organs while recruiting leukocytes to the 
tumor site. To analyze whether CD47 activation induced immunogenic cell death 
(ICD), we evaluated damage- associated molecular patterns (DAMP) exposure (calreti-
culin, CRT) and release (ATP, heat shock proteins 70 and 90, high- mobility group box 
1, CRT). Furthermore, we gave prophylactic antitumor vaccination, determining im-
munological memory. Our data indicate that PKHB1 induces caspase- independent 
and calcium- dependent cell death in leukemic cells while sparing non- tumor murine 
and human cells. Moreover, our results show that PKHB1 can induce ICD in leukemic 
cells as it induces CRT exposure and DAMP release in vitro, and prophylactic vaccina-
tions inhibit tumor establishment in vivo. Together, our results improve the knowl-
edge of CD47 agonist peptides potential as therapeutic tools to treat leukemia.
K E Y W O R D S
acute lymphoblastic leukemia, cancer vaccine, CD47, DAMP, immunogenic cell death
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1  | INTRODUC TION
Immunogenic cell death (ICD) is a type of regulated cell death that acti-
vates an adaptive immune response against dead- cell- associated anti-
gens, inducing tumor cell immunogenicity.1,2 ICD is characterized by the 
exposure or release of endogenous immunogenic biomolecules, namely 
damage- associated molecular patterns (DAMP).3 In physiological con-
ditions, DAMP are inside the cells, but when exposed or released, in 
case of stress, injury, or cell death, they bind receptors on immune 
cells.4,5 The main DAMP related to ICD exposed at the cell surface 
and/or released to the extracellular media are calreticulin (CRT)6-8 and 
other endoplasmic reticulum (ER) proteins such as heat shock proteins 
70 and 90 (HSP70 and HSP90, respectively),9,10 secretion of ATP11-
13 and the non- histone chromatin protein high- mobility group box 1 
(HMGB1).14,15 Collectively, these DAMP recruit antigen- presenting 
cells (APC) to ICD sites and stimulate the uptake, processing, and pre-
sentation of dead- cell- associated antigens, resulting in an adaptive 
immune response.1,16-18 However, DAMP release is not sufficient to 
determine whether a molecule will induce ICD; thus, in vivo vaccination 
experiments are the gold standard to identify ICD inducers.19,20
A subset of chemotherapeutic agents including doxorubicin, 
mitoxantrone, oxaliplatin, bortezomib, cyclophosphamide, and an-
thracycline have the ability to trigger ICD,18,21 hence activating an-
ticancer immune responses.1 These drugs are used to treat different 
types of cancer, including hematological malignancies such as acute 
lymphoblastic leukemia (ALL).
Acute lymphoblastic leukemia is the most common type of child-
hood cancer, accounting for 80% of cases, and is the second most 
common acute leukemia in adults.22-24 The 5- year survival rate in 
adults is about 30%- 50% compared to 90% in children.25-27 ALL can 
affect B cells (B- ALL) or T cells (T- ALL); T- ALL has a high risk of re-
lapse as a result of acquired therapy resistance.28 Chemoresistance 
is one of the most important reasons for failure in cancer treat-
ments. Some cells are selected in a micro- evolutive process of 
survival after therapy induction, leading to the eventual relapse of 
nearly one case out of five.29-31 Because treatment options are lim-
ited for these patients, their prognosis is poor. Thus, the develop-
ment of new treatments able to stimulate the immune system, such 
as ICD- inducers, is important to fight chemoresistant malignancies.
CD47 is a potential therapeutic target for refractory hematological 
malignancies, by blocking its function using monoclonal antibodies32 or 
by its activation with peptides.33,34 CD47 is a transmembrane protein 
expressed ubiquitously and reported to be overexpressed in different 
types of hematological malignancies, including ALL.35 CD47 plays many 
biological functions as a result of its interaction with at least two major 
ligands: signal- regulatory protein alpha (SIRPα) and the extracellular ma-
trix protein, thrombospondin- 1 (TSP1). SIRPα is present in APC such as 
macrophages and dendritic cells (DC), with which it controls a “don’t eat 
me” signal that regulates programmed cell removal.36 TSP1 mediates cell 
adhesion, migration, proliferation and death.37 Thus, CD47 appears as a 
promising therapeutic target addressed by many approaches: for exam-
ple, blockade of CD47- SIRPα interaction by monoclonal antibodies me-
diates innate,32 as well as adaptive, immune responses.38 Additionally, 
treatment with an anti- CD47 monoclonal antibody (CC2C6) has shown 
to induce caspase- independent cell death in T- ALL cell lines.39
More recently, CD47 activation by peptides derived from the 
C- terminal domain of TSP- 1 induces a caspase- independent and 
calcium- dependent cell death in different cancer cell lines.33,34,40,41 
Indeed, CD47 engagement to PKHB1, the first- described serum- 
stable soluble CD47- agonist peptide, induced changes in ER mor-
phology, CRT exposure, reactive oxygen species (ROS) production 
and dissipation of the mitochondrial membrane potential in cells 
from patients with CLL.33
The present work is focused on determining whether PKHB1 is 
able to induce a selective ICD in T- ALL cell lines, while conserving 
the principal characteristics of CD47- mediated cell death.
2  | MATERIAL S AND METHODS
2.1 | Blood and PBMC isolation
Peripheral blood was collected from 10 healthy volunteers after 
obtaining written informed consent. This study was approved by 
the Institutional Ethics Committee at the Universidad Autónoma 
de Nuevo León, College of Biological Sciences. The animal study 
was approved by the Animal Ethical Committee (CEIBA), Number: 
01/2015. All experiments were conducted according to Mexican 
regulation NOM- 062- ZOO- 1999.
Blood from killed mice was obtained by cardiac puncture, 
whereas human blood was collected by venipuncture. PBMC isola-
tion was carried out by density gradient centrifugation using Ficoll- 
Hypaque- 1119 (Sigma- Aldrich, St Louis, MO, USA). White blood cells 
were obtained, washed and counted. Cells (4 × 105) were seeded in 
a 96- well plate with RPMI medium. CD4+/CD8+ determination was 
done using specific primary antibodies (CD4; MT310 sc- 19641 and 
CD8; 32- M4 sc- 1177; Santa Cruz Biotechnology, Dallas, TX, USA).
2.2 | Spleen, thymus, lymph node, and bone marrow 
cell extraction
Spleen, thymus, lymph node, and bone marrow cells were obtained 
from female BALB/c mice post- death. Spleen cells were obtained 
through perfusion, thymocytes and lymphatic node cells were ob-
tained by maceration, and bone morrow cells (femur and tibia) were 
flushed with PBS. Every cell suspension was washed twice with PBS 
and counted using Trypan blue staining.
2.3 | Cell culture
CCRF- CEM ATCC CCL- 119 and MOLT- 4 ATCC CRL- 1582 (human T- acute 
lymphoblastic leukemia, T- ALL), and L5178Y- R ATCC CRL- 1722 (murine 
lymphoblastic T- cell line) were obtained from ATCC. Human and murine 
PBMC, human CD4+ and CD8+ T cells, and primary lymphoid organ’s 
cells were obtained from healthy individuals. Cells were maintained in 
RPMI- 1640 medium supplemented with 10% FBS, 2 mmol/L l- glutamine, 
100 U/mL penicillin- streptomycin (GIBCO by Life Technologies, Grand 
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Island, NY, USA), and incubated at 37°C in a controlled humidified atmos-
phere with 5% CO
2
. Cell count was carried out using Trypan blue (0.4% 
Sigma- Aldrich), a Neubauer chamber and an optic microscope (Zeiss 
Primo Star) as proposed by the ATCC’s standard protocols.
2.4 | Flow cytometry, cell death 
induction, and inhibition
Annexin- V- allophycocyanin (Ann- V- APC 0.1 μg/mL; BD Pharmingen, 
San Jose CA, USA), propidium iodide (PI, 0.5 μg/mL; Sigma- Aldrich), 
and tetramethylrhodamine ethyl ester (TMRE, 20 nmol/L; Sigma- 
Aldrich) were used for phosphatidylserine exposure, cell viability, 
and mitochondrial transmembrane potential (ΔΨm) quantification, 
respectively, in a BD Accuri C6 flow cytometer (BD Biosciences, 
Franklin Lakes, NJ, USA) (total population 10 000 cells). Data were 
analyzed using FlowJo software (LLC, Ashland, OR, USA). Then, 
1 × 106 cells/mL were treated for 2 hours with PKHB1 (as indi-
cated). For the inhibition assays, calcium chelator, BAPTA (5 mmol/L, 
CalbioChem; Merck, Billerica, MA, USA) or the pan- caspase inhibi-
tor Q- VD- OPh (QVD, 10 μmol/L; BioVision, Milpitas, CA, USA) was 
added 30 minutes before PKHB1.
2.5 | Complete blood count
Heparinized blood acquired from mice was assessed using the 
 automatic Hematology Analyzer BC 7000 (KontroLab, Rome, Italy). 
Blood smears were carried out and fixed with methanol, stained 
with Wright’s, and observed under the microscope to carry out dif-
ferential blood white cell counts.
2.6 | Calreticulin exposure
Next, 1 × 106 cells/mL were plated, treated with PKHB1, and incu-
bated for 2 hours. Cells were harvested, washed, and stained with 
Calreticulin- PhycoErythrin (FMC- 75; Enzo Life Science, Farmingdale, 
NY, USA) antibody (1:1000) in FACS buffer. After 1 hour of incuba-
tion in darkness at room temperature, cells were washed and resus-
pended in 100 μL FACS buffer to be assessed by flow cytometry. 
For confocal microscopy (Olympus X70; Olympus, Tokyo, Japan), 
poly- l- lysine was added to sterile coverslips placed inside a six- well 
plate for 24 hours, then washed with PBS and 1 × 106 cells/mL were 
seeded. PKHB1 was added and incubated for 2 hours. Then, the 
cells were stained with Calreticulin- PE antibody (1:500) and Hoechst 
33342 (Thermo Scientific Pierce, Rockford, IL, USA), incubated for 
1 hour, and assessed by confocal microscopy.
2.7 | Western blot
In a serum- free culture medium, 1 × 106 cells/mL were seeded and 




 for each cell line) or left alone 
(control) for 2 hours. Supernatants were recovered and lysed with lysis 
buffer (20 mmol/L Tris pH 6.8, 2 mmol/L EDTA, 300 mmol/L NaCl and 
SDS 2%). Protein concentration was measured using the DC Protein 
Assay kit (Bio- Rad, Hercules, CA, USA) and 50 μg protein was loaded 
into SDS- PAGE gels. After blotting, nitrocellulose filters were probed 
with primary antibodies (1:1000) against HMGB1 (HAP46.5: sc- 56698), 
HSP70 (C92F3A- 5: sc- 66048), HSP90 (F- 8: SC- 13119) and Calreticulin 
(F- 4: sc373863). Anti- mouse or anti- rabbit- HRP served as secondary 
antibodies (Santa Cruz Biotechnology). Visualization was carried out 
with ECL substrate system (Thermo Scientific, Waltham, MA, USA).
2.8 | ATP release assay





 for each cell line) for 2 hours. Supernatants were used to as-
sess extracellular ATP by a luciferase assay (ENLITEN kit, Promega, 
Madison, WI, USA) following the manufacturer’s instructions. 
Bioluminescence was assessed in a microplate reader (Synergy HT, 
Software Gen5; BioTek, Winooski, VT, USA) at 560 nm.
2.9 | High- mobility group box 1 release assay





each cell line) leukemic cells (1 × 106 cells/mL) were used to measure 
extracellular HMGB1 using the HMGB1 ELISA kit for CEM, MOLT- 4 
or L5178Y- R cells (BioAssay ELISA kit human or mouse, respectively; 
US Biological Life Science Salem, MA, USA), following the manufac-
turer’s instructions. Absorbance was assessed at 450 nm.
2.10 | In vivo model
Six- to- eight- week- old BALB/c female mice were maintained in con-
trolled environmental conditions (25°C and 12 hours light/dark 
cycle) and were supplied with rodent food LabDiet 5001 (LabDiet, 
St. Louis, MO, USA) and water ad libitum.
2.11 | Prophylactic vaccinations
L5178Y- R cells (1.5, 3, 5 × 106) were treated with 300 μmol/L 
PKHB1 (CC
100
) for 2 hours. Cell death was confirmed using Trypan 
blue staining and flow cytometry. Treatment was carried out as fol-
lows: PKHB1- treated L5178Y- R cells were inoculated s.c. in 100 μL 
PBS into the left hind leg (day - 7); 2 × 106 viable cells were inoculated 
into the right hind leg 7 days later42 (day 0). Tumors were measured 
three times per week until necropsy (day 60).
2.12 | Tumor establishment, drug 
administration and tumor measurement
Tumor was established by s.c. injection of 1 × 106 L5178Y- R cells in 
100 μL PBS into the left hind leg. When the tumor reached 100 mm3, 
the first PKHB1 i.p. injection (200 μg) was applied (day 0). To reach com-
plete remission, PKHB1 injection (200 μg) was applied once a week for 
6 weeks (days 7, 14, 21, 28 and 35); mice in complete remission were 
used for long- term memory assay. Tumor volume and weight were meas-
ured three times per week using a caliper (Digimatic Caliper; Mitutoyo 
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Corporation, Kawasaki, Japan) and a digital scale (AWS-600-BLK 
American Weigh Scales Inc. Norcross, GA, USA). Tumor volume was de-
termined with the formula: tumor volume (mm3) = 4π/3 * A * B * C where 
4π / 3 is a mathematical constant, A= width, B= high, and C= depth.
2.13 | Long- term memory assay
Mice in complete remission after PKHB1 treatment were rechal-
lenged with 2 × 106 cells in 100 μL PBS into the opposite limb, and 
tumor volume was measured as described above.
2.14 | Histology and immunohistochemistry
Tissues and organs were obtained and fixed in 10% neutral formalin, 
embedded in paraffin, sectioned (5 μm thickness) and stained with H&E 
(Sigma- Aldrich). Histopathological analysis was done by an external 
veterinarian pathologist (National professional certificate 2593012). 
Immunohistochemistry was done using CD4; MT310 sc- 19641 and 
CD8; 32- M4 sc- 1177 (Santa Cruz Biotechnology) primary antibodies, 
adding the universal biotinylated secondary antibody (VECTASTAIN 
Universal Quick HRP kit; Vector Laboratories, Burlingame, CA, USA) 
following the manufacturer instructions, and developed with diamin-
obenzidine substrate (ImmPACT DAB; Vector Laboratories). Finally, 
hematoxylin- counterstained slides were coverslipped using resin as 
mounting solution and observed under the microscope.
2.15 | Statistical analysis
Mice were randomly assigned to different groups for all in vivo studies. 
Experiments were repeated three independent times. Mann- Whitney test 
and two- tailed unpaired Student’s t test were carried out using GraphPad 
Prism Software (San Diego CA, USA) and presented as mean value ± SD. P- 
values were considered significant as follows: P < .05; P < .01 and P < .001.
3  | RESULTS
3.1 | CD47 agonist peptide PKHB1 induces cell 
death in human and murine tumor lymphoblastic  
T- cell lines
The thrombospondin- 1 mimetic peptide PKHB1 has shown cytotoxic-
ity in several neoplastic cell lines.33,34 However, its effects on human 
F I G U RE  1 PKHB1 induces cell death in T- cell acute lymphoblastic leukemia cell lines. Cell death was measured by Annexin- V- 
allophycocyanin (Annexin- V- APC) and propidium iodide (PI) staining and graphed. Dot plots of (A) CEM, (B) MOLT- 4 human leukemia cells, 
and (C) L5178Y- R murine cell line, without treatment (Control) and treated with 100, 200 and 300 μmol/L PKHB1 for 2 h. Charts represent 
the means (± SD) of triplicates of at least three independent experiments (right side for each cell line)
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ALL- derived CEM and MOLT- 4 cell lines, as well as on the murine ho-
mologous L5178Y- R cell line (a murine T- cell lymphoblastic tumor cell 
line) has not been tested. Therefore, we assessed the effects of PKHB1 
on these cells. PKHB1 induces cell death in a concentration- dependent 
way, because the cells incubated for 2 hours with increasing concen-
trations (100, 200 and 300 μmol/L) of PKHB1 showed an increase 
in the number of Ann- V- APC/PI positive CEM (Figure 1A), MOLT- 4 
(Figure 1B) and L5178Y- R (Figure 1C) cells. The cytotoxic concentra-
tion that induces approximately 50% of cell death (CC
50
) in CEM is 
200 μmol/L, in MOLT- 4 is 300 μmol/L, and in L5178Y- R is 200 μmol/L.
3.2 | PKHB1 prompts caspase- independent 
but calcium- dependent cell death with 
loss of mitochondrial membrane potential in CEM, 
MOLT- 4 and L5178Y- R cells
Once we determined that PKHB1 induces quick phosphatidyl-
serine exposure and plasma membrane permeability in T- ALL cell 
lines, we next assessed whether PKHB1- induced cell death in 
T- ALL cells shared the principal biochemical features previously 
described for CD47- mediated cell death; these include caspase 
independence,43 a sustained calcium influx and mitochondrial 
membrane potential (ΔΨm) loss.33,44 Thus, we preincubated the 
cells with a pan- caspase inhibitor (Q- VD- OPH) or an extracellular 
Ca2+ chelator (BAPTA) and cell death was tested. Caspase inhibi-
tion did not prevent PKHB1- induced killing of CEM (from 51% to 
48%), MOLT- 4 (from 57% to 51%), and L5178Y- R (from 52% to 
49%) cells. Nevertheless, extracellular calcium chelation signifi-
cantly reduced PKHB1- induced cell death in all cases: CEM (from 
51% to 18%), MOLT- 4 (from 57% to 38%), and L5178Y- R (from 
52% to 21%) (Figure 2A). Calcium dependence for death induced 
by an immobilized anti- CD47 (B6H12) was also corroborated in 
CEM cells (Figure S1).
Treatment with the PKHB1 CC
50
 also induced loss of ΔΨm in T- 
ALL (Figure 2B) being 49% in CEM, 61% in MOLT- 4, and of 51% in 
L5178Y- R.
F I G U RE  2 PKHB1 induces caspase- 
independent but calcium- dependent 
cell death and loss of mitochondrial 
membrane potential on leukemia cell lines. 
A, Graph represents cell death percentage 
of T- cell acute lymphoblastic leukemia (T- 
ALL) cells without treatment (Control) or 
treated with PKHB1 (200 μmol/L, 2 h) and 
left alone (−) or preincubated for 30 min 
with QVD (10 μmol/L) or Ca2+ chelator 
(BAPTA, 5 mmol/L) in the different cell 
lines tested. B, Loss of ΔΨm induced by 
PKHB1 (200 μmol/L, 2 h) was measured 
in T- ALL cells, and representative 
cytofluorometric plots are shown for each 
cell line tested. Charts (right) represent 
the means (± SD) of triplicates of at least 
three independent experiments. TMRE, 
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3.3 | PKHB1 treatment spares non- cancerous 
primary leukocytes derived from humans and mice
Our workgroup previously reported that PKHB1 did not induce 
significant cell death in residual CD5− B lymphocytes and T cells 
from CLL patients, and it neither induced kidney nor liver damage 
in mice.33 Thus, we tested the selectivity of PKHB1 in human PBMC 
(Figure 3A) and CD4+ and CD8+ human T cells (Figure 3B,C) from 
healthy donors. Additionally, we tested PKHB1 selectivity in mu-
rine PBMC (Figure 3D) and primary cultures of bone marrow (BM), 
spleen, thymus, and lymph nodes of healthy (without tumor or treat-
ment) BALB/c mice through indirect cell viability analysis (Figure 3E) 
through MTT analysis, as we wanted to determine general cell af-
fectation (cytotoxic, cytostatic, or antiproliferative effects). PKHB1 
treatment did not significantly affect cell viability of human or 
murine non- cancerous cells (Figure 3), even though all organs ex-
pressed CD47 at a similar level to the neoplastic cells (Figure S2). 
These results showed the selectivity of PKHB1 to induce cell death 
in malignant cells only.
3.4 | L5178Y- R tumor- bearing BALB/c mice treated 
with PKHB1 show leukocyte infiltration to the tumor 
site and improved leukocyte cell number
After verifying that PKHB1 treatment did not affect healthy leukocytes 
in vitro, we assessed these effects in vivo. Immunocompetent female 
BALB/c mice were used to bear L5178Y- R tumor cells, and mice were 
treated weekly with 200 μg PKHB1 i.p. After 18 days, all controls had 
to be killed, and some PKHB1- treated mice were randomly selected 
to be killed for comparison. Tumors were dissected, and their mor-
phological and cellular differences were analyzed (Figure 4A). The 
control group presented undifferentiated lymphoid cells, presum-
ably L5178Y- R cells, some of them carrying out mitosis (Figure 4A 
left). Conversely, tumors in PKHB1- treated mice contained a mixture 
of lymphocytes and polymorphonuclear cells (PMN) (Figure 4A mid-
dle). Moreover, complete tumor regression in most of the mice was 
observed at day 30, where histological slides show what seems to 
be an antitumor immune response in the inoculation site (Figure 4A 
right). Because anticancer immune response is characterized by tumor 
infiltrating lymphocytes (TIL), we decided to carry out immunohisto-
chemistry of tumor sections, which indicated the presence of CD4+ 
and CD8+ cells in PKHB1- treated mice (Figure 4B).
In addition, we carried out cell counts from lymphoid organs that 
belonged to control, PKHB1- treated or healthy mice. Noticeably, in 
PKHB1- treated mice, a significant increase in cell number of BM, 
spleen and thymus cells, and a significant decrease in cell number 
of lymph nodes were observed (Figure 4C). Moreover, cell num-
ber of the same organs in PKHB1- treated mice was similar to that 
of healthy mice. Additionally, the white blood cell (WBC) differen-
tial was carried out and showed no significant difference between 
healthy and PKHB1- treated mice, whereas untreated tumor- bearing 
mice presented a significant difference from the other two groups in 
all leukocyte types (Figure 4D). Altogether, the above suggests that 
PKHB1 improves the antitumor immune system of tumor- bearing 
mice and indicates possible participation of the immune system in 
complete tumor regression.
FIGURE 3 PKHB1 spares non- cancerous primary leukocytes from mice and humans in vitro. A, Cell death of total PBMC treated with PKHB1 
was measured by Annexin- V/propidium iodide (PI) staining, and each donor is indicated as a square (n = 10 donors). B, Percentage of CD4+, and 
CD8+ T cells from each donor, left untreated (white square) or treated with PKHB1 (black square) (n = 6 donors). C, Cell death of CD4+ and CD8+ 
human cells was measured by Annexin- V- allophycocyanin (Annexin- V- APC) and graphed. D, Cell death of murine PBMC treated with PKHB1 
was measured by Ann/PI staining. Each mouse is indicated as a circle (n = 10 mice). E, Cell viability of cells from bone marrow, spleen, thymus and 
lymph nodes from healthy mice (without tumor nor treatment) measured by MTT assays (n = 9 mice). NS= Not significant
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F I G U RE  4 PKHB1- treatment of L5178Y- R tumor- bearing mice induces leukocyte infiltration to the tumor site and improves leukocyte 
cell number. A, Histology from tumors from control (day 18) and PKHB1- treated mice (days 18 and 30) stained with H&E. Mitotic cells (red 
arrow), lymphocytes (blue arrow), eosinophils (yellow arrow), giant cells (black arrow), necrosis (brown arrow) and, normal tissue (green 
arrow). B, For immunohistochemical staining, CD4+ and CD8+ cells were labeled in tumor tissue of control and PKHB1- treated mice. Arrows 
point to cells with positive labeling. C, Cell count of lymphoid organs from mice with tumor without treatment (Control), from mice with 
tumor treated with PKHB1 or from mice without tumor and without treatment (Healthy) was carried out using Trypan blue staining (n = 6 
mice). D, Different types of leukocytes from control, PKHB1- treated and healthy mice are displayed in the graph, obtained using hematic 
biometry analysis. Results shown are representative of triplicates of at least three experiments. NS= Not significant
F I G U RE  5 PKHB1 induces calreticulin exposure. A, Left charts are representative of surface calreticulin (CRT) detection in CEM (upper), 
MOLT- 4 (middle) and L5178Y- R (bottom) cells using FACS. Negative controls, with IgG isotype antibodies, are shown in dotted (IgG- C) and 
solid (IgG- PK) lines, whereas gray (Control) is the basal CRT and black are cells treated (PKHB1). Right charts represent the means (± SD) of 
triplicates of at least three independent experiments. B, ECTO- CRT was observed in the cells treated with PKHB1 by CRT- PE staining and 
the nucleus was stained with Hoechst 33342 and visualized by confocal microscopy 40× (Mechanic zoom 7, Olympus X70; Olympus, Tokyo, 
Japan). Results shown are representative of triplicates of three independent experiments. CRT-PE = Calreticulin-PhycoErythrin
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3.5 | PKHB1 treatment induces DAMP 
exposure and release in T- ALL cells
Previous results showed that PKHB1 could be an ICD inducer; 
thus, we assessed the exposure and release of several DAMP in 
T- ALL cells. In Figure 5, it can be observed that CEM, MOLT- 4, and 
L5178Y- R cells incubated with the CC
50
 of PKHB1 presented a 
significant increase in CRT exposure, analyzed by flow cytometry 
(Figure 5A), and confocal microscopy (Figure 5B).
Then, we measured the expression and release of HSP90, HSP70, 
CRT and HMGB1. The presence of these DAMP was determined by 
western blot in cellular lysates and supernatant of untreated cells 




 for each cell line tested. 
Figure 6A shows the decrease in the expression of HSP90, HSP70, 
CRT, and HMGB1 in cellular lysates of cells treated with PKHB1. 
Conversely, expression of these DAMP increased in PKHB1- treated 
supernatants compared with the untreated cells (Figure 6B). These 
results indicate that PKHB1 treatment prompts the release of heat- 
shock proteins, CRT, and HMGB1 to the extracellular medium.
As HMGB1 release was barely detected by western blot, an ELISA 
assay was carried out. HMGB1 release varied depending on the cell 
line studied and on the concentration of PKHB1 used. Using PKHB1 
CC
100
, in CEM, MOLT- 4 and L5178Y- R cell lines, HMGB1 release 
was sixfold, fourfold and twofold, respectively, compared to the un-
treated control, whereas using PKHB1 CC
50
, MOLT- 4 cells HMGB1 
release was eightfold with respect to the control (Figure 7A).
F I G U RE  6 Heat shock protein (HSP)90, HSP70, calreticulin (CRT) and high- mobility group box 1 (HMGB1) protein expression and release 
in response to treatment with PKHB1. Western blot and densitometry analyses were carried out using cellular lysates (A) or supernatants (B) 
of CEM, MOLT- 4 and L5178Y- R cells untreated and treated with two concentrations of PKHB1. Loading controls, β- actin, and Ponceau red 
were used to determine densitometry analyses of relative protein expression. Results shown are representative of triplicates of at least three 
independent experiments. NS= Not significant
 82 
 
264  |     USCANGA- PALOMEQUE Et AL.
Another important indicator that immunogenic death is taking 
place is ATP- release. Therefore, a bioluminescence assay was carried 





, the presence of ATP significantly increased (Figure 7B).
3.6 | PKHB1- treated cells as prophylactic vaccine 
prevented tumor establishment of L5178Y- R cells
Considering the previous data, noting that PKHB1 treatment induces 
ICD, the next step was to carry out a prophylactic vaccination, which is 
the gold standard to confirm whether PKHB1 treatment induced ICD 
in vivo. The vaccine is based in the use of L5178Y- R cells treated in vitro 
with PKHB1 CC
100
. Four groups of mice were used as follows: (i) control 
group without vaccine; (ii) 1.5M vaccine group, with 1.5 × 106 PKHB1- 
treated cells; (iii) 3M vaccine group, with 3 × 106 PKHB1- treated cells; 
and (iv) 5M vaccine group with 5 × 106 PKHB1- treated cells. Results 
showed that vaccination containing PKHB1- treated cells prevented the 
establishment of L5178Y- R tumor and a greater number of dead cells 
as a result of the peptide, and showed better response against tumor 
cells inoculated 7 days after receiving the vaccine (Figure 8). In the con-
trol group, six out of six mice (100%) developed tumor after inocula-
tion with viable cells (Figure 8A top left), whereas three out of four mice 
(75%) developed tumor in the 1.5M vaccine group (Figure 8A top right), 
seven out of 14 mice (50%) developed tumor in the 3M vaccine group 
(Figure 8A lower left), and none of the mice (0%) in the 5M vaccine 
group developed the tumor (Figure 8A lower right). The 60- day survival 
rates of mice in each group were consistent with tumor growth, being 
100% in the 5M vaccine group (Figure 8B).
3.7 | PKHB1- treatment induced long- term 
prevention of tumor establishment
Additionally, we assessed long- term tumor prevention in mice that 
presented complete tumor regression after PKHB1 treatment. In 
these experiments one out of six mice (≈17%) rechallenged with 
2 × 106 L5178Y- R viable cells developed tumor, whereas in the 
naïve control group, six out of six (100%) presented tumor growth 
(Figure 8C). Survival percentage was graphed using Kaplan- Meier 
curve, where rechallenged mice showed 90% survival (Figure 8D).
4  | DISCUSSION
There are few scientific reports on the use of synthetic peptides 
that can induce ICD.45-47 Herein, we assessed the ability of PKHB1, 
the first serum- stable CD47- agonist peptide: (i) to induce selective 
cell death in T- ALL cells with conserved characteristics of CD47- 
mediated cell death; and (ii) to determine whether this type of cell 
death is immunogenic. We observed that PKHB1 induced death 
in CEM, MOLT- 4, and L5178Y- R cells (Figure 1), in a fast caspase- 
independent process that implicates phosphatidylserine expo-
sure along with plasma membrane permeabilization, and loss of 
mitochondrial membrane potential (Figure 2) that is selective for 
malignant cells (Figure 3). These features have largely implicated 
CD47- induced cell death.33,34,39,40,44 In addition, we observed that 
calcium dependence for cell death induced by PKHB1 was con-
served in T- ALL cells, as previously observed in CLL cells.33
Our results showed that treatment with PKHB1 in tumor- bearing 
mice induces leukocyte infiltration to the tumor site and improves leu-
kocyte cell number in different lymphoid organs (Figure 4). Increasing 
evidence suggests that ICD induces an antitumor immune response, 
increasing tumor infiltration of T cells. ICD stimulates the recruitment 
of DC through DAMP release. DC process tumor antigens and present 
antigens to T cells, helping to kill tumor cells. Thus, infiltration of T cells 
into the tumor site can be explained by exposure and secretion of CRT, 
and secretion of ATP and HMGB1 by the dying cells, which stimulate 
DC recruitment into the tumor microenvironment, antigen processing 
and presentation to T cells which then infiltrate the tumor site.48,49 
F I G U RE  7 PKHB1 induces high- mobility group box 1 (HMGB1) and ATP release in CEM, MOLT- 4 and L5178Y- R cell lines. Cells were 




 for 2 h, then 100 μL supernatant of each sample was taken to measure HMGB1 release by ELISA (A) 
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Indeed, PKHB1 prompted DAMP exposure and release on T- ALL cells. 
As CRT is one of the principal molecules necessary to determine that 
cell death is immunogenic,6,18 we demonstrated its exposure, by flow 
cytometry and confocal microscopy, on T- ALL after PKHB1 treatment 
(Figure 5). Diverse studies in the immunology field highlight the impor-
tance of CRT exposure as an “eat me” signal6,15,50,51 that helps antigen 
uptake by APC by binding to low- density lipoprotein receptor- related 
protein 1 (LRP1).7 There is a tight correlation between CRT and CD47 
expression in cancer cells.51 Indeed, recently, it was determined that 
treatment of breast cancer cell lines with thrombospondin- 1 (TSP- 
1) promoted interaction of TSP- 1 with CRT and CD47 and induced 
cell autophagy and tumor growth inhibition in xenografted mice.52 
These results support the idea that TSP- 1 or peptides derived from 
TSP- 1 can induce cell death through CD47 activation and its correla-
tion with CRT exposure. Also, HSP70 and HSP90, HMGB1 and ATP 
were released by PKHB1 treatment on CEM, MOLT- 4 and L5178Y- R 
cell lines (Figures 6,7). Release of these molecules is involved in the 
activation of the immune system and induction of potent anticancer 
immunity.17,53,54
However, DAMP release is not sufficient to ensure ICD induc-
tion, and in vivo vaccination is considered the gold standard.1,18,21 
Our in vivo assays showed that PKHB1 activates short- and long- 
term immunological memory and induces a protective antican-
cer response in an immunocompetent murine model, as tumor 
F I G U RE  8 PKHB1 induces short- and long- term immunological memory through prophylactic vaccination or prior exposure to the tumor 
and treatment. A, Graphs indicate tumor growth in unvaccinated mice (Control; n = 6) or vaccinated with 1.5 × 106 (1.5M; n = 4), 3 × 106 (3M; 
n = 8) or 5 × 106 (5M; n = 6) CC
100
 PKHB1- treated L5178Y- R cells and rechallenged with 2 × 106 living L5178Y- R cells. Each line represents 
one mouse. B, Survival in vaccinated mice over time. C, Long- term antitumor memory of mice in remission rechallenged with 3 × 106 viable 
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growth was prevented in most cases (Figure 9). We observed 
that increasing the number of PKHB1- treated cells in the vaccine 
improves its protective antitumor response (Figure 8). Previous 
reports using other ICD inducers also prevented tumor growth, 
such as in the case of melphalan, an alkylating agent used in 
melanoma treatment, where C57BL6 mice were injected with 
melphalan- killed murine B78 melanoma cells and rechallenged 
10 days later with B78 viable cells, resulting in 40% of mice 
without tumor.55 Similar results were obtained using doxoru-
bicin in a mouse colon carcinoma (CT26) cell line.42 The use of 
this vaccine helps to stimulate anticancer immunity through the 
maturation of DC and cytotoxic T- cell activation56 as well as 
enhancing NK cytotoxic activity.57
Immunotherapy is a promising treatment option against can-
cer,58 using host immune defenses against cancer and seeking to 
endow cancer cells with immunogenicity.59 The increased immu-
nogenicity of tumor cells triggers antitumor immune responses 
that could offer long- term therapeutic effects.1 The finding that 
certain drugs are able to induce the awakening of the immune re-
sponse by releasing DAMP and generating ICD triggered investi-
gations to look for these types of agent.1,42,57,60 Anthracyclines, 
platinum derivatives, alkylating agents, and proteasome inhibi-
tors are chemotherapeutic drugs with large amounts of evidence 
for triggering ICD.61 Other therapeutic modalities that show ICD 
induction are photodynamic therapy,62 radiotherapy,63 oncolytic 
viruses,64,65 high hydrostatic pressure,66 and other phytochemi-
cal agents such as shikonin67,68 and capsaicin.69,70
Overall, our results highlight the advantages of the potential 
therapeutic use of targeting CD47 through peptide- based strat-
egies, such as PKHB1, leading us to consider that this peptide 
could be used in other types of cancer. However, the molecu-
lar pathway by which PKHB1 induces this type of death through 
CD47 signaling remains unclear, as does whether this type of 
treatment could be used therapeutically. Therefore, we believe 
that CD47 agonist peptides deserve further investigation, which 
might lead to the possibility of being scaled in the near future to 
clinical phases.
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F I G U RE  9 Schematic representation 
of CD47- mediated immunogenic cell 
death. PKHB1 induces fast immunogenic 
cell death in T- cell acute lymphoblastic 
leukemia cells (T- ALL) leading to damage- 
associated molecular patterns (DAMP) 
release. Giving prophylactic antitumor 
vaccine of tumor cells previously 
treated with PKHB1 prevented tumor 
establishment in vivo. CRT, calreticulin; 
HMGB1, high- mobility group box 1; HSP, 
heat shock protein; ICD, immunogenic cell 
death; TSP- 1, thrombospondin- 1 
 85 
 
     |  267USCANGA- PALOMEQUE Et AL.
REFERENCES
 1. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death 
in cancer therapy. Annu Rev Immunol. 2013;31:51-72.
 2. Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell 
death: recommendations of the Nomenclature Committee on Cell 
Death 2018. Cell Death Differ. 2018;25(3):486-541.
 3. Land WG. The role of damage- associated molecular patterns (DAMPs) 
in human diseases: part II: DAMPs as diagnostics, prognostics and thera-
peutics in clinical medicine. Sultan Qaboos Univ Med J. 2015;15(2):e157.
 4. Rubartelli A, Lotze MT. Inside, outside, upside down: damage- 
associated molecular- pattern molecules (DAMPs) and redox. Trends 
Immunol. 2007;28(10):429-436.
 5. Garg AD, Dudek AM, Agostinis P. Cancer immunogenicity, dan-
ger signals, and DAMPs: what, when, and how? BioFactors. 
2013;39(4):355-367.
 6. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin expo-
sure dictates the immunogenicity of cancer cell death. Nat Med. 
2007;13(1):54-61.
 7. Garg AD, Krysko DV, Verfaillie T, et al. A novel pathway combining 
calreticulin exposure and ATP secretion in immunogenic cancer cell 
death. EMBO J. 2012;31(5):1062-1079.
 8. Fucikova J, Kasikova L, Truxova I, et al. Relevance of the chaperone- 
like protein calreticulin for the biological behavior and clinical out-
come of cancer. Immunol Lett. 2018;193:25-34.
 9. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, 
Dhodapkar MV. Bortezomib enhances dendritic cell (DC)- mediated 
induction of immunity to human myeloma via exposure of cell sur-
face heat shock protein 90 on dying tumor cells: therapeutic impli-
cations. Blood. 2007;109(11):4839-4845.
 10. Garg AD, Galluzzi L, Apetoh L, et al. Molecular and translational 
classifications of DAMPs in immunogenic cell death. Front Immunol. 
2015;6:588.
 11. Elliott MR, Chekeni FB, Trampont PC, et al. Nucleotides released 
by apoptotic cells act as a find- me signal to promote phagocytic 
clearance. Nature. 2009;461(7261):282.
 12. Aymeric L, Apetoh L, Ghiringhelli F, et al. Tumor cell death and ATP 
release prime dendritic cells and efficient anticancer immunity. 
Cancer Res. 2010;70(3):855-858.
 13. Martins I, Wang Y, Michaud M, et al. Molecular mechanisms of 
ATP secretion during immunogenic cell death. Cell Death Differ. 
2014;21(1):79-91.
 14. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin pro-
tein HMGB1 by necrotic cells triggers inflammation. Nature. 
2002;418(6894):191-195.
 15. Inoue H, Tani K. Multimodal immunogenic cancer cell death as a 
consequence of anticancer cytotoxic treatments. Cell Death Differ. 
2014;21(1):39-49.
 16. Tesniere A, Panaretakis T, Kepp O, et al. Molecular characteristics of 
immunogenic cancer cell death. Cell Death Differ. 2008;15(1):3-12.
 17. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, 
Vandenabeele P. Immunogenic cell death and DAMPs in cancer 
therapy. Nat Rev Cancer. 2012;12(12):860.
 18. Bezu L, Gomes-da-Silva LC, Dewitte H, et al. Combinatorial strat-
egies for the induction of immunogenic cell death. Front Immunol. 
2015;6:187.
 19. Kepp O, Senovilla L, Vitale I, et al. Consensus guidelines for 
the detection of immunogenic cell death. Oncoimmunology. 
2014;3(9):e955691.
 20. Garg AD, More S, Rufo N, et al. Trial watch: immunogenic cell death 
induction by anticancer chemotherapeutics. OncoImmunology. 
2017;6(12):e1386829.
 21. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunogenic 
cell death in cancer and infectious disease. Nat Rev Immunol. 
2017;17(2):97-111.
 22. Jabbour E, O’Brien S, Konopleva M, Kantarjian H. New insights into 
the pathophysiology and therapy of adult acute lymphoblastic leu-
kemia. Cancer. 2015;121(15):2517-2528.
 23. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a com-
prehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577.
 24. National Cancer Institute. SEER cancer statistics review, 1975-
2015. Leukemia, annual incidence rates (acute lymphocytic leu-
kemia). https://seer.cancer.gov/statfacts/html/alyl.html Accessed 
August, 2018.
 25. McNeer JL, Bleyer A, Conter V, Stock W. Acute lymphoblastic 
leukemia. In: Bleyer A, Barr R, Ries L, Whelan J, Ferrari A, eds. 
Cancer in Adolescents and Young Adults. New York: Springer; 
2017:151-175.
 26. McNeer JL, Bleyer A. Acute lymphoblastic leukemia and lympho-
blastic lymphoma in adolescents and young adults. Pediatr Blood 
Cancer. 2018;65(6):e26989.
 27. Jaime-Pérez JC, Fernández LT, Jiménez-Castillo RA, et al. Age acts 
as an adverse independent variable for survival in acute lympho-
blastic leukemia: data from a cohort in Northeast Mexico. Clin 
Lymphoma Myeloma Leuk. 2017;17(9):590-594.
 28. Li Y, Buijs-Gladdines JG, Canté-Barrett K, et al. IL- 7 receptor 
mutations and steroid resistance in pediatric T cell acute lym-
phoblastic leukemia: a Genome Sequencing Study. PLoS Med. 
2016;13(12):e1002200.
 29. Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat relapsed child-
hood acute lymphoblastic leukemia. Blood. 2012;120(14):2807-2816.
 30. Pogorzala M, Kubicka M, Rafinska B, Wysocki M, Styczynski J. 
Drug- resistance profile in multiple- relapsed childhood acute lym-
phoblastic leukemia. Anticancer Res. 2015;35(10):5667-5670.
 31. Thompson PA, Tam CS, O’Brien SM, et al. Fludarabine, cyclophos-
phamide, and rituximab treatment achieves long- term disease- free 
survival in IGHV- mutated chronic lymphocytic leukemia. Blood. 
2016;127(3):303-309.
 32. Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognos-
tic factor and therapeutic antibody target on human acute myeloid 
leukemia stem cells. Cell. 2009;138(2):286-299.
 33. Martinez-Torres AC, Quiney C, Attout T, et al. CD47 agonist pep-
tides induce programmed cell death in refractory chronic lympho-
cytic leukemia B cells via PLCγ1 activation: evidence from mice and 
humans. PLoS Med. 2015;12(3):e1001796.
 34. Denèfle T, Boullet H, Herbi L, et al. Thrombospondin- 1 mimetic 
agonist peptides induce selective death in tumor cells: design, 
synthesis, and structure- activity relationship studies. J Med Chem. 
2016;59(18):8412-8421.
 35. Chao MP, Alizadeh AA, Tang C, et al. Therapeutic antibody tar-
geting of CD47 eliminates human acute lymphoblastic leukemia. 
Cancer Res. 2011;71(4):1374-1384.
 36. Barclay AN, van den Berg TK. The interaction between signal reg-
ulatory protein alpha (SIRPα) and CD47: structure, function, and 
therapeutic target. Annu Rev Immunol. 2014;32:25-50.
 37. Soto-Pantoja DR, Kaur S, Roberts DD. CD47 signaling pathways 
controlling cellular differentiation and responses to stress. Crit Rev 
Biochem Mol Biol. 2015;50(3):212-230.
 38. Liu X, Pu Y, Cron K, et al. CD47 blockade triggers T cell- 
mediated destruction of immunogenic tumors. Nat Med. 
2015;21(10):1209-1215.
 39. Leclair P, Liu CC, Monajemi M, Reid GS, Sly LM, Lim CJ. CD47- 
ligation induced cell death in T- acute lymphoblastic leukemia. Cell 
Death Dis. 2018;9(5):544.
 40. Mateo V, Lagneaux L, Bron D, et al. CD47 ligation induces caspase- 
independent cell death in chronic lymphocytic leukemia. Nat Med. 
1999;5(11):1277-1284.
 41. Sick E, Jeanne A, Schneider C, Dedieu S, Takeda K, Martiny 
L. CD47 update: a multifaceted actor in the tumour 
 86 
 
268  |     USCANGA- PALOMEQUE Et AL.
microenvironment of potential therapeutic interest. Br J 
Pharmacol. 2012;167(7):1415-1430.
 42. Casares N, Pequignot MO, Tesniere A, et al. Caspase- dependent 
immunogenicity of doxorubicin- induced tumor cell death. J Exp 
Med. 2005;202(12):1691-1701.
 43. Oldenborg PA. CD47: a cell surface glycoprotein which regulates 
multiple functions of hematopoietic cells in health and disease. 
ISRN Hematol. 2013;2013:1-19.
 44. Manna PP, Frazier WA. The mechanism of CD47- dependent killing 
of T cells: heterotrimeric Gi- dependent inhibition of protein kinase 
A. J Immunol. 2003;170(7):3544-3553.
 45. Zhou H, Forveille S, Sauvat A, et al. The oncolytic peptide LTX- 315 
triggers immunogenic cell death. Cell Death Dis. 2016;7(3):e2134.
 46. Pasquereau-Kotula E, Habault J, Kroemer G, Poyet JL. The anti-
cancer peptide RT53 induces immunogenic cell death. PLoS ONE. 
2018;13(8):e0201220.
 47. Sakakibara K, Sato T, Kufe DW, VonHoff DD, Kawabe T. CBP501 in-
duces immunogenic tumor cell death and CD8 T cell infiltration into 
tumors in combination with platinum, and increases the efficacy of 
immune checkpoint inhibitors against tumors in mice. Oncotarget. 
2017;8(45):78277.
 48. Wang YJ, Fletcher R, Yu J, Zhang L. The immunogenic effects of 
chemotherapy- induced tumor cell death. Genes Dis. 2018;5:194-203.
 49. Lanitis E, Dangaj D, Irving M, Coukos G. Mechanisms regulat-
ing T- cell infiltration and activity in solid tumors. Ann Oncol. 
2017;28(suppl_12):xii18-xii32.
 50. Gardai SJ, McPhillips KA, Frasch SC, et al. Cell- surface calretic-
ulin initiates clearance of viable or apoptotic cells through trans- 
activation of LRP on the phagocyte. Cell. 2005;123(2):321-334.
 51. Chao MP, Jaiswal S, Weissman-Tsukamoto R, et al. Calreticulin is 
the dominant pro- phagocytic signal on multiple human cancers and 
is counterbalanced by CD47. Sci Transl Med. 2010;2(63):63-94.
 52. Chen Q, Fang X, Jiang C, Yao N, Fang X. Thrombospondin promoted 
anti- tumor of adenovirus- mediated calreticulin in breast cancer: re-
lationship with anti- CD47. Biomed Pharmacother. 2015;73:109-115.
 53. Fucikova J, Kralikova P, Fialova A, et al. Human tumor cells killed 
by anthracyclines induce a tumor- specific immune response. Cancer 
Res. 2011;71(14):4821-4833.
 54. Rodríguez-Salazar MD, Franco-Molina MA, Mendoza-Gamboa 
E, et al. The novel immunomodulator IMMUNEPOTENT CRP 
combined with chemotherapy agent increased the rate of immu-
nogenic cell death and prevented melanoma growth. Oncol Lett. 
2017;14(1):844-852.
 55. Dudek-Perić AM, Ferreira GB, Muchowicz A, et al. Antitumor immu-
nity triggered by melphalan is potentiated by melanoma cell surface- 
associated calreticulin. Cancer Res. 2015;75(8):1603-1614.
 56. Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang XY. 
Therapeutic cancer vaccines: past, present, and future. Adv Cancer 
Res. 2013;119:421-475.
 57. Showalter A, Limaye A, Oyer JL, et al. Cytokines in immunogenic 
cell death: applications for cancer immunotherapy. Cytokine. 
2017;97:123-132.
 58. Papaioannou NE, Beniata OV, Vitsos P, Tsitsilonis O, Samara P. 
Harnessing the immune system to improve cancer therapy. Ann 
Transl Med. 2016;4(14):261.
 59. Li X. The inducers of immunogenic cell death for tumor immuno-
therapy. Tumori J. 2018;104(1):1-8.
 60. Pol J, Vacchelli E, Aranda F, et al. Trial Watch: immunogenic cell 
death inducers for anticancer chemotherapy. Oncoimmunology. 
2015;4(4):e1008866.
 61. Vacchelli E, Aranda F, Eggermont A, et al. Trial Watch: tumor- 
targeting monoclonal antibodies in cancer therapy. Oncoimmunology. 
2014;3(1):e27048.
 62. Tanaka M, Kataoka H, Yano S, et al. Immunogenic cell death due to 
a new photodynamic therapy (PDT) with glycoconjugated chlorin 
(G- chlorin). Oncotarget. 2016;7(30):47242-47251.
 63. Golden EB, Apetoh L. Radiotherapy and immunogenic cell death. 
Semin Radiat Oncol. 2015;25(1):11-17.
 64. Diaconu I, Cerullo V, Hirvinen ML, et al. Immune response 
is an important aspect of the antitumor effect produced 
by a CD40L- encoding oncolytic adenovirus. Cancer Res. 
2012;72(9):2327-2338.
 65. Yamano T, Kubo S, Fukumoto M, et al. Whole cell vaccination 
using immunogenic cell death by an oncolytic adenovirus is ef-
fective against a colorectal cancer model. Mol Ther Oncolytics. 
2016;3:16031.
 66. Fucikova J, Moserova I, Truxova I, et al. High hydrostatic pressure 
induces immunogenic cell death in human tumor cells. Int J Cancer. 
2014;135(5):1165-1177.
 67. Lin TJ, Lin HT, Chang WT, et al. Shikonin- enhanced cell immuno-
genicity of tumor vaccine is mediated by the differential effects of 
DAMP components. Mol Cancer. 2015;14(1):174.
 68. Yin S, Yang NS, Lin TJ. Molecular basis of shikonin- induced immu-
nogenic cell death: insights for developing cancer therapeutics. 
Receptors Clin Investig. 2016;3:1-5.
 69. D’Eliseo D, Manzi L, Velotti F. Capsaicin as an inducer of damage- 
associated molecular patterns (DAMPs) of immunogenic cell 
death (ICD) in human bladder cancer cells. Cell Stress Chaperones. 
2013;18(6):801-808.
 70. Jin T, Wu H, Wang Y, Peng H. Capsaicin induces immuno-
genic cell death in human osteosarcoma cells. Exp Ther Med. 
2016;12(2):765-770. 
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section at the end of the article.
How to cite this article: Uscanga-Palomeque AC, Calvillo-
Rodríguez KM, Gómez-Morales L, et al. CD47 agonist 
peptide PKHB1 induces immunogenic cell death in T- cell 




























1.2. PKHB1 tumor cell lysate induces antitumor immune system 
stimulation and tumor regression in syngeneic mice with tumoral T 
lymphoblasts 
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Based on the results obtained previously, showing that PKHB1 induces 
immunogenic cell death in T-ALL cells, it was evaluated whether cells killed by PKHB1 
were able to induce according ex vivo immune responses. 
First, PKHB1 and 4NGG (inactive control) peptides were manually synthesized 
using solid support, purified by HPLC, and >99% pure lyophilized peptide fractions were 
used this time to determine the minimal lethal dose (CC100) of PKHB1 in L5178Y-R cells, 
measuring cell death by Ann-V-APC and PI staining using flow cytometry. At the PKHB1-
CC100 (300 µM), 4NGG did not augment L5178Y-R cell death with respect to untreated 
controls. As previously reported, extracellular calcium chelation but not caspase inhibition 
reduced PKHB1-induced cell death. Pharmacological inhibitors of reactive oxygen 
species production (N-acetyl cysteine), autophagy (spautin-1) or necroptosis (NEC-1) did 
not prevent cell death neither. Moreover, PKHB1 treatment increased the fluorescence of 
cells marked with CRT-PE (anti-calreticulin antibody) with respect to untreated cells. The 
previous confirmed that PKHB1 activates a particular caspase-independent RCD pathway 
in L5178Y-R cells that induces phosphatidylserine and calreticulin exposure, and suggests 
that this pathway is not regulated by the canonical initiators of autophagy or necroptosis. 
To asses the ability of L5178Y-R cells killed by PKHB1 (PKHB1 tumor cell lysates, 
PKHB1-TCL) to induce immunogenic cell responses, activation of bone marrow-derived 
DCs by PKHB1-TCL was first tested. DCs were left alone or co-cultured with PKHB1-
TCL for 24 h, washed, recovered, and stained with monoclonal antibodies against a DC 
maturation marker (anti-CD11c-AF488) and co-stimulatory molecules (anti-CD80-FITC 
or anti-CD86-APC). Compared to non-pulsed DCs, DCs pulsed with PKHB1-TCL had a 
similar levels of CD11c+ staining, but a higher levels of CD80 and CD86. Moreover, flow 
cytometry analysis showed that the supernatants of DCs pulsed with PKHB1-TCL had 
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higher levels of tumor necrosis factor alpha (TNFa). The previous suggests that PKHB1-
TCL can induce the maturation of DCs. 
To assess whether these PKHB1-TCL-pulsed DCs were able to prime T cells, CD3+ 
cells were obtained by positive selection of mouse PMBCs using magnet-activated cell 
sorting, and co-cultured with non-pulsed DCs, or with PKHB1-TCL-pulsed DC for four 
days. 
On the one hand, flow cytometry evaluation of Th1/Th2-related cytokine (TNFa, 
IFNy, IL-5 and IL-4) release showed that in the supernatants of T cells co-cultured with 
PKHB1-TCL-pulsed DC, there were significantly higher levels of TNFa, IFNy and IL-2 
compared to the supernatants of T cells co-cultured with non-pulsed DC, where there was 
a minor TNFa release, and no release IFNy, IL-5 nor IL-4 nor IL2. The pattern of cytokine 
production by theoretically primed T cells corresponds to an anti-tumor Th1 response 
phenotype. 
On the other hand, it was evaluated whether hypothetically primed T cells maturated 
to a L5178Y-R-cytotoxic phenotype. For this, L5178Y-R cells were stained with calcein-
AM (which is fluorescent in metabolically active cells) and left alone or co-cultured with 
unprimed or with theoretically primed T cells. After 24 h, calcein-AM fluorescence in 
L5178Y-R cells was measured by flow cytometry. L5178Y-R cells cultured alone or co-
cultured with unprimed T cells, did not lose calcein-AM fluorescence, while important 
populations (~75%) of calcein-AM negative L5178Y-R cells appeared when co-cultured 
with hypothetically primed T-cells, indicating T cell cytotoxicity to L5178Y-R cells. 
Altogether, the data suggests that L5178Y-R PKHB1-TCL activate the maturation of DC 
to a phenotype able to prime tumor-specific T cell responses without need of further 
adjuvanticity. 
Given the strong immunogenicity of PKHB1-TCL, it was hypothesized that its 
application to established tumors could have an impact on tumor growth in vivo. 
Therefore, mice were inoculated with viable L5178Y-R cells, and waited for tumors to 
reach 100 mm3 before the first immunization with the PKHB1-TCL or with vehicle. Three 
more doses were administered 3, 6 and 9 days after. Contrary to controls, where tumor 
grew and killed all mice after 11 days, PKHB1-TCL significantly reduced tumor growth 
by the time of the last dose, when it reached its maximum volume (day 9), and after which 
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begun to decrease until 30 days after tumor establishment, improving overall survival. 
Mice that achieved remission and controls of similar age were (re-)challenged with 
L5178Y-R cells after >60 days post-remission. While tumor grew and killed all controls, 
none of the immunized mice developed the tumor and all survived re-challenge, 
confirming the long-term immunological memory provided by PKHB1-TCL treatment.
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Résumé de l’article 2 
 
La leucémie lymphoïde aiguë (LAL) est le cancer pédiatrique le plus courant. 
Actuellement, les options de traitement pour les patients atteints de LAL récidivante et 
réfractaire reposent principalement sur les immunothérapies. Cependant, les cancers 
hématologiques sont couramment associés à une faible immunogénicité et une faible 
tolérance immunitaire, ce qui peut contribuer à la rechute de la leucémie et aux difficultés 
associées au développement d'immunothérapies efficaces contre cette maladie. Nous 
avons récemment démontré que PKHB1, un peptide agoniste CD47 dérivé de TSP1, 
induisait la mort cellulaire immunogène (ICD) dans la LAL sur cellules T (T-ALL). La 
mort cellulaire induite par PKHB1 sur les lignées cellulaires T-ALL et leur homologue 
murin, L5178Y-R (lignée cellulaire lymphoblastique tumorale T-murine), a induit 
l'exposition et la libération des molécules associées aux dangers (DAMP). De plus, une 
vaccination prophylactique avec des cellules L5178Y-R traitées par PKHB1 a empêché 
l'établissement de la tumeur in vivo dans tous les cas. En raison du potentiel immunogène 
des cellules traitées par PKHB1, dans cette étude, nous avons évalué leur capacité à 
induire des réponses immunitaires antitumorales ex vivo et in vivo dans une tumeur 
établie. Nous avons d'abord confirmé la sélectivité de la mort cellulaire induite par PKBH1 
dans les cellules tumorales L5178Y-R et observé que l'exposition à la calréticuline 
augmentait lorsque la mort cellulaire augmentait. Ensuite, nous avons constaté que le lysat 
de cellules tumorales (TCL) obtenu à partir de cellules tumorales L5178YR traitées par 
PKHB1 (PKHB1-TCL) était capable d'induire, ex vivo, la maturation des cellules 
dendritiques, la production de cytokines et les réponses antitumorales des cellules T. 
Enfin, nos résultats montrent que in vivo, le traitement par PKHB1-TCL induisait une 
régression tumorale chez des souris syngéniques transplantées avec des cellules L5178Y-
R, augmentant leur survie globale et les protégeant de l'établissement des tumeurs après 
une rechallenge tumorale. Dans l'ensemble, nos résultats mettent en évidence 
l'immunogénicité de la mort cellulaire induite par l'activation de PKHB1 de CD47 en tant 
qu'outil thérapeutique potentiel pour surmonter la faible immunogénicité et la tolérance 
immunitaire dans la T-ALL.
 95 
Resumen del artículo 2 
 
La leucemia linfocítica aguda (LLA) es el cáncer pediátrico más común. 
Actualmente, las opciones de tratamiento para pacientes con LLA en recaída y refractaria 
se basan principalmente en inmunoterapias. Sin embargo, los cánceres hematológicos se 
asocian comúnmente con una baja inmunogenicidad y tolerancia inmune, lo que puede 
contribuir a la recaída de la leucemia y las dificultades asociadas con el desarrollo de 
inmunoterapias efectivas contra esta enfermedad. Recientemente demostramos que 
PKHB1, un péptido agonista de CD47 derivado de TSP1, induce la muerte celular 
inmunogénica (ICD) en la LLA de células T (LLA-T). La muerte celular inducida por 
PKHB1 en las líneas celulares T-ALL y su homóloga murina, L5178Y-R (línea celular de 
linfoblastos tumorales T-murinos), indujo la exposición y liberación de patrones 
moleculares asociados al daño (DAMP). Además, una vacunación profiláctica con células 
L5178Y-R tratadas con PKHB1 impidió el establecimiento del tumor in vivo en todos los 
casos. Debido al potencial inmunogénico de las células tratadas con PKHB1, en este 
estudio evaluamos su capacidad para inducir respuestas inmunes antitumorales ex vivo e 
in vivo en un tumor establecido. Primero confirmamos la selectividad de la muerte celular 
inducida por PKBH1 en células tumorales L5178Y-R y observamos que la exposición a 
calreticulina aumentaba cuando aumentaba la muerte celular. Luego, descubrimos que el 
lisado de células tumorales (TCL) obtenido a partir de células tumorales L5178YR 
tratadas con PKHB1 (PKHB1-TCL) fue capaz de inducir ex vivo la maduración de las 
células dendríticas, la producción de citocinas y las respuestas antitumorales de las células 
T. Finalmente, nuestros resultados muestran que in vivo, el tratamiento con PKHB1-TCL 
induce la regresión tumoral en ratones singénicos trasplantados con células L5178Y-R, 
aumentando su supervivencia general y protegiéndolos de un mayor establecimiento 
tumoral después de la reexposición tumoral. En conjunto, nuestros resultados destacan la 
inmunogenicidad de la muerte celular inducida por la activación de CD47 por PKHB1 
como una herramienta terapéutica potencial para superar la baja inmunogenicidad y la 
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Acute lymphocytic leukemia (ALL) is the most common pediatric cancer. Currently, treatment options for patients with relapsed
and refractory ALL mostly rely on immunotherapies. However, hematological cancers are commonly associated with a low
immunogenicity and immune tolerance, which may contribute to leukemia relapse and the difficulties associated with the
development of effective immunotherapies against this disease. We recently demonstrated that PKHB1, a TSP1-derived CD47
agonist peptide, induces immunogenic cell death (ICD) in T cell ALL (T-ALL). Cell death induced by PKHB1 on T-ALL cell lines
and their homologous murine, L5178Y-R (T-murine tumor lymphoblast cell line), induced damage-associated molecular patterns
(DAMPs) exposure and release. Additionally, a prophylactic vaccination with PKHB1-treated L5178Y-R cells prevented tumor
establishment in vivo in all the cases. Due to the immunogenic potential of PKHB1-treated cells, in this study we assessed their
ability to induce antitumor immune responses ex vivo and in vivo in an established tumor. We first confirmed the selectivity of cell
death induced byPKBH1 in tumor L5178Y-R cells and observed that calreticulin exposure increasedwhen cell death increased.%en,
we found that the tumor cell lysate (TCL) obtained from PKHB1-treated L5178YR tumor cells (PKHB1-TCL) was able to induce, ex
vivo, dendritic cells maturation, cytokine production, and T cell antitumor responses. Finally, our results show that in vivo, PKHB1-
TCL treatment induces tumor regression in syngeneic mice transplanted with L5178Y-R cells, increasing their overall survival and
protecting them from further tumor establishment a-er tumor rechallenge. Altogether our results highlight the immunogenicity
of the cell death induced by PKHB1 activation of CD47 as a potential therapeutic tool to overcome the low immunogenicity and
immune tolerance in T-ALL.
1. Introduction
T cell acute lymphoblastic leukemia (T-ALL) is a hema-
tological malignancy that affects mostly pediatric patients,
as they account for 80% of the cases [1, 2]. It represents
the second most common acute leukemia in adults, with
a 5-year survival rate of about 30-50% [3–5] with a high
risk of relapse [6]. %e use of nelarabine for relapsed and
refractory T-ALL only results in responses in a substantial
minority of patients [7]. Among other treatments, allogeneic
hematopoietic cell transplantation (HCT) is proposed in
patients with high-risk or relapsed/refractory disease, and
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!-secretase inhibitors for patients with NOTCH1 mutations
are currently in clinical trials. Multiagent chemotherapy
is proposed for older and unfit patients. However, T-ALL
treatments have lagged behind those proposed for B-cell
ALL, and the development of new therapeutic approaches
against this aggressive malignancy remains a challenge. Since
the T-ALL high risk of relapse has been attributed to its
low immunogenicity and immune tolerance [6], the immune
system stimulation able to induce immunological memory
against tumor cells appears as a challenging but promising
goal.
With this aim, whole tumor cell lysates (TCLs) have been
shown to be able to prompt antitumor immune responses
in preclinical murine models for glioblastoma, breast, and
ovarian cancer and in clinical trials for melanoma, prostate,
and ovarian cancer [8]. &ese immune responses are corre-
lated with damage-associated molecular patterns (DAMPs)
induction and the availability of the tumor neoantigens, both
of which are promoted in accordance with the specific cell
death inductor [9]. DAMPs interact with dendritic cells’
(DCs’) receptors (CD91, Toll-like receptor 4, purinergic
receptors, among others), promoting their maturation and
increasing antitumor activity [10]. &us, TCL can be used to
induce an immunogenic response fromDCs against multiple
tumor antigens, triggering a polyclonal tumor-specific T cell
response [11].
Cancer treatment with DCs pulsed with tumor antigens
has proved effective antitumor responses in mesothelioma,
glioma, and breast cancer [12–14]. However, the use of
TCL as therapeutic vaccines has been also shown to be a
useful strategy to elicit antitumor immune responses, while
overcoming immunosuppressive mechanisms of the tumor
microenvironment [8]. TCLs hold more promises as cancer
vaccines than individual tumor-associated antigens (TAAs)
because they can elicit immune responses to multiple TAAs
[15]. However, the availability and types of neoantigens, the
amount of DAMPs released, and the overall immunogenicity
of the TCL strongly rely on the cell death inductor [9].&us, it
is important to find effective cell death inductors that are able
to provide an immunogenic TCL able to induce antitumor
immune responses.
CD47 activation through coated [16–18] or soluble anti-
CD47 antibodies [19, 20], or immobilized [16] or sol-
uble peptides derived from the C-terminal domain of
thrombospondin-1 [21, 22], is an effective way to induce
cell death in different types of cancerous cells, even in cells
coming from patients that are resistant to chemotherapy
[21, 22]. &us, a TCL obtained through CD47 activation
might help to understand the implications of CD47-mediated
cell death in the activation of antitumor immune responses.
Recently, we have shown that treatment of T-ALL cells with
the CD47-agonist peptide, PKHB1, induced immunogenic
cell death (ICD) [23]. ICD was induced by PKHB1 in
T-ALL cells, while it spares CD19 and CD3 lymphocytes
[21], human and murine PBMCs, CD4 and CD8 T cells,
and cells from murine lymphoid organs [23]. We found
that PKHB1-treatment induces the exposure and release of
several DAMPs (calreticulin (CRT), HSP70, HSP90, ATP,
and HMGB1) in human T-ALL cell lines (CEM, MOLT-4)
and their murine counterpart (L5178Y-R cells) [23]. In vivo,
prophylactic vaccination experiments with PKHB1-treated
cells prevented tumor establishment in immunocompetent
BALB/c mice [23]. &ese results demonstrated that CD47
activation by PKHB1 was able to induce DAMPs release
and provide neoantigens able to elicit an antitumor immune
response that prevented tumor establishment. However, the
therapeutic potential of this type of ICD was not studied.
In the present work we focused on determining whether
the induction of ICD by PKHB1 has a therapeutic potential.
Due to the immunogenicity of PKHB1-treated cells, we used
the TCL obtained from PKHB1-treated L5178Y-R tumor cells
(PKHB1-TCL) and focused on determining their ability to
induce antitumor immune responses ex vivo and in vivo in an
established L5178Y-R tumor developed in syngeneic BALB/c
mice.
2. Material and Methods
2.1. T Cells and Dendritic Cells (DCs). &is study was
approved by the Animal Ethical Committee (CEIBA), of the
School of Biological Sciences Number: 01/2015. All exper-
iments were conducted according to Mexican regulation
NOM-062-ZOO-1999.
&e blood from sacrificed BALB/c mice was obtained
by cardiac puncture. Peripheral blood mononuclear cells
(PBMCs) isolation was performed by density gradient cen-
trifugation using Ficoll-Hypaque-1119 (Sigma-Aldrich, St
Louis, MO, USA). Murine CD3+ cells were isolated from
total PBMCs by positive selection using magnetic-activated
cell sorting (MACS) microbead technology with anti-CD3"-
biotin and anti-biotin microbeads (Miltenyi Biotech; >98%
purity and >98% viability), as stated by manufacturer’s
instructions.
To obtain bone marrow-derived dendritic cells (DCs),
a.er sacrifice, mice bone marrow was removed from femur
and tibia of female BALB/cmice by flushing into RPMI-1640.
Eluted cells were cultured for 5 days with 20 ng/mL of IL-4
and GM-CSF (R&D Systems, Minneapolis, MN, USA) until
approximately 70% of the cells were CD11c+.
2.2. Cell Culture. L5178Y-R cell line (murine cancerous T
lymphoblasts) was obtained from the ATCC. L5178Y-R,
primary murine CD3+, and DCs were maintained in RPMI-
1640medium supplemented with 10% of fetal bovine serum,
2mM L-glutamine, and 100U/mL penicillin-streptomycin
(GIBCO by Life Technologies, Grand Island, NY, USA), and
incubated at 37∘C in a controlled humidified atmosphere
with 5% CO2. Cell count was performed using trypan blue
(0.4% Sigma-Aldrich), a Neubauer chamber, and an optic
microscope (Zeiss Primo Star) as proposed by the ATCC’s
standard protocols.
2.3. Cell Death Analysis. Annexin-V-allophycocyanin (Ann-
V-APC 0.1#g/ml; BD Pharmingen, San Jose, CA, USA) and
propidium iodide (PI, 0.5#g/ml Sigma-Aldrich) were used
to assess phosphatidylserine exposure, cell death, and cell
viability quantification, respectively, in a BD Accuri C6 flow
cytometer (BD Biosciences, Franklin Lakes, NJ, USA) (total
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population: 10,000 cells). Data was analyzed using FlowJo
so$ware (LLC, Ashland, OR, USA). 1X106 cells/mL were
seeded and le$ untreated or treated for 2 hwith 150!Mor 300
!M of PKHB1 (KRFYVVMWKK) or 150 !M of the control
peptide 4NGG (KRFYGGMWKK) (as indicated) in serum-
free media.
For cell death inhibitions we used the calcium chelator
BAPTA (5mM), the antioxidant N-Acetyl Cysteine (NAC,
5mM), the pan-caspase inhibitors Q-VD-OPH (QVD, 10
!M) and Z-VAD-FMK (Z-VAD, 50!M), the autophagic
inhibitor Spautin-1 (SP-1, 15 !M), and the necroptotic
inhibitor Necrostatin-1 (Nec-1, 50 !M). We pretreated the
cells 30minutes with the inhibitor before the treatment with
PKHB1 (150 !M).
2.4. Calreticulin Exposure. L5178Y-R cells were plated (1x106
cells/mL), le$ untreated or treated with 300 !M of 4NGG
or 150 !M or 300 !M of PKHB1, and incubated for 2 h.
Cells were harvested, washed, and stained with Calreticulin-
Phycoerythrin (Calreticulin-PE, FMC-75; Enzo Life Science,
Farmingdale, NY, USA) antibody (1:1000) in FACS buffer.
A$er 1 h in darkness at room temperature (RT), cells were
washed and resuspended in 100!L FACS buffer (PBS 1x and
2% of fetal calf serum) to be assessed by flow cytometry in a
BD Accuri C6 flow cytometer (BD Biosciences) (total popu-
lation: 10,000 cells). Datawas analyzed using FlowJo so$ware.
2.5. DCs Markers. DCs (1 × 106 cells/mL) were stained in
100 !L of FACS buffer with the indicated antibodies at RT
for 30 minutes and then washed twice with PBS. -e cell
surface markers were evaluated by flow cytometry with the
fluorescent label-conjugated antibodies, anti-CD11c-Alexa-
fluor 488 (R&D Systems), anti-CD80-FITC, and anti-CD86-
APC, from BD Biosciences (San Jose, CA, USA).
2.6. Cocultures. DCs-PKHB1 tumor cell lysate: DCs were
resuspended in fresh medium at a concentration of 1 ×
10
6 cells/mL. DCs were le$ untreated (control), or PKHB1-
treated tumor cells were added at a concentration of 3 ×
10
6 cells/mL to give a range of 1:3 DCs to PKHB1-treated
tumor cells ratios. Coculture was le$ for 24 hours. -en the
supernatantwas removed, and thewell waswashed twicewith
PBS before doing the next coculture (with the addition of T-
lymphocytes).
DCs-T-lymphocytes: Control DCs or DCs previously
cocultured with PKHB1-TCL were maintained in fresh
medium at a concentration of 1 × 106 cells/mL. -en,
allogeneic BALB/c mCD3+ cells were added to each well at
3 × 106 cells/mL to give a range of 1:3DC to CD3+ cells ratios.
Coculture was le$ for 96 hours.-en, the lymphocytes were
collected (by obtaining the supernatant), washed with PBS,
and resuspended in freshmedium at a concentration of 5x106
cells/mL to be used in the next coculture (T- lymphocytes
with cancer cells).
T-Lymphocytes-L5178Y-R cells: viable L5178Y-R cells
were plated at a concentration of 1 × 105 cells/mL. -en,
unprimed (previously cocultured with control DCs) or
primed (previously cocultured with DCs-PKHB1-TCL) allo-
geneic BALB/c mCD3+ cells were added to each well at 5 ×
10
5 cells/mL to give a range of 1:5 tumor to effector ratios.
Coculture was le$ for 24 hours, before cytokine or calcein
assessment.
2.7. Cytokine Release Assay. -e supernatants from the indi-
cated cultures were collected for IL-2, IL-4, IL5, and TNF#
assessment (BD CBA Mouse -1/-2 Cytokine Kit, San
Jose, CA, USA) by flow cytometry following manufacturer’s
instructions. IFN$ was assessed using an ELISA kit (Sigma-
Aldrich) and using the Synergy HTTM (BioTek Instruments,
Inc., Winooski, VT, USA) plate reader at 570 nmwavelength,
following manufacturer’s instructions.
2.8. Calcein Assay. L5178Y-R cells (1 × 106 cells/mL) were
stained with (0.1!L/mL) of Calcein-AM fromBDBiosciences
(San Jose, CA) for 30minutes and washed twice (PBS sterile).
A$er this, T cells previously primed with DCs pulsed with
PKHB1-TCL or with unpulsed DC were added in a 1:5 ratio.
-e L5178Y-R-T-lymphocytes’ coculture was incubated at
37
∘C and 5%CO2 for 24 h. Finally, L5178Y-R-calcein negative
cells were assessed in a BD Accuri C6 flow cytometer (BD
Biosciences) (total population: 10,000 cells). Data was then
analyzed using FlowJo so$ware.
2.9. In Vivo Model. Six-to-eight-week-old BALB/c female
mice were maintained in controlled environmental condi-
tions (25∘C and 12 h light/dark cycle) and were supplied with
rodent food (LabDiet, St. Louis, MO, USA) and water ad
libitum.
Tumor was established by subcutaneous injections of
2x106 L5178Y-R cells in 100 !L PBS, in the le$ hind. Tumor
volume and mice weight were measured three times a
week using a caliper (Digimatic Caliper Mitutoyo Corpo-
ration, Japan) and a digital scale (American Weigh Scale-
600-BLK, USA), respectively. Tumor volume was deter-
mined with the following formula: tumor volume (mm3)
= 4%/3∗A(length)∗B(width)∗C(height). When the tumor
reached 100mm3, the first therapeutic vaccine of PKHB1-
tumor cell lysate (PKHB1-TCL) was applied as follows:
L5178Y-R cells (5x106) were treated in vitro with 300 !M
PKHB1 for 2 h (CC100) in serum-free RPMI medium. Cell
death was confirmed as previously indicated. Treated cells
were inoculated subcutaneously in 100 !l serum-free media,
in the right hind, twice a week. Controls were treated with
100 !l serum-free media.
For long memory assessment, we used six näıve mice
(control) and six mice in complete remission a$er PKHB1-
TCL treatment (tumor free >60 days). Both groups were
injected with 2x106 living L5178Y-R cells in 100!L PBS, in
the le$ hind. -e latter group was named PKHB1-TCL-
Rechallenge. We then assessed tumor volume and survival,
as described previously.
2.10. Statistical Analysis. Mice were randomly assigned to
different groups for all in vivo studies. At least three inde-
pendent experiments were repeated three independent times.
Mann-Whitney tests and two-tailed unpaired Student’s t-tests
were performed using GraphPad Prism So$ware (San Diego
CA, USA) and presented as mean values ±SD. -e ' values
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were considered significant as follows: p<0.05, p<0.01, and
p<0.001.
3. Results and Discussion
3.1. Calreticulin Exposure Correlates with Cell Death Induced
by PKHB1. ICD is characterized by DAMPs exposure or
release, and anticancer immune memory generation [24].
CRT exposure has been continuously reported as one of
the principal DAMPs necessary for the correct maturation
of DCs and antigen presentation [25, 26]. (e activation
of CD47 by PKHB1 induces CRT exposure in CLL cells
[21]. Additionally, we recently reported that PKHB1 induces
immunogenic cell death with DAMPs release (CRT, HMGB1,
HSP79, HSP90, and ATP) and CRT exposure in T -ALL
human cell lines and their murine counterpart, the L5178Y-
R cell line (a murine T cell lymphoblastic tumor cell line)
[23]. However, correlation between CRT exposure and cell
death induced by CD47 was not established; for that pur-
pose, here we assessed this feature using the L5178Y-R cell
line.
First, we assessed cell death induced by the control pep-
tide 4NGG, which does not bind to CD47 [21], and cell death
induced by different concentrations of PKHB1.We found that
4NGG (300 !M) was not able to induce cell death in L5178Y-
R cells, while PKHB1 induced a concentration-dependent cell
death, reaching CC50 (cytotoxic concentration for 50% of the
cells) at 150 !M and CC100 (cytotoxic concentration for 100%
of the cells) at 300 !M.
Next, to evaluate the characteristics of the cell death
induced by PKHB1, we used several cell death inhibitors.
We have previously demonstrated that cell death induced
through CD47 activation by PKHB1 is a fast and atypi-
cal caspase-independent and calcium-dependentmechanism
[21, 23]. (us, we assessed cell death using the calcium
chelator BAPTA, as positive control of cell death inhibition
by PKHB1, and the antioxidant NAC (N-Acetyl Cysteine)
which inhibits several cell death modalities that involve
ROS production [27]; as apoptotic pan-caspase inhibitors we
used Q-VD-OPH [28] and Z-VAD-FMK (which also inhibits
pyroptosis, [29]); we also used the autophagic inhibitor
Spautin-1 [30] and the necroptotic inhibitor Necrostatin-
1 [31]. In Figure 1(c) we can observe that that only the
calcium chelator, BAPTA, was able to inhibit PKHB1-cell
death. Effectively cell death induced by CD47 activation
seems to be mostly cytoplasmic and mediated by calcium
augmentation [21, 23], and due to the velocity of the process
it seems to be a different mechanism of cell death from the
commonly described to date.
Using 300 !M of PKHB1 for two hours induced 97%
of cell death (defined as CC100), and calreticulin exposure
was observed for 90% of the cells. (e PKHB1-tumor cell
lysate of L5178Y-R cells (PKHB1-TCL)was generatedwith this
CC100. Figure 1 describes the PKHB1-induced CRT exposure
in a PKHB1-concentration and cell death-dependent ways:
indeed, the increasing number of Ann-V-APC/PI positive
cells with increasing concentration of PKHB1 (Figures 1(a)
and 1(b)) is correlated with an increasing CRT exposure
(Figures 1(d) and 1(e)).
Calreticulin exposure and cell death have been shown
to be correlated when using various agents inducing ICD
[26], such as IMMUNEPOTENT CRP [32] and shikonin
[33]; however in some cases, CRT has been reported to be
exposed premortem [26]. We recently found that the CC100
was necessary for the highest release of HMGB1, HSP70,
and HSP90 in L5178Y-R cells [23]. (is observation led us
hypothesize that since the PKHB1-TCL is rich in DAMPs, it
might induce DCs maturation and antigen presentation to T
cells promoting antitumor responses.
3.2. PKHB1-TCL InducesMaturation of BoneMarrow-Derived
DCs. To determine if PKHB1-TCL was able to induce the
maturation of DCs, bone marrow-derived murine DCs were
le. untreated (control) or pulsed for 24 h with the previously
obtained PKHB1-TCL. We assessed cytokine production
by PKHB1-TCL, but we did not find a significant release
of TNF", IFN#, IL-5, IL-4, or IL-2 (Supplementary Table
1). A.er coculture, DCs were washed twice with PBS to
remove any background noise given by the PKHB1-TCL. DCs
cocultured with PKHB1-TCL show morphological changes
(data not shown) and a significant increase in the expression
of costimulatory molecules (CD80 and CD86) passing from
50% to 78%, while maintaining the expression of the DCs
marker CD11c (Figures 2(a) and 2(b)). Furthermore, only
DCs-PKHB1-TCLs show a significant increase in TNF"
release in comparison with unstimulated DCs (Figure 2(c)).
Several types of TCL are able to induce DCs maturation
at different degrees [8]; however most of them use LPS [33]
or other adjuvants such as phytoextracts [34] and bacterial
ghosts [35] in combination with the TCL. Our results show
that PKHB1-induced cell death is able to promote DCs mat-
uration and secretion of TNF", even in the absence of other
immune-stimulants. (e mature DC phenotype was charac-
terized by the expression of the endocytic receptor CD11c
[36], CD80, and CD86 [37], which increased significantly
(p=0.0005 and p=0.0066, respectively) in DCs cocultured
with PKHB1-TCL. We can observe a slight nonsignificant
decrease in the expression of CD11c (Figures 2(a) and 2(b));
this differentiationmarker can be downregulated by dendritic
cells a.er their activation by TLR agonists [38].(e secretion
of TNF" has been associated with a mature phenotype, as it
acts as an autocrine maturation factor for DCs [37]. Several
TCLs are able to induce its secretion at several degrees,
ranging from 20 pg/mL to 250 pg/mL [39, 40]. Here we found
that DCs pulsed with PKHB1-TCL induced the secretion of
TNF" at a 270 pg/mL concentration, indicating the efficient
maturation of DCs by PKHB1-TCL.
3.3. PKHB1-TCL Induces an Antitumor TCell Response. Once
we determined that PKHB1-TCL was able to induce DCs
maturation, we assessed if the pulsed DCs (DCs-PKHB1-
TCL) were able to prime T cells. First, CD3+ cells were
cocultured for four dayswith pulsed or unpulsedDCs, andwe
assessed TNF", IFN#, IL-5, IL-4, and IL-2 cytokine release.
Table 1 shows that coculture of pulsed DCs with primary T-
lymphocytes induces the release of TNF", IFN#, and IL-2,
while IL-5 and IL-4 release were not detected. (e secretion
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Figure 1: PKHB1 induces cell death and calreticulin exposure in L5178Y-R cell line. (a) Cell death wasmeasured by Annexin-V-allophycocyanin
(Annexin-V-APC) and propidium iodide (PI) staining and graphed. Dot plots of L5178Y-R cells untreated (control) and treated with control
peptide 4NGG (300 !M) or CC50 (150 !M) and CC100 (300 !M) of PKHB1 for 2 h. (b) Graph represents the means (±SD) of triplicates of
three independent experiments obtained as in (a). (c) Cell death induced by PKHB1was assessed as in (a) with cells le.without pretreatment
(control) or pretreated (30minutes) with BAPTA, N-Acetyl Cystein (NAC), Q-VD-OPH (QVD), Z-VAD-FMK (Z-VAD), Spautin-1 (SP-1), or
Necrostatin-1 (Nec-1). (d) Calreticulin exposure induced by 4NGG (300 !M) and PKHB1 (CC50 and CC100, 2 h) was measured using FACS
in L5178Y-R cell line, and representative histograms are shown. (e) Graph represents the means (±SD) of triplicates of three independent
experiments obtained as in (c).
of TNF", IFN#, and IL-2 is associated with a /1 phenotype
[41], which promotes an antitumor immune response [42].
Next, primed (cocultured with pulsed DCs-PKHB1-TCL)
or unprimed (coculturedwith unpulsedDCs) T-lymphocytes
were collected and cocultured during 24 hwith L5178Y-R cells
(previously stained with calcein-AM). A.er 24 h of coculture,
supernatants were obtained, and we assessed IFN#, IL-4, and
IL-2 cytokine release. A significant increase in IL-2 and IFN-
# release was observed in the supernatants of T-lymphocytes
previously cocultured with DCs-PKHB1-TCL (Figure 3).
Once we observed that PKHB1-TCL induced IFN# and
IL-2 release, suggesting /1 responses [41], we assessed
antitumor cell cytotoxicity. For this purpose, we evaluated
the loss of calcein in L5178Y-R cells. Results show that only
T-lymphocytes cocultured with pulsed DCs-PKHB1-TCL
induce a significant increase in the calcein negative L5178Y-R
cells, in comparison with the T-lymphocytes cocultured with
control DCs (not pulsed with PKHB1-TCL) (Figure 4). /is
confirms the correct antigen presentation by DCs-PKHB1-
TCL and the T cell cytotoxicity against L5178Y-R cancer cells.
Detection of IL-2, INF#, and TNF" in supernatants of
DCs and T cell cocultures indicates the establishment of an
efficient anticancer immune response./ese observations are
in agreement with the results observed in our cocultures of T
cells with DCs-PKHB1-TCL./e secretion of these cytokines
suggests a /1 phenotype [41] which was confirmed by the
loss in cell viability of L5178Y-R cells cocultured with primed
T cells.
Several cytotoxic agents have been demonstrated to
induce ex vivo antitumor T cell responses, such as borte-
zomib in myeloma [43] and doxorubicin in colon carcinoma
[44]. Also the allogeneic off-the-shelf dendritic cell vaccine,
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Bone marrow-derived murine DCs were le/ with medium alone (DCs-control) or pulsed (DCs-PKHB1-TCL) during 24h with a PKHB1-TCL.0en, DCs were
cocultured during 4 days with T-lymphocytes, and the supernatants were collected to quantify TNF!, IFN", IL-5, IL-4, and IL-2 release, by FACS. Numbers










































































































































Figure 2: PKHB1-tumor cell lysate induces the maturation of bone marrow-derived dendritic cells. (a) Bone marrow-derived murine DCs were
le/ only withmedium (control) or pulsed during 24 hwith a PKHB1-TCL. DCs were then stained to assess cell surfacemarkers (CD11c, CD80,
or CD86) by FACS, and representative histograms are shown. (b) DCs were treated as in (a) and the means obtained by FACS were graphed.
(c) DCs were treated as in (a) and the supernatants were collected to quantify TNF! release, by FACS. Graphs represent the means (±SD) of
triplicates of at least three independent experiments.
currently in clinical trials for acutemyeloid leukemia [45], has
demonstrated these responses ex vivo and in vivo in patients.
3.4. PKHB1-TCL Induces Tumor Regression. Once we estab-
lished the ex vivo antitumor immune response induced by
PKHB1-TCL, we assessed if the in vivo injection of PKHB1-
TCL was able to diminish tumor growth and improve overall
survival in syngeneic mice transplanted with L5178Y-R cells.
First 2x106 L5178Y-R cells were inoculated in BALB/c mice.
When the tumor reached 100mm3, a mice control-group was
le/ without treatment (Control; n = 7), and a second group
was treated with PKHB1-TCL two times per week (PKHB1-
TCL; n = 9) (Figure 5(a)). Tumor growth was measured: we
observed that PKHB1-TCL-treated mice showed significantly
diminished tumor growth a/er day 10 (7 days a/er the first
treatment), which continued to decrease until no tumor was
detected by day 30 (Figure 5(b)). Tumor growth diminution
was reflected in overall mice survival, as PKHB1-TCL-treated
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Figure 3: IFN-! and IL-2 secretion by unprimed or primed T cells cocultured with L5178Y-R cells. (a) L5178Y-R cells were cocultured with
unprimed T-lymphocytes (previously cocultured with unstimulated DCs-Control) or primed T-lymphocytes (previously cocultured with
pulsed DCs-PKHB1-TCL) in a 1:5 tumor to effector ratio, for 24 h, and the supernatants were collected and assayed for (a) IFN-! release by













































































Figure 4: Primed T cells’ cytotoxicity in L5178Y-R cells. (a) L5178Y-R cells were stained with calcein-AM and cocultured with unprimed
T-lymphocytes (previously cocultured with unstimulated DCs-Control) or primed T-lymphocytes (previously cocultured with pulsed DCs-
PKHB1-TCL) in a 1:5 tumor to effector ratio for 24 h..e percentage of L5178Y-R calcein negative cells was assessed by FACS; representative
histograms are shown. (b) Graphs represent the means (±SD) of triplicates of three independent experiments obtained as in (a).
mice presented an 80% of survival over time (more than 150
days), while all control mice perished by day 11 (Figure 5(c)).
To assess immunological memory against tumor antigens
a0er PKHB1-TCL-treatment, mice in complete remission
(tumor free >60 days) were rechallenged with living L5178YR
cells. Compared to näıve mice (control), in which a primary
L5178YR cell challenge resulted in rapid tumor progression,
those that were in remission were completely resistant to
a rechallenge of L5178YR cells (Figure 6(a)). Furthermore,
as no tumor developed, we observed a 100% of survival of
the PKHB1-TCL-Rechallenged mice while all control mice
perished by day 12 (Figure 6(b)).
It has been proved that other TCLs reduce tumor volume
in different types of cancer, as, for example, combined with
CpG in a glioblastoma mouse tumor model [46]. Addition-
ally, in clinical trials TCLs have been tested in melanoma,
prostate, mesothelioma, ovarian, and colorectal cancers [8].
.ese TCLs are usually produced using radiation, repeated
freezing, and thawing, among others. Here we show that
PKHB1-CD47 activation, which has been shown to effectively
induce cell death in different types of cancer [21, 22], includ-
ing cells coming from refractory patients [21, 22], can provide
an immunogenic TCL which is able to promote an antitumor
immune response, even in the absence of adjuvants.
Interestingly, we observed that tumor volume began to
diminish 7 days a0er the first administration of PKHB1-
TCL reaching tumor regression by day 28 (Figure 5(c))..is
waiting time corresponds with the time needed for T cells to
expand and activate an antitumor immune response [47].
Other types of TCL have been able to induce tumor
regression, increasing the survival rate in patients with
melanoma and prostate cancer [8]; however, they do so only
in combination with adjuvants, such as the case of CpG
oligodeoxynucleotides, which are TLR9-agonist [46].
We recently demonstrated that PKHB1 treatment of
tumor-bearing mice induced long-term tumor prevention
in 90% of the mice that presented complete tumor regres-
sion [23]. Here we demonstrated that PKHB1-TCL induces
long-term immunological memory against tumor antigens,
preventing tumor establishment in 100% of the mice a0er
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Figure 5: PKHB1-TCL treatment in L5178Y-R-tumor-bearing mice induce tumor regression. (a) Schema of PKHB1-TCL (5 × 106 CC100 PKHB1-
treated L5178Y-R cells) treatment started when tumor reached 100mm3, and then PKHB1-TCL was administrated every 3 days for two weeks
(for a total of four injections). (b) Graph indicates tumor volume (±SD) of untreated mice (control; n = 7) or PKHB1-TCL-treated mice


















































Figure 6: PKHB1-TCL therapeutic vaccination induces long-term antitumor memory. Mice in remission a.er therapeutic vaccinations were
rechallenged with 2x106 L5178Y-R viable cells. (a) Graph indicates tumor growth in control mice (control, n = 6) or mice in remission a.er a
previous treatment with PKHB1-TCL that were rechallenged with living L5178Y-R cells (PKHB1-TCL-Rechallenge, n= 6). (b) Kaplan-Meier
survival graph of mice treated as in (a) over time. Control: n = 6; PKHB1-TCL-Rechallenge, n= 6.
L5178YR cells rechallenge (Figure 6). 0is underlines the
immunogenicity of CD47-mediated cell death, when admin-
istering a CD47 agonist peptide or CD47-killed cells. 0is
long lasting immunological memory has been promoted also
by a TCL obtained by repeated freezing and thawing and
radiation-treated glioma cells, where nearly a 100%of survival
was observed [48].
Although immunotherapy with pulsed DCs, primed T-
lymphocytes, or CAR-T cells is the principal approach used to
stimulate antitumor immune responses, here we demonstrate
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Figure 7: Schematic representation of CD47-mediated immunogenic cell death in vitro, ex vivo, and in vivo. PKHB1 induces selective ICD
in L5178Y-R cell line leading to damage-associated molecular patterns (DAMP) release. DAMPs promote dendritic cell (DC) maturation
and subsequence antigen presentation and T cell activation to induce cancer cell death. Moreover, PKHB1-treated cells administrated as a
therapeutic vaccine induce tumor regression in syngeneic mice bearing L5178Y-R tumors. CRT, calreticulin; HMGB1, high-mobility group
box 1; HSP, heat shock protein; ICD, immunogenic cell death; TSP-1, thrombospondin-1.
that the crude TCL obtained fromPKHB1 treatment is able to
induce tumor regression in 80%of themice, while preventing
tumor establishment in 100% of the rechallenged mice that
survived a,er PKHB1-TCL-treatment.
4. Conclusions
In this work we determined that the ICD induced by the
CD47-agonist peptide, PKHB1, has a therapeutic potential,
as the PKHB1-TCL was able to induce antitumor immune
responses ex vivo and in vivo in an established L5178Y-
R tumor. .is was done by promoting the maturation of
DCs, which trigger T cell antitumor effects, including INF!
release and L5178Y-R cell cytotoxicity, leading to tumor
regression (Figure 7). Additionally, PKHB1-TCL-treatedmice
developed long-term immunological memory. .ese results
highlight the immunogenicity of the cell death induced by
CD47 activation by PKHB1 as a potential therapeutic tool to
overcome the low immunogenicity of cancer cells, such as T-
ALL.
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Supplementary Table 1. TNF , IFNγ, IL-5, IL-4, and IL-2 cytokine release by PKHB1-
tumor cell lysate. L5178Y-R cells were treated for 2h with PKHB1(300μM) and the 
supernatants were collected to quantify TNF , IFNγ, IL-5, IL-4, and IL-2 release, by FACS. 
 

















2. Study of the Mechanism of Immunogenic Cell Death induced 
by PKHB1 in breast cancer 
The results in the present chapters gave rise to a patent: EP3650036A1, held by Sorbonne 
Université and Universidad Autónoma de Nuevo León. 
 
2.1. Article 3. PKHB1, a thrombospondin-1 peptide-mimic, induces 
antitumor effect through immunogenic cell death induction in 




Many therapies can activate molecular pathways in cancer cells that guide them to 
self-destruct in a regulated fashion. However, not all these therapies succeed to activate 
the host’s anti-tumor immune system to combat the disease. These immunologically silent 
outcomes during cell death induction are largely responsible of the selective pressure in 
the tumor microenvironment that results in relapse of treatment-resistant cancer cell sub-
clones. 
In the opposite case, therapies able to lead cancer cells to additionally generate 
adjuvant molecules while dying (i.e., DAMPs) can generally awake the host’s anti-tumor 
immune system to recognize these cells as antigenic, fight them, and generate 
immunological memory (Galluzzi et al., 2016). Therapies able to tigger such ICD largely 
account for the long-term success of many anticancer treatments. 
As mentioned in the previous chapter, our team had recently reported the ability of 
PKHB1, a serum-stable peptide-mimic of the thrombospondins C-terminus, to induce ICD 
in  T-ALL, as proved in vitro, ex vivo and in vivo. The caspase-independent, calcium-
dependent, regulated cell death mechanism activated by PKHB1 in T-ALL was similar to 
that described by the same peptide in chronic lymphocytic leukemia (Martinez-Torres et 
al., 2015). Moreover, PKHB1 had demonstrated to efficiently kill cell lines from breast, 
lung and colon cancer (Denèfle et al., 2016). Therefore, it was assessed whether PKHB1 
could induce ICD in other, non-leukemic types of cancer as well.  
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2.1. PKHB1, a thrombospondin-1 peptide-mimic, induces antitumor 
effect through immunogenic cell death induction in breast cancer cells 
 
Article to be submitted for publication at “Journal for Immunotherapy of Cancer” 
in July, 2021 
 
Breast cancer is the most common type of cancer worldwide, and the triple-negative 
phenotype represents a highly aggressive and therapy-resistant type of cancer. To evaluate 
whther PKHB1 could induce ICD in breast cancer cells as it did in T-ALL, the human cell 
lines MCF7 and the triple-negative MDA-MB-231, as well as its murine homolog 4T1, 
were used. Breast cancer cells were cultured in presence of PKHB1, and different 
parameters related to cell death were assessed by flow cytometry, using fluorescent probes 
(Ann-V-APC for phosphatidylserine exposure; PI for plasma membrane permeability; 
TMRE, to stain mitochondria with intact membrane potential; hydroetidine for 
intracellular reactive oxygen species, ROS; and Fluo-4, intracellular calcium 
concentration). In the three cases PKHB1 induced dose-dependent cell death, as shown 
by an increased Ann-V-APC and PI staining. PKHB1-induced cell death provoked the 
loss of the mitochondrial membrane potential, ROS production, and increased 
intracellular calcium concentration, as shown by loss of TMRE staining, and high 
hydroetidine and Fluo-4 staining, respectively. Pharmacological inhibition of the 
molecular initiators of apoptosis (Z-VAD), necroptosis (NEC-1) or autophagy (SP-1) did 
not prevent cell death in any case. However, an extracellular calcium chelator (BAPTA) 
prevented cell death, and pre-incubation of cells with inhibitors of PLC (U73122) and 
intracellular calcium channels (dantrolene and 2-APB) significantly reduced cell death. 
Altogether this suggests that PKHB1 induces a regulated cell death subroutine similar to 
that induced in CLL and T-ALL. 
To test the in vivo potential of PKHB1 treatment, 4T1 cells were implanted in 
immunocompetent (BALB/c) mice. Three days after inoculation, tumors reached 100 mm3 
and mice were subjected to a daily treatment with vehicle (control group) or PKHB1, and 
tumor volume was measured until day 16, when the experiment was put to an end as mice 
in the control group needed to be euthanized. PKHB1 reduced tumor growth after one 
 113 
week, and by the time of sacrifice tumor volumes were significantly reduced. 
Histopathology analyses showed that tumors in PKHB1-treated mice showed cell debris 
and immune cells infiltration. Compared to the control group, the blood of PKHB1-treated 
mice had a greater amount of T (CD3+) cells, maintaining a similar percentage of helper 
T (CD3+/CD4+) cells and a significantly higher amount of cytotoxic T (CD3+/CD8+) cells. 
All T cell populations were similar in the spleens of both groups. The lymph nodes of 
PKHB1-treated mice had significantly higher proportion of CD3+ cells, and although CD4+ 
populations were also higher, CD8+ populations were lower. Finally, more CD3+ cells were 
found in the tumors of PKHB1-treated mice, with significantly lower CD4+ populations 
and higher CD8+ populations. 
Based on these previous results, it was hypothesized that PKHB1 could induce ICD 
in breast cancer cells as it does in T-ALL. To assess this, first, 4T1, MDA-MB-231 and 
MCF7 cells were cultured in presence of PKHB1, and production of DAMPs was 
evaluated. Exposure of calreticulin, HSP70 and HSP90 to the membranes of live cells was 
measured by flow cytometry, and in the case of calreticulin, confirmed by fluorescence 
microscopy. Release of HMGB1 and ATP was measured by ELISA and by luciferase 
assays, respectively, in cell-free supernatants. Compared to untreated and to IgG controls, 
4T1, MDA-MB-231 and MCF7 cells treated with PKHB1 showed a significant increase 
in calreticulin-, HSP70- and HSP90-related fluorescence intensity, and supernatants of 
PKHB1-treated cells had significantly higher levels of HMGB1 and ATP, indicating that 
PKHB1 treatment induces DAMPs production in breast cancer cells. 
Next, ex vivo experiments were performed. Mouse bone marrow-derived DC were 
cultured alone or co-cultured with 4T1 cells killed by PKHB1 (PKHB1-TCL). After 24 h 
co-culture, compared to non-exposed DC, DC exposed to PKHB1-TCL expressed 
significantly higher levels of maturation markers CD80 and CD86, maintaining DC 
marker CD11c levels. In addition, higher TNFa concentrations were found in supernatants 
of DC co-cultured with PKHB1-TCL, suggesting that DC pulsed with PKHB1-TCL 
maturated to a pro-inflammatory phenotype. 
The ability of PKHB1-TCL-pulsed DC to prime T cells, was evaluated in following 
experiments using T cells extracted from mouse blood, which were left alone (unprimed) 
or co-cultured with PKHB1-TCL-pulsed DC (primed). These T cells, were then co-
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cultured with 4T1 cells to compare their cytokine release and cytotoxic activity. Compared 
to those of their unprimed counterparts, supernatants of 4T1 co-cultures with primed T 
cells had higher concentrations of IFNy and IL-2, and similar IL-4 concentration, 
suggesting a Th1 response phenotype. To perform the T cell cytotoxicity experiments, 
viable 4T1 cells were stained with calcein and either left alone, or co-cultured with 
unprimed or primed T-cells. Compared to 4T1 cells cultured alone or co-cultured with 
unprimed T cells, a significantly higher proportion of 4T1 cells that were co-cultured with 
PKHB1-TCL-pulsed DC-primed T cells lost their calcein staining, indicating T-cell 
cytotoxicity against 4T1 tumor cells. 
Prophylactic vaccination is the goldstandard to evaluate ICD (Kroemer et al., 
2013a). To this end, mice were immunized with tumor cell lysates (TCL) obtained by in 
vitro treatment with PKHB1 or with a known ICD inducer in breast cancer, epirubicin 
(EPI), used as positive control. One week after, mice were inoculated with viable cancer 
cells and tumor burden was monitored. The tumors grew in non-inoculated control mice, 
killing all of them in 20 around days. In contrast, immunizations with PKHB1-TCL or 
with EPI-TCL prevented correct tumor establishment in most mice, reflected in higher 
survival rates. 
As we witnessed the strong immune responses triggered by the PKHB1-TCL, we 
wondered if using PKHB1-TCL as therapeutic cancer vaccine for mice that were already 
sick, could have an impact on tumor progression. To assess this, the mice were inoculated 
with viable cancer cells, and waited for tumors to reach 100 mm3, to then treat with vehicle, 
PKHB1-TCL or EPI-TCL. All mice being treated with vehicle had to be euthanized before 
day 23 as the disease progressed with tumor growth. Conversely, in mice treated PKHB1-
TCL or with EPI-TCL, most of the tumors stopped growing after four applications of the 
therapeutic immunization, leading to cancer remission and an overall increased survival. 
Finally, long-term immunological memory of immunized mice against 4T1 cells 
was assessed. For this, the mice that had undergone complete remission after prophylactic 
or therapeutic vaccination with PKHB1-TCL (>60 days of being tumor free), or naïve 
mice of similar ages (control), were (re)challenged with live 4T1 cells, and tumor growth 
was measured. In all controls, the tumors grew and mice died before day 23, while none 
of the immunized mice developed the tumors, reaching 100% 60-days survival after re-
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challenge. Furthermore, 4T1 cells were stained with calcein and co-cultured with 
splenocytes obtained from naïve mice or from mice in remission, and after 24 h co-culture, 
there was a significantly higher ratio of calcein-negative 4T1 cells that were co-cultured 
with the long-immunized mice. 
Altogether, these results demonstrate that PKHB1 induces ICD in breast cancer 
cells, and strongly support the use of PKHB1 and PKHB1-TCL as therapeutic tools to 
treat breast cancer, including the triple negative phenotype.
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Résumé de l’article 3 
 
Arrière-plan. Le cancer du sein est le cancer le plus fréquemment diagnostiqué et la 
principale cause de décès par cancer chez les femmes dans le monde. Les progrès récents 
dans le domaine de l'onco-immunologie démontrent les effets immunostimulateurs 
bénéfiques de l'induction de la mort cellulaire immunogène (CIM). Le CIM augmente 
l'infiltration tumorale par les cellules T et est associé à un meilleur pronostic chez les 
patientes atteintes d'un cancer du sein triple négatif (CBNT) avec maladie résiduelle. Le 
but de cette étude était d'évaluer l'effet antitumoral du peptide mimétique de la 
thrombospondine-1, PKHB1, contre les cellules cancéreuses du sein, et l'immunogénicité 
de la mort cellulaire induite par PKHB1 in vitro, ex vivo et in vivo. 
Méthodes. Les caractéristiques de la mort cellulaire ont été évaluées par cytométrie en 
flux en utilisant des inhibiteurs de mort cellulaire. L'effet antitumoral de PKHB1 a été 
évalué en observant le volume de la tumeur, le poids et la distribution des lymphocytes 
(in vivo). Les caractéristiques de la mort cellulaire immunogène ont été évaluées, in vitro, 
par l'exposition ou la libération de modèles moléculaires associés aux dommages 
(DAMP), et leur effet dans l'activation d'une réponse immunitaire antitumorale (ex vivo). 
De plus, in vivo, l'immunogénicité de la mort a été déterminée par l'évaluation de la 
capacité des cellules cancéreuses tuées par PKHB1 (PKHB1-TCL) à empêcher 
l'établissement de tumeurs des cellules cancéreuses du sein, ainsi que leur capacité à 
générer un anti -mémoire immunologique tumorale. 
Résultats. Nos résultats ont montré que PKHB1 induit des altérations mitochondriales, la 
production de ROS, l'accumulation intracellulaire de Ca2 + ainsi que la mort cellulaire 
dépendante du calcium dans les cellules cancéreuses du sein, y compris les sous-types 
triple négatifs. Le traitement in vivo par PKHB1 induit une réduction du volume et du 
poids de la tumeur et favorise l'infiltration intratumorale des lymphocytes T CD8 +. De 
plus, PKHB1 est capable d'induire une exposition à la calréticuline (CRT), une libération 
d'ATP et de HMGB1. De plus, le lysat de cellules tumorales obtenu par le traitement avec 
PKHB1 (PKHB1-TCL) induit la maturation des cellules dendritiques et la réponse 
antitumorale des cellules T. Enfin, PKHB1-TCL a pu induire une réponse antitumorale 
contre les cellules cancéreuses du sein dans une application prophylactique et 
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thérapeutique in vivo et les deux applications de la mémoire antitumorale à long terme 
induite par PKHB1-TCL. 
Conclusions. 
Le peptide mimétique de la thrombospondine-1, PKHB1, a un effet antitumoral et induit 
l'activation du système immunitaire par induction de la mort cellulaire immunogène dans 
les cellules cancéreuses du sein.
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Resumen del artículo 3 
 
Antecedentes. El cáncer de mama es el cáncer que se diagnostica con más frecuencia y la 
principal causa de muerte por cáncer en mujeres en todo el mundo. Los avances recientes 
en el campo de la oncoinmunología demuestran los efectos inmunoestimuladores 
beneficiosos de la inducción de la muerte celular inmunogénica (MCI). La MCI aumenta 
la infiltración tumoral por las células T y se asocia con un mejor pronóstico en pacientes 
afectadas por cáncer de mama triple negativo (TNBC) con enfermedad residual. El 
objetivo de este estudio fue evaluar el efecto antitumoral del PKHB1, un péptido mimético 
de la trombospondina-1, contra células de cáncer de mama, y la inmunogenicidad de la 
muerte celular inducida por PKHB1 in vitro, ex vivo e in vivo. 
Métodos. Las características de la muerte celular se evaluaron mediante citometría de flujo 
utilizando inhibidores de la muerte celular. Se evaluó el efecto antitumoral de PKHB1 
observando el volumen tumoral, peso y distribución de linfocitos. La MCI se evaluó, in 
vitro, mediante la exposición o liberación de patrones moleculares asociados a daño 
(DAMP) y su efecto en la activación de una respuesta inmune antitumoral (ex vivo). 
Además, in vivo, la inmunogenicidad de la muerte se determinó mediante la evaluación 
de la capacidad de las células cancerosas muertas por PKHB1 (PKHB1-TCL) para 
prevenir el establecimiento tumoral e inducir la regresión tumoral de las células de cáncer 
de mama trasplantadas, así como su capacidad para generar una memoria inmunológica 
antitumoral a largo plazo. 
Resultados. Nuestros resultados mostraron que PKHB1 induce alteraciones 
mitocondriales, producción de ROS, acumulación de Ca2+ intracelular y muerte celular 
dependiente de calcio en células de cáncer de mama, incluidos subtipos triple negativos. 
PKHB1 tiene un efecto antitumoral in vivo que conduce a la reducción del volumen y 
peso del tumor y promueve la infiltración de células T CD8+ intratumoralmente. PKHB1 
es capaz de inducir calreticulina (CRT), exposición a HSP70 y HSP90, liberación de ATP 
y HMGB1. Además, el lisado de células tumorales obtenido por el tratamiento con 
PKHB1 indujo la maduración de las células dendríticas y las respuestas antitumorales de 
las células T. Finalmente, PKHB1-TCL fue capaz de inducir una respuesta antitumoral 
contra las células de cáncer de mama in vivo, en una aplicación profiláctica, mientras que 
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en un entorno terapéutico indujo la regresión del tumor; ambas aplicaciones indujeron 
memoria antitumoral a largo plazo. 
Conclusiones. 
El péptido mimético de la trombospondina-1, PKHB1, tiene un efecto antitumoral in vivo 
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Background. Breast cancer is the most commonly diagnosed cancer and the leading cause 
of cancer death in women worldwide. Recent advances in the field of immuno-oncology 
demonstrate the beneficial immunostimulatory effects of immunogenic cell death (ICD) 
induction. ICD increases tumor infiltration by T cells and is associated with improved 
prognosis in patients affected by triple-negative breast cancer (TNBC) with residual 
disease. The aim of this study was to evaluate the antitumoral effect of PKHB1, a 
thrombospondin-1 peptide mimic, against breast cancer cells, and the immunogenicity of 
the cell death induced by PKHB1 in vitro, ex vivo and in vivo. 
Methods. Characteristics of cell death were evaluated by flow cytometry using cell death 
inhibitors. The antitumoral effect of PKHB1 was evaluated observing the tumor volume, 
weight and lymphocytes distribution. Characteristics of immunogenic cell death were 
evaluated, in vitro, by the exposure or release of damage associated molecular patterns 
(DAMPs), and their effect in the activation of an antitumor immune response (ex vivo). In 
addition, in vivo, the immunogenicity of death was determined through the evaluation of 
the capacity of cancer cells killed by PKHB1 (PKHB1-TCL) to prevent tumor 
establishment of breast cancer cells, as well as their capacity to generate a long-term anti-
tumor immunological memory.  
Results. Our results showed that PKHB1 induces mitochondrial alterations, ROS 
production, intracellular Ca2+ accumulation as well calcium-dependent cell death in breast 
cancer cells, including triple-negative subtypes. PKHB1 has antitumor effect in vivo 
leading to tumor volume and weight reduction and promotes intratumorally CD8+ T cell 
infiltration. Furthermore, PKHB1 is able to induce calreticulin (CRT), HSP70 and HSP90 
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exposure, ATP and HMGB1 release. Additionally, the tumor cell lysate obtained by the 
treatment with PKHB1 induced dendritic cell maturation, and T cell antitumor responses. 
Finally, PKHB1-TCL in vivo was able to induce an antitumor response against breast 
cancer cells in a prophylactic application, whereas in therapeutic setting induced tumor 
regression and both applications induced long-term antitumor memory.   
 
Conclusions.  
PKHB1, a Thrombospondin-1 peptide mimic, has in vivo antitumor effect and induce 





Breast cancer is the most frequent type of cancer among women; its innate and 
acquired treatment-resistance to current therapies is the principal problem to treat it, 
causing the greatest number of cancer-related deaths. While systemic therapies have 
increased the survival rates of breast cancer patients, the dramatic variations in response 
rates of patients with distinct clinicopathologic parameters (1), as well as innate or 
acquired resistance to current therapies (2), make relevant the search for new effective 
treatments on the different molecular subtypes of breast cancer, in particular those 
associated with poor prognosis. 
Recently several clinical studies have demonstrated the beneficial immunostimulatory 
effects of immunogenic cell death (ICD) induction (3), recognized as a critical 
determinant for the efficiency of cancer therapies. Indeed, this peculiar cell death type is 
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capable of stimulating a long-term anti-tumor immune response against dead cancer cell 
antigens (4). Additionally, inducing ICD increases tumor tissues infiltration by T cells, 
which plays an essential role in mediating a positive response to chemotherapy and is 
associated with improving clinical outcomes in all subtypes of breast cancer (3,5). 
Recent reports by our group demonstrate that PKHB1, a peptide mimic of 
thrombospondin-1 (TSP-1), stable in the serum of mice and human, induces a cell death 
involving CD47 activation, in different cancer cells, especially in hematological 
malignancies (6–9). The ability of PKHB1 to induce cell death was also observed in 
leukemic cells from patients with aggressive and chemo-resistant phenotypes (6–9). 
Additionally, our group demonstrated that PKHB1 induces ICD in T cell acute 
lymphoblastic leukemia (8), and that PKHB1-tumor cell lysate was able to induce 
complete tumor reduction and immunological memory against leukemic cells (10). 
However, little is known about the cell death mechanism, the immunogenicity and the 
antitumor effect of PKHB1 in solid cancers with different molecular characteristics and 
poor prognosis such as breast cancer (including the triple negative subtype). 
Therefore, the aim of this study was to evaluate the antitumor potential of PKHB1 in breast 
cancer cells (in vitro and in vivo) including triple negative subtypes, and to determine if it 




PKHB1 and 4NGG peptides were synthesized manually, using Fmoc-protected amino 
acids and standard solid phase peptide synthesis (SPPS) methods, as described previously 
(6). The detailed methods are described in supplemental material and methods. 
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Cell culture.  
MCF-7, MDA-MB-231 and 4T1 cell lines were obtained from the ATCC. MCF-7 and 
MDA-MB-231 cell lines were maintained in DMEM-F12 medium (GIBCO by Life 
Technologies, Grand Island, NY, USA), while 4T1 cell line was maintained in RPMI-
1640 medium., both were supplemented with 10% of fetal bovine serum, 2mM L-
glutamine, 100U/mL penicillin-streptomycin (GIBCO by Life Technologies, Grand 
Island, NY, USA), and incubated at 37ºC in a controlled humidified atmosphere with 5% 
CO2. Cell count was performed following the ATCC’s standard protocols. 
 
Cell death induction and inhibition analysis. 
 5x104 cells were plated in 24 wells dishes and left untreated or treated for 2h with 100 
μM, 200 μM or 300 μM of PKHB1 (KRFYVVMWKK) or 300 μM of the control peptide 
4NGG (KRFYGGMWKK). Annexin-V-allophycocyanin (Ann-V-APC 0.1μg/ml; BD 
Pharingen, San Jose CA, USA), and propidium iodide (PI, 0.5μg/ml Sigma-Aldrich) were 
used to assess phosphatidylserine exposure, cell death, and cell viability quantification, 
respectively, in a BD AccuryC6 flow cytometer (BD Biosciences, Franklin Lakes, NJ, 
USA) (total population 10,000 cells). Data was analyzed using FlowJo software (LLC, 
Ashland, OR, USA). 
To decipher the cell death signaling pathway, the calcium chelator BAPTA (5 mM), the 
pan-caspase inhibitor Z- VAD-FMK (Z-VAD, 50μM), the antioxidant N-Acetyl Cysteine 
(NAC, 5 mM), the necroptotic inhibitor Necrostatin-1 (Nec-1, 50 μM), the autophagic 
inhibitor spautin-1 (SP-1, 15 μM), the PLC inhibitor U73122 (1.25 μM) and the ER 
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receptor inhibitors dantrolene (50 μM) and 2-aminoethoxydiphenyl borate (2-APB, 40 
μM) were used. Cells were treated 30 minutes with the different inhibitors or the calcium 
chelator before treatment with PKHB1 (CC50).  
Intracellular Ca2+ levels assay. 
5x104 cells/well in 24 wells dishes (Life Science) were incubated 2h with PKHB1 (CC50) 
or left untreated in complete medium. Then, cells were detached, washed with KREBS 
buffer, and resuspended in 200μL of RINGER buffer with 0.001µg/mL of Fluo-4 AM 
(Life Technologies) and 0.001 µg/mL of Pluronic F-127 (Life Technologies), incubated 
37ºC for 30min. Next, cells were washed with RINGER buffer and assessed by BD 
Accury C6 flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) (total population 
10,000 cells). 
 
In vivo model. 
This study was approved by the Animal Ethical Committee (CEIBA), of the School of 
Biological Sciences, number: CEIBA-2018-003. All experiments were conducted 
according to Mexican regulation NOM-062-ZOO-1999. Female BALB/c mice (six-to-
eight-week-old; 22±2g weight) were maintained in controlled environmental conditions 
(25ºC and 12 h light/dark cycle) and supplied with rodent food (LabDiet, St. Louis, MO, 
USA) and water ad libitum, and they were monitored daily for health status. Mice were 
randomly assigned to different groups for all studies. 
Tumor establishment. 
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5x105 live 4T1 cells in 100 μL of PBS were injected subcutaneously in the left hind. 
Tumor volume and mice weight were measured three times per week using a caliper 
(Digimatic Caliper Mitutoyo Corporation, Japan) and a digital scale (American Weigh 
Scale-600-BLK, USA), respectively. Tumor volume was determined with the formula: 
tumor volume (mm3) = (Length x width2)/2. When tumor reached 100 mm3, mice were 
treated daily with 400μg of PKHB1 in 200μL of sterile water by intraperitoneal injection, 
control mice were treated with 200μL of sterile water. Additionally, 16 days after tumor 
cells inoculation, mice were anaesthetized with an intraperitoneal injection of ketamine 
(80 mg/kg body weight) and xylazine (10 mg/kg body weight) and were euthanized by 
cervical dislocation, and tumors from Control or PKHB1 treated mice, were obtained and 
fixed in 3.7% neutral formalin, embedded in paraffin, sectioned (5 μm thickness) and 
stained with H&E (MERCK). Histopathological analyses were done by an external 
veterinarian pathologist (National professional certificate 2593012).  
T cells evaluation.   
16 days after tumor inoculation, mice treated or untreated were anaesthetized and 
sacrificed as described above. Blood was obtained by cardiac puncture and the peripheral 
blood mononuclear cells (PBMCs) isolation was performed by density gradient 
centrifugation using Ficoll-Hypaque-1119 (Sigma-Aldrich, St Louis, MO, USA). The 
spleen, lymph node and tumor were harvested and filtered through a cell strainer (70µM) 
with PBS (PBMCs were obtained from the spleen as described above), then 1x106 
cells/mL were plated and the percent of CD3+, CD4+ and CD8+ T cells was observed by 
flow cytometry with the Mouse T lymphocyte subset antibody cocktail (from BD 
Bioscience), following the manufacturer’s instructions. 
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Calreticulin, HSP70 and HSP90 exposure. 
5x104 cells/well were plated in 24-well plates and treated with PKHB1 (CC50) for 2h. 
Then, cells were detached, washed and incubated for 1h at (room temperature) RT with 2 
μg/mL of anti-Calreticulin (FMC-75, Enzo Life Science), 0.8 μg/mL anti-HSP70 (F-3, 
Santa Cruz Biotechnology), 0.8 μg/mL anti-HSP90 (F-8, Santa Cruz Biotechnology) in 
FACS buffer, cells were washed and incubated for 30 min in darkness at RT with goat 
anti-mouse IgG (Alexa Fluor 488) (H + L, Life Technologies) (1:1500) in FACS buffer, 
cells were then washed, resuspended in FACS buffer with 7-AAD (Life Technologies) 
(1:1000) and incubated in the dark for 10min at RT. The surface exposure of CRT, HSP70 
and HSP90 was determined by flow cytometry among viable (7-AAD-negative) cells. 
 
Immunofluorescence microscopy. 
2.5x105 cells/well in a 6 well dishes were left untreated (Control) or treated with PKHB1 
(CC50) and incubated for 2h. Then, cells were washed with PBS and stained with 
Calreticulin-PE antibody (2μg/ml) and Hoechst 33342 (0.5μg/ml) (Thermo Scientific 
Pierce, Rockford, IL, USA), incubated for 1h in FACS buffer at RT, thus, cells were 
washed twice, maintained in PBS and assessed by confocal microscopy (Olympus X70; 
Olympus, Tokyo, Japan). 
 
ATP and High-mobility group box 1 release assay. 
2.5x105 cells/well in a 6 well dishes were left untreated (Control) or treated with PKHB1 
(CC50) for 2h. Supernatants were recovered, centrifuged at 1600rpm/10 minutes and used 
to assess extracellular ATP by a luciferase assay (ENLITEN kit, Promega, Madison, WI, 
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USA), or used to measure extracellular HMGB1 using the HMGB1 ELISA kit for MDA-
MB-231, MCF-7 and 4T1 cells (BioAssay ELISA kit human or mouse, respectively; US 
Biological Life Science Salem, MA, USA) following the manufacturer’s instructions. 
Bioluminescence was assessed in a microplate reader (Synergy HT, Software Gen5; 
BioTek, Winooski, VT, USA) at 560 nm, and absorbance was assessed at 450 nm. 
 
T-cells isolation. 
Mice were anaesthetized and sacrificed as described above, and blood was obtained by 
cardiac puncture. PBMCs isolation was obtained as described above. Murine CD3+ cells 
were isolated from total PBMCs by positive selection using magnetic-activated cell 
sorting (MACS) microbead technology with anti-CD3e-biotin and anti-biotin microbeads 
(Miltenyi Biotech; >98% purity and >98% viability), as stated by manufacturer’s 
instructions. 
 
Differentiation of bone marrow derived dendritic cells (BMDCs). 
After sacrifice of anaesthetized mice, bone marrow was removed from femur and tibia by 
flushing into RPMI-1640. Eluted cells were cultured for 5 days with 20ng/mL of IL-4 and 
GM-CSF (R&D Systems, Minneapolis, MN, USA) until approximately 70% of the cells 
were CD11c+. 
 
Evaluation of DCs maturation.  
CD11c, CD80 and CD86 were evaluated by flow cytometry with the fluorescent label-
conjugated antibodies, antiCD11c-Alexa-fluor 488 (R&D Systems), antiCD80-FITC and 
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antiCD86-APC, from BD Biosciences (San Jose, CA, USA). 1x106 DCs /mL were stained 
in 100µL of FACS buffer with the indicated antibodies at RT for 30 minutes and then 
were washed twice with PBS, centrifugated at 1600rpm/10min and resuspended in 100μl 
of FACS buffer. 
 
DCs + PKHB1 tumor cell lysate co-culture. 
DCs were resuspended in fresh medium (1x106 cells/mL), left untreated (control) or 
incubated with 3x106 4T1 cells/mL of PKHB1-tumor cell lysate, to give a range of 1:3 
(DCs to PKHB1-tumor cell lysate) and co-culture was left for 24 h. Then the supernatant 
was obtained, and the well was washed twice with PBS before the next co-culture. 
 
DCs + T-lymphocytes co-culture. 
Control DCs or DCs previously co-cultured with PKHB1-TCL were maintained in fresh 
medium at 1x106 cells/mL. Then, allogeneic BALB/c mCD3+ cells were added at 3x106 
cells/mL to give a range of 1:3 (DCs to CD3+ cells), co-culture was left for 96 h. Then, 
lymphocytes were collected (in the supernatant), washed with PBS, and resuspended in 
fresh medium at 5x106 cells/mL for their use in the next co-culture. 
 
T-Lymphocytes + 4T1 cells co-culture. 
 1x105 cells/mL viable 4T1 cells were plated. Then, allogeneic BALB/c mCD3+ cells 
were added to each well at 5x105 cells/mL, unprimed (previously co-cultured with control 
DCs) or primed (previously co-cultured with DCs-PKHB1-TCL) to give a range of 1:5 
(tumor to effector). Co-culture was left for 24 h for cytokine or calcein assessment. 
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Cytokine release assay 
Supernatants from the indicated co-cultures were obtained for the assessment of IL-2, IL-
4, IL5, and TNFa (BD CBA Mouse Th1/Th2 Cytokine Kit, San Jose, CA, USA) by flow 
cytometry following manufacturer’s instructions. IFNγ was assessed using an ELISA kit 
(Sigma-Aldrich) and the Synergy HTTM (BioTek Instruments, Inc., Winooski, VT, USA) 
plate reader at 570 nm wavelength, following manufacturer’s instructions. 
 
Calcein assay  
4T1 cells (1x106 cells/mL) were stained with (0.1mL/mL) Calcein-AM from BD 
Biosciences (San Jose, CA) in FACS buffer at 37 °C and 5% CO2 for 30 min, washed 
twice with PBS. Thus, T cells primed or unprimed were added in a 1:5 (tumor to effector) 
ratio. Co-culture was incubated at 37 °C and 5% CO2 for 24 h. Finally, calcein positive or 
negative 4T1 cells were assessed in a BD AccuryC6 flow cytometer (BD Biosciences) 
(total population 10,000 cells). Data was then analyzed using FlowJo software.  
 
PKHB1-TCL preparation 
4T1 cells (1.5x106 cells/mL per mice) were plated and, after adherence, cells were then 
treated with 400 μM of PKHB1 (CC100) for 2 h, or EPI 10 µM (CC100) for 24 h. After 
treatments, cells were obtained, centrifugated at 1600 rpm/10 min and resuspended in 
100μL of serum free medium/mice. Cell death was confirmed using Trypan blue staining 
and flow cytometry. Finally, the PKHB1-TCL or EPI-TCL were inoculated by 
subcutaneous injection in the right flank.   
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Prophylactic vaccination  
Vaccination was carried out as follows: PKHB1-TCL or EPI-TCL was inoculated s.c. in 
100 μL of serum free medium into the right hind leg (day -7), seven days later viable 
(5x105) 4T1 cells were inoculated into the left hind leg (day 0). Tumor volume and weight 
were measured as described above.  
 
PKHB1-TCL treatment  
Tumor was established by subcutaneous injection of 5x105 4T1 cells in 100 μL of PBS, in 
the left hind. Tumor volume and mice weight were measured as described above. When 
tumor reached 100 mm3 the first treatment of PKHB1-TCL or EPI-TCL was applied. 
Tumor cell lysates were inoculated subcutaneously in 100 µl of serum free medium, in the 
right hind, twice a week for a total of four applications in a two-weeks period. Control 
mice were treated with 100 µl of serum free medium. 
 
Long-term antitumor effect evaluation  
Mice in complete remission after prophylactic or therapeutic 4T1-PKHB1-TCL 
application were re-challenged with 5x105 4T1 viable cells in 100 μL of PBS in the left 
hind and tumor volume was measured as described above.  
 
Long-term splenocytes-cytotoxicity 
Mice in complete remission after prophylactic or therapeutic PKHB1-TCL application 
were re-challenged with 5x105 4T1 viable cells in 100 μL of PBS in the left hind. Three 
days after tumor inoculation mice were sacrificed, spleens were harvested, filtered through 
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a cell strainer (70µM) with PBS, and PBMCs were obtained as described above. 
Splenocytes were recovered and co-cultured with 4T1 cells (previously stained with 
calcein-AM) at 44:1 ratio (respectively). Finally, calcein positive or negative cells were 
assessed as described above.  
 
Statistical Analysis  
Mice were randomly assigned to different groups for all in vivo studies. At least three 
independent experiments were repeated three independent times. Mann-Whitney tests and 
two-tailed unpaired Student's t-tests were performed using GraphPad Prism Software (San 
Diego CA, USA) and presented as mean values ±SD. The p values were considered 




PKHB1 induces breast cancer cell death. 
 
The potency of PKHB1was previously demonstrated in hematopoietic malignancies (6,8). 
Its effectiveness was not yet evaluated for solid tumors in vivo. Thus, after peptide 
synthesis and characterization (Supplemental material and methods, table sup.1 and figure 
sup.1), we evaluated here its effect in two types of human breast cancer cell lines, I) MCF-
7 (luminal subtype) and II) MDA-MB-231 (triple negative subtype), as well as on the 
murine 4T1 cell line (mimics triple negative subtype(11)). We observed that PKHB1 
induces cell death in a concentration-dependent way in MCF-7 (figure 1A), MDA-MB-
 134 
231 (figure 1B) and 4T1 (figure 1C) cells, as they showed an increase in the percentage 
of double-positive Ann-V-APC/PI staining (figure sup. 2). We determined that the 
cytotoxic concentration that induces approximately 50% of cell death (CC50) in MDA-
MB-231 and MCF-7 is 200 μM while in 4T1 is 300 μM. 
Next, we evaluated mitochondrial damage and cytosolic Ca2+ augmentation, and observed 
that PKHB1 (CC50) induced loss of mitochondrial membrane potential (figure 1D), ROS 
production (figure 1E) and intracellular Ca2+ augmentation (figure 1F) in all cell lines.  
Afterwards, we searched to determine the cell death effectors and evaluated Ca2+-
dependence, ROS-dependence, and we used inhibitors of caspases (zVAD), necroptosis 
(Nec-1) and autophagy (SP-1) and assessed cell death. We found that PKHB1-induced 
cell death in all cells was only inhibited when using the calcium chelator BAPTA, as 
previously observed for leukemia cells (6,8), suggesting a similar cell death mechanism 
and common signaling pathway among solid and liquid cancers. To assess this hypothesis, 
we used a PLC inhibitor (U73122) and ER receptor inhibitors (dantrolene, for ryanodine 
receptors, and 2-APB, for IP3 receptors). We determined that PKHB1-cell death is 
inhibited when blocking the ER-Ca2+-channels with U73122, dantrolene and 2-APB 
(figure 1J, K and L) in breast cancer cells, confirming our hypothesis. 
 
PKHB1 has antitumor effects in breast cancer and promotes intratumorally CD8+ 
T cell infiltration. 
To evaluate in vivo the potential antitumor effect of PKHB1, 4T1 breast cancer cells were 
grafted onto BALB/c mice. Daily treatments were initiated once the tumor volume 
reached 100 mm3, and 16 days after the cell transplant, tumor volume of the control mice 
had reached 1500 mm3 requiring the sacrifice of the animals, while the tumor volume of 
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the PKHB1-treated mice reached a maximum volume of 890 mm3 (at day 8) which started 
to decrease, reaching a volume of 570 mm3 at day 16 (figure 2A). The decrease in tumor 
volume was correlated with the decrease in tumor weight, going from 1.5 grams in the 
controls to 0.40 grams in PKHB1-treated mice (figure 2B). The decrease in tumor volume 
in mice treated with PKHB1, led us to evaluate the involvement of T cells in the observed 
effect. First, we analyzed histological sections of  tumors from control (figure 2C) or 
PKHB1-treated mice (figure 2D): results revealed that tumors from control mice showed 
tumor cells with moderate mitotic activity (blue arrows), whereas the PKHB1-treated mice 
showed sporadic mitotic activity, extensive necrosis with abundant accumulation of 
cellular debris (green arrows), and abundant inflammatory exudate, composed of 
polymorphonuclear elements, eosinophils and lymphoplasmacytic cells (red arrows). 
Additionally, we evaluated if the cell number and distribution of T lymphocytes in 
peripheral blood, spleen, lymph nodes, and tumor site, changed after PKHB1 treatment. 
We observed (figure 2E) that the percentage of CD3+ cells increased in blood, lymph 
nodes, and tumors of PKHB1-treated mice, while it was maintained in spleen. When we 
assessed CD4+ cells, the percentage of cells significantly augmented in lymph nodes 
while it significantly diminished in the tumor site (figure 2F). Furthermore, CD8+ T cells 
significantly increased in peripheral blood and specially in tumor site, while they 
significantly diminished in lymph nodes (figure 2G). Finally, we determined if 
splenocytes from PKHB1-treated mice could induce an antitumor cell cytotoxicity. For 
this purpose, we evaluated the decrease in calcein stained 4T1 cells after co-culture with 
splenocytes obtained from control or PKHB1-treated mice. In figure 2H, results show that 
splenocytes from PKHB1-treated mice induced a significant decrease in calcein stained 
4T1 cells (75%) in comparison with control mice (40%). 
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PKHB1 induces DAMPs exposure and release in breast cancer cell lines. 
 
As we observed that PKHB1 induced cell death in breast cancer cell lines and CD8+ T 
lymphocyte-recruitment in tumor site, we wondered if cell death induced by PKHB1 was 
able to induce DAMPs’ exposure/release in breast cancer cells. The first step was to 
evaluate the exposure of CRT (the principal DAMP related with ICD). Our results show 
that PKHB1-treatment was able to induce 59%, 63%, and 50% of CRT positive cells in 
MCF-7 (figure 3A), MDA-MB-231 (figure 3B), and 4T1 (figure 3C) cells. The CRT 
exposure was confirmed by immunofluorescence microscopy and we observed that 
PKHB1 induced CRT exposure in all the cases (figure 3 D, E and F).  Additionally, 
PKHB1-treatment induced 24 ± 3, 3.2 ± 1.3 and 4.23 ± 2-fold of HSP70 exposure (fig 3 
G), 2 ± 0.6, 2.7 ± 0.6 and 7 ± 1.85-fold of HSP90 exposure (fig 3 H) in MCF-7, MDA-
MB-231 and 4T1 cells, respectively when compared with untreated cells. 
Finally, the presence of HMGB1 and ATP was assessed in the supernatants of treated and 
untreated breast cancer cells. In figure 3, results showed a significant release of HMGB1 
(figure 3I) and ATP (figure 3J) in the supernatants of PKHB1-treated cells, when 
compared with untreated cells.  
 
PKHB1-TCL induces maturation of bone marrow-derived DCs and anti-tumor T-
cell responses. 
 
To assess the immunogenicity of the dead cells obtained upon treatment with PKHB1, 
4T1 cells were treated with CC100 of PKHB1. The PKHB1-tumor cell lysate (PKHB1-
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TCL) was then prepared as described in the methods section, and its ability to induce DCs 
maturation was evaluated. Thus, bone marrow-derived murine DCs were left untreated 
(Control) or pulsed for 24 h with the PKHB1-TCL. After co-culture, the DCs pulsed with 
PKHB1-TCL show a significant increase in the expression of co-stimulatory molecules 
CD80 and CD86 passing from 50% to 66% and 90%, respectively, while maintaining the 
expression of the DCs marker CD11c (figure 4A). Furthermore, DCs pulsed with 
PKHB1-TCL show a significant increase in TNFa release in comparison with 
unstimulated DCs (figure 4B). Once we determined that PKHB1-TCL was able to induce 
DCs maturation, we assessed if the pulsed DCs (DCs-PKHB1-TCL) were able to prime 
T cells. First, primary T lymphocytes (CD3+ cells) were co-cultured for 96h with pulsed 
or unpulsed DCs and the release of TNFa, IFNg, IL-5, IL-4, and IL-2 was assessed. 
Results showed that co-culture of pulsed DCs with primary T lymphocytes induced the 
release of TNFa, IFNg, and IL-2, while IL-5 and IL-4 releases were not detected (table 
S2).  
Next, primed (co-cultured with pulsed DCs-PKHB1-TCL) or unprimed (co-cultured with 
unstimulated DCs) T-lymphocytes were collected and co-cultured during 24h with viable 
4T1 cells (previously stained with calcein-AM). Then a significant increase of IFN-γ and 
IL-2 release was observed in the supernatants of primed T-lymphocytes when being co-
cultured with 4T1 cells, while no difference was observed in IL-4 release (figure 4 C and 
D). To assess antitumor cell cytotoxicity, we evaluated the decrease in calcein-stained 
4T1 cells after co-culture with primed or unprimed T-lymphocytes. Results showed that 
only T-lymphocytes co-cultured with pulsed DCs-PKHB1-TCL induced a significant 
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decrease in calcein stained 4T1 cells (figure 4E), in comparison with the 4T1 cells co-
cultured with unprimed T lymphocytes (figure 4E).  
 
Prophylactic vaccination with PKHB1-TCL prevented tumor establishment of 4T1 
cells. 
 
Considering that PKHB1 treatment induces tumor decline, infiltration of CD8+ cells into 
the tumor, DAMPs’ exposure and release, and the antitumor immune response ex vivo, 
the next step was to carry out the Gold Standard of ICD (prophylactic vaccination) to 
confirm if PKHB1 induced ICD. The vaccine was based in the subcutaneous inoculation 
of the 4T1-PKHB1-TCL, 7 days before the transplantation of viable 4T1 cells, while mice 
were inoculated with 4T1-EPI-TCL used as a positive control, and controls without TCL 
were injected with serum-free medium (figure 5A). Results showed that vaccination with 
PKHB1-TCL prevented tumor establishment in 80% of mice compared to 70% for mice 
treated with EPI-TCL. 0% of survival was observed in the Control group inoculated with 
serum-free medium (figure 5B). Additionally, survival rates of mice in each group were 
consistent with tumor growth, observing respectively 80% and 70% of survival in mice 
vaccinated with PKHB1-TCL and EPI-TCL by day 60, while control mice perished by 
day 21 (figure 5C). 
 
Treatment with PKHB1-TCL induces tumor regression 
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After ex-vivo and in vivo results, we evaluated if the immunogenicity of PKHB1-TCL 
was able to diminish tumor growth and improve overall survival in syngeneic mice 
bearing 4T1 tumors. First, 4T1 viable cells were inoculated in BALB/c mice. When tumor 
reached 100 mm3, a control-group was treated with serum-free medium, a second group 
was treated with PKHB1-TCL and the third group was treated with EPI-TCL. All mice 
were treated two times per week for a total of four treatments (figure 5D). Tumor growth 
measurements show that PKHB1-TCL-treated mice had diminished tumor growth after 
day 10 (7 days after the first treatment), which continued to decrease until no tumor was 
detected by day 18, in the group of EPI-TCL the tumor diminished after day 10 (7 days 
after the first treatment) which continued to decrease until no tumor was detected by day 
16 (figure 5E). Tumor growth diminution was reflected in overall mice survival, as 
PKHB1-TCL-treated mice presented a 78% of survival, while the EPI-TCL-treated mice 
presented 67% of survival, and all control mice perished by day 23 (figure 5F).  
 
PKHB1-TCL prophylactic and therapeutic vaccinations induce long-term 
antitumor effect. 
 
To assess the long-term antitumor effect response against 4T1 breast cancer cells induced 
by PKHB1-TCL in a prophylactic or therapeutic application, mice in complete remission 
(tumor free >60 days) were re-challenged with living 4T1 cells. Tumor volume analysis 
showed that, contrary to naïve mice (Control), which showed a correct 4T1 tumor 
establishment, mice in remission after PKHB1-TCL prophylactic or therapeutic 
application showed a slight increase in tumor volume at day 2, which immediately 
disappears by day 6 (figure 6A). These results correlate with mice’s survival, where we 
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observed that compared to naïve mice, in which a primary 4T1 cells challenge resulted in 
a 0% of survival by day 23, those that were in remission after prophylactic or therapeutic 
application of PKHB1-TCL were completely resistant to a re-challenge with 4T1 cells, 
resulting in a 100% of survival (figure 6B). Furthermore, we determined if splenocytes 
from re-challenged mice can induce an antitumor cell cytotoxicity. For this purpose, we 
evaluated the decrease in calcein stained 4T1 cells after co-culture with splenocytes 
obtained from naïve or re-challenged mice. In figure 6 D, results showed that splenocytes 
from re-challenged mice induced a significant decrease in calcein stained 4T1 cells (60%) 





Here we described for the first time the mechanism of cell death induced by PKHB1 in 
breast cancer cells, which conserves the principal molecular characteristics (caspase-
independent, calcium-dependent, PLC-dependent and IP3R and RYR receptors-dependent 
cell death with the presence of ROS, loss of mitochondrial membrane potential and the 
intracellular accumulation of Ca2+) reported mainly in leukemic cells (6,8–10). These 
results highlight the mechanism of cell death induced by PKHB1 as a conserved 
mechanism, especially among different types of tumor cells including the triple-negative 
phenotype. Additionally, we recently reported the overexpression of PLCg1 and its 
importance in the cell death induced by PKHB1 in CLL cells (6). Whereas, in breast 
cancer the PLCg1 is over-expressed in patients with poor clinical outcome (12). In this 
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sense, the mechanism of PKHB1-cell death, might have an advantage in the cancer cells 
that overexpress PLCg1.  
Our results also revealed the antitumor effect of PKHB1 against 4T1-breast cancer cells 
in vivo, as PKHB1-treatment diminished tumor volume and weight. Additionally, T cells 
distribution observed in PKHB1-treated mice suggests that PKHB1 promote an antitumor 
immune response, since it involves the increase of  T-cells (in blood, lymph node and 
tumor), trafficking of CD4+ cells to lymph nodes, and tumor CD8+ cells infiltration (13). 
Our results are promising due do it has been reported that extensive tumor infiltration by 
cytotoxic CD8+ T cells is strongly associated with patient’s survival and response to 
therapy, even in different phenotypes of breast cancer (14,15). Furthermore, splenocytes 
from PKHB1-treated mice were more cytotoxic against breast cancer cells than 
splenocytes from control mice, probably for the immunogenicity of the cell death 
triggered by PKHB1 (13,16). 
The low immunogenicity of tumor cells is a main obstacle of antitumor therapies, 
therefore a way to reactivate potent antitumor immune responses is through the emission 
of DAMPs (17) and dead cells-derived antigens, which can be achieved in the ICD (3,18). 
Here we demonstrated that PKHB1 is capable of inducing CRT, HSP70 and HSP90 
exposure, HMGB1 and ATP release, which can promote the uptake of dying cells, and the 
recruitment, maturation and cross-presentation activity of antigen-presenting cells (APCs) 
(16,19). In these sense, we demonstrated that PKHB1-TCL is able to promote a mature 
phenotype of DCs (20) since this induced a significant increase in the co-stimulatory 
molecules CD80 and CD86, as well as the significant release of TNFa, such as different 
ICD-inductors (21). Additionally, we observed that DCs pulsed with the PKHB1-TCL 
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promote the antitumor specific cytotoxicity of T cells, which confirm the phenotypic and 
functional maturation of DCs.  
On the other hand, vaccination assays involving syngeneic models are the gold standard 
to formally identify ICD inducers, since this demonstrates the tumor rejection capacity of 
the immunized host (17,22). Our results show that the prophylactic application of EPI-
TCL and PKHB1-TCL prevented tumor establishment and increased survival in 80% of 
the mice, without using adjuvants and with only one vaccination, in comparison with 
others ICD-inductors (---). Also, we used Epirubicin, a well-known ICD inductor with 
major side-effects in human (23–25)  as a positive control, highlighting its ability to 
prevent the establishment of breast cancer in 70% of the mice. Our results are in line with 
the protective potential of established ICD inducers including oxaliplatin, doxorubicin, 
iadurobicin, mitoxantrone and specific forms of radiotherapy (in colon cancer) which 
presented between 80%-90% of tumor-free mice (26–28) while the antibody 7A7 (anti-
EGFR) induced 50% of survival (lung cancer) (29), and  especially with the fact that an 
ICD-inductor should display elevated tumor-free survival (>50%) (30).   
The therapeutic application of the dead cells killed by a potential ICD inducer can be used 
as a confirmatory trial for ICD inductors, to evaluate their ability to mediate therapeutic 
effects depending on the immune system against established neoplasms (22). In this sense, 
our results show that when we treated tumor bearing mice with only four applications of 
PKHB1-TCL, tumor volume decreased 7 days after the first administration, reaching 
tumor regression on day 18 in approximately 80% of mice, while in the group of EPI-TCL 
the tumor diminished 7 days after the first treatment which continued to decrease until 
tumor regression on day 16. Our results highlight the immunogenicity of the PKHB1-
induced cell death, since the therapeutic application of the PKHB1-TCL induced tumor 
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remission even in the absence of adjuvants.  Additionally, we determined the therapeutic 
potential of the EPI-TCL for first time, as a novel strategy for the application of 
chemotherapy-ICD inductors. These results differentiate the PKHB1-TCL from other 
therapeutic strategies with tumor lysates against melanoma, prostate and ovarian cancer, 
which have been poorly evaluated and were mainly used in combination with adjuvants 
(31,32).  
The success of the therapeutic application of PKHB1-TCL in breast cancer was similar to 
the T-ALL model (10), despite their intrinsic molecular differences (11,33–35).  
The perspectives for cell therapy against cancer are based on the development of T cell 
responses, resulting in effective rejection of tumors and long-term protection (36,37). 
From this fact, the induction of ICD eventually results in long-lasting protective antitumor 
immunity (38). Our results demonstrate that PKHB1-TCL induces long-term antitumor 
effect since 100% of mice in remission after PKHB1-TCL prophylactic or therapeutic 
application survived at the re-challenge with 4T1 cells. Although immunotherapy with 
pulsed DCs, primed T lymphocytes or CAR-T cells is the main approach used to stimulate 
antitumor immune responses, they represent greater technical complexity, higher cost, 
among other disadvantages regarding the use of crude PKHB1-TCL (39–41).  
Overall, our results demonstrate that PKHB1 is an ICD inductor in breast cancer cells and 
highlight a new approach for TSP-1 peptides mimic, which could induce ICD as a 
conserved mechanism of cell death in different types of tumor cells, including solid 
cancers, additionally, our results provide evidence for a novel strategy in the obtention 
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FIGURE LEGENDS  
 
Figure 1. PKHB1 induces cell death in breast cancer cell lines. Cell death analysis in (A) MCF-
7, (B) MDA-MB-231 and (C) 4T1 cells, without treatment (Control), treated with the control 
peptide 4NGG or PKHB1 for 2h. (D) Representative graphs and quantification of the loss of ΔΨm 
measured through TMRE, (E) ROS levels measured through Hydroethidine staining and 
intracellular Ca2+ by Fluo-4 staining, by flow cytometry in cells left alone or treated with PKHB1 
for 2h. (F) Cell death induced by PKHB1 was assessed as in A, B and C in cells left without pre-
treatment (-) or pre-treated (30 minutes) with BAPTA, Z-VAD-FMK (Z-VAD), N-Acetyl Cystein 
(NAC), Necrostatin-1 (Nec-1) or Spautin-1 (SP-1). Cell death induced by PKHB1 was assessed 
as in G, H and I in cells left without pre-treatment (-) or pre-treated (30 minutes) with dantrolene, 
2-APB or U73122. Graph represents the means (±SD) of triplicates of three independent 
experiments. NS= Not significant. 
 
Figure 2. PKHB1 treatment induces tumor reduction and T cells distribution. Mice were 
inoculated s.c. with 5x105 4T1 viable cells and when tumor reached 100mm3 were treated with 
sterile water (Control, n=6) or PKHB1 (400µg of PKHB1 daily, n=6), tumor volume was 
measured tree times per week. (A) Graphs indicate tumor growth in PBS-treated (Control) or 
PKHB1-treated mice (PKHB1). (B) Graphs indicate the tumor volume of control and treated mice 
at day 16. Histology from tumors of control or PKHB1-treated mice stained with H&E. Tumor 
cells (black arrows), mitotic cells (blue arrows), cellular debris (green arrows) and immune system 
cells infiltration (red arrows). (E, F and G) Graphs show the percent of CD3+, CD4+ and CD8+ 
cells in blood, spleen, lymph node and tumor of control or PKHB1-treated mice at day 16. (H) 
Graphs show the percent of calcein negative 4T1 cells after the co-culture with splenocytes of 
control (n=4), or PKHB1 treated mice (n=4). NS= Not significant. 
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Figure 3. PKHB1 induces exposure and release of DAMPs in breast cancer cells. 
Representative FACS histograms of CRT exposure (filled histograms) and IgG isotype antibodies 
(open histograms) of 7-AAD negative (A) MCF-7, (B) MDA-MB-231 and (C) 4T1 cells, untreated 
(Control) or treated with PKHB1 for 2 h. Calreticulin exposure observed by confocal microscopy 
in (D) MCF-7, (E) MDA-MB-231 and (F) 4T1 cells untreated (Control) or treated with PKHB1 
using CRT-PE staining and Hoechst 33342. Representative graphs of the ratio of HSP70 (G) or 
HSP90 (H) exposure of 7-AAD negative cells, untreated (Control) or treated with PKHB1 for 2h. 
Representative graphs of the (I) HMGB1 or (J) ATP release in the supernatants of control or 
PKHB1 treated cells. Graphs shown are means (± SD) of triplicates of three independent 
experiments. CRT-PE= Calreticulin-PhycoErythrin. 
 
Figure 4. PKHB1-Tumor cell lysate induces antitumor immune response ex vivo. (A) 
Representative histograms from flow cytometry analyses of CD80, CD86 or CD11c expression 
on DCs left with medium (CTR) or pulsed 24h with a PKHB1-TCL, graphs of the means obtained 
by FACS (right side). (B) DCs were treated as in A and the supernatants were collected to quantify 
TNFa release, by FACS. Supernatants of T lymphocytes+4T1 cells (unprimed or primed) co-
culture were collected and assayed for IFN-γ (C), (D) IL-4 and IL-2 release. (E) Representative 
histograms from flow cytometry analyses of 4T1 cells stained with calcein-AM and co-cultured 
with T lymphocytes (unprimed or primed). Graphs shown are means (± SD) of triplicates of three 
independent experiments. NS= Not significant. 
 
Figure 5. PKHB1-TCL induce tumor elimination in a prophylactic and therapeutic 
application.  
(A) Schema of PKHB1-TCL or EPI-TCL prophylactic application. (B) Graph indicates the mean 
of the tumor growth in mice treated with serum-free medium (Control; n=10) or mice receiving a 
prophylactic vaccination with PKHB1-TCL (Prophylactic-PKHB1-TCL, n=10) or EPI-TCL 
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(Prophylactic-EPI-TCL, n=10). (C) Kaplan Meier survival graph of mice treated as in B over time. 
(D) Schema of PKHB1-TCL or EPI-TCL therapeutic application. (E) Graph indicates the mean 
of the tumor growth in mice treated with serum-free medium (Control; n=9), PKHB1-TCL 
(Therapeutic-PKHB1-TCL, n=9) or EPI-TCL (Therapeutic-EPI-TCL, n= 9), arrows indicate days 
of TCL or serum free medium inoculation. (F) Kaplan Meier survival graph of mice treated as in 
E over time.  
 
Figure 6. PKHB1-TCL prophylactic and therapeutic application induces long-term 
antitumor effect, schematic representation of the PKHB1-effect. Mice in remission (30 days) 
after PKHB1 prophylactic or therapeutic PKHB1-TCL application were re-challenged with 5x105 
4T1 viable cells. (A) Graph indicates tumor growth in PBS-treated mice (Control; n=9), 
prophylactic re-challenged mice (Prophylactic remission-4T1 rechallenge, n=9) or therapeutic re-
challenged mice (Therapeutic remission-4T1 rechallenge, n=9). Each line represents the mean of 
the tumor volume per group. (B) Kaplan Meier survival graph of mice treated as in A over time. 
(C) Graphs show the percent of calcein negative 4T1 cells after co-culture with splenocytes control 
(n=4), prophylactic (n=4) or therapeutic (n=4) rechallenged mice. (D) PKHB1 induces ROS 
production, intracellular Ca2+ accumulation, loss of mitochondrial membrane potential (ΔΨm), 
leading to DAMPs exposure and release in breast cancer cells. Neoantigens and DAMPs 
exposure/release induced by PKHB1 promotes DCs maturation, which triggers T-cell activation 
to induce cancer cytotoxicity. (E) On the other hand, PKHB1-treatment in vivo induces T-cells 
redistribution in lymph nodes, peripheral blood and intratumorally, leading to tumor reduction. 
(F) PKHB1-TCL prophylactic vaccination prevented tumor establishment. (G) PKHB1-TCL 
therapeutic application induced tumor remission. (H) PKHB1-treatment, PKHB1-TCL 
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Supplemental material and methods. 
 
PKHB1 and 4NGG Syntheses and Characterizations 
 
Both peptides were synthesized manually by solid-phase peptide synthesis on a 
Chlorotrytil resin (Merck Chemicals, Darmstadt, Germany) as described by Denèfle et al., 
2016.  
All commercial chemicals and solvents were reagent grade. All reactions performed in 
organic solvents were carried out with the use of standard techniques for the exclusion of 
moisture. All reactions were performed under argon or nitrogen in oven-dried glassware 
using anhydrous solvents and standard syringe techniques. All Fmoc carbamate protected 
amino acid derivatives; HBTU, HOBt and 2-CTC resin (100−200 mesh, loading 1.6 
mmol/g) were purchased from Iris Biotech (Marktredwitz, Germany). Reagents such as 
DIEA, piperidine, DMF, IPA, Ac2O, MeOH, TFA, and TIS were obtained from Sigma-
Aldrich (St. Louis, MO, USA). The peptides PKHB1 and 4NGG were of >95% purity 
(determined by analytical reverse phase LC−MS). 
Manual Loading of the First Amino Acid. Solid-phase peptide synthesis was performed 
in polypropylene Torviq syringes (20 mL). The 2-CTC resin was previously swelled in 
strictly anhydrous DCM (distilled) for 2 h. Side chain protected Fmoc-Aa-OH (0.30 
mmol, 1 equiv) was coupled to 2-CTC resin (400 mg, loading 1.6 mmol/g) in the presence 
of DIEA (1.2 mmol, 4 equiv) in DCM (4 mL). The unreacted sites on the resin were 
capped by washing with a mixture of DCM/MeOH/DIEA (17:2:1) repeated 3 times. Thus, 
loading was reduced to 0.80 mmol/g for optimal peptide growth.  
Manual Solid Phase Peptide Synthesis. Fmoc group was split off by treatment with 
piperidine/DMF (1:4) (1 × 1 min, 1 × 10 min). Activation step and coupling (4h for each 
step) were carried out with Fmoc-Aa-OH (1.2 mmol, 4 equiv), HBTU (1.2 mmol, 4 equiv) 
as coupling agent, HOBt (1.2 mmol, 4 equiv) as auxiliary nucleophile, and DIEA (2.4 
mmol, 8 equiv) as base. When elongation of the peptide chain was completed, a washing 
step with MeOH was added after final N-terminal Fmoc removal in order to totally shrink 
the resin under vacuum.  
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Final Side Chain Deprotection and Cleavage from the Resin. The crude peptide was 
treated with the following cleavage cocktail: TFA/H2O/TIS (95/2.5/2.5, 10 mL). The 
peptide was precipitated using cooled Et2O (3 × 30 mL), and recovered after centrifugation 
(3 × 5 min, 7800 rpm). Diethyl ether was removed, and the peptide pellets were dried 
(under nitrogen flow). The resulting crude peptide was dissolved in aqueous 0.1% (v/v) 
TFA. Purification was conducted on reverse-phase HPLC Prep C18 column, eluting with 
0.1% TFA in water (solvent A) and 0.1% TFA in acetonitrile (solvent B).  
Purification. Preparative scale purification of peptides was performed by reverse phase 
HPLC on a Waters system consisting of a quaternary gradient module (Water 2535) and 
a dual wavelength UV/visible absorbance detector (Waters 2489), piloted by Empower 
Pro 3 software using the following columns: preparative Macherey- Nagel column 
(Nucleodur HTec, C18, 250 mm × 16 mm i.d., 5 μm, 110 Å) and preparative Higgins 
analytical column (Proto 200, C18, 150 mm × 20 mm i.d., 5 μm, 200 Å) at a flow rate of 
14 mL/min and 20 mL/min, respectively. Small-scale crudes (<30 mg) were purified using 
semipreparative Ace column (Ace 5, C18, 250 mm × 10 mm i.d., 5 μm, 300 Å) at a flow 
rate of 5 mL/min. Purification gradients were chosen to get a ramp of approximately 1% 
solution B per minute in the interest area, and UV detection was done at 220 and 280 nm. 
Peptide fractions from purification were analyzed by LC−MS. All LC−MS or HPLC 
analyses were performed on C18 columns. The pure fractions were gathered according to 
their purity and then freeze-dried using an Alpha 2/4 freeze-dryer from Bioblock Scientific 
to get the expected peptide as a white powder. Final peptide purity (>95%) of the 
corresponding pooled fractions was checked by LC−MS.  
LC−MS analysis. Analytical HPLC was conducted on a X-Select CSH C18 XP column 
(30 mm × 4.6 mm i.d., 2.5 μm), eluting with 0.1% formic acid in water (solvent A) and 
0.1% formic acid in acetonitrile (solvent B), using the following elution gradient: 0−3.2 
min, 0−50% B; 3.2−4 min, 100% B. Flow rate was 1.8 mL/min at 40 °C. The mass spectra 
(MS) were recorded on a Waters ZQ mass spectrometer using electrospray positive 
ionization [ES+ to give (MH)+ molecular ions] or electrospray negative ionization [ES− 
to give (MH)− molecular ions] modes. The cone voltage was 20 V. 
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1) Peptides characterization 
 
TABLE 1. SUMMARIZED ANALYTICAL DATA OF PKHB1 AND 4NGG. 
PEPTIDE MW (g/mol) a m/z (ESI) b tR (min) c 










a. Real molecular weight. b. Mass-to-charge ratio (m/z) observed by electrospray ionization (ESI) 
corresponding to total mass (M+H) and derived fractions. c. Retention times (tR) observed using the 


















 Peak Number  Compound  Time  AreaAbs  Area %Total  Width  Height  Mass Found
 1  1.58  2e+006  100.00  0  3e+007
 Peak ID  Compound  Time  Mass Found
 1  1.58
m/z




















Supplementary Figure 1. LC-MS analysis of PKHB1 and 4NGG. Chromatograms (upper) of purified 
PKHB1 (A) and 4NGG (B) samples in water (5 mg/mL) show a single peak (1), representing 100% of the 
total area under the curve at tR= 1.58 min and tR=1.26 min for PKHB1 and 4NGG respectively, under the 
conditions described above. Coupled mass spectrum (lower) show intense peaks at a mass-to-charge ratio 


















 Peak Number  Compound  Time  AreaAbs  Area %Total  Width  Height  Mass Found
 1  1.26  2e+006  100.00  0  4e+007
 Peak ID  Compound  Time  Mass Found
 1  1.26
m/z















Supplementary Table 2. TNFa, IFNγ, IL-5, IL-4, and IL-2 cytokine release in co-cultures of 
T lymphocytes with control or pulsed DCs. Bone marrow-derived murine DCs were left with 
medium alone (DCs-Control) or pulsed (DCs-PKHB1-TCL) during 24h with a PKHB1-TCL. 
Then, DCs were co-cultured during 4 days with T-lymphocytes, and the supernatants were 
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3.1. Homotrimerization Approach in the Design of Thrombospondin-1 
Mimetic Peptides with Improved Potency in Triggering Regulated Cell 
Death of Cancer Cells 
 
Article published in the “Journal of Medicinal Chemistry” on August 12th, 2019 
(doi: 10.1021/acs.jmedchem.9b00024). 
 
Based on the natural homotrimeric assembly of TSP1, it was hypothesized that a 
homotrimeric variant of PKHB1 could have an improved potency. To achieve this, a click 
chemistry strategy was considered, using an azide-derivative of PKHB1 with an 
aminopentanoic acid spacer to bind a tertiary amine matrix. This peptide construct was 
synthesized on solid support, cleaved and, using copper-catalyzed azide−alkyne 
cycloaddition, the azido-derivative was attached to three-propargyl amine. Unfortunately, 
the resulting [PKHB1]3 was not soluble in water, so, we went back to PKHB1 sequence 
to try to generate a more soluble monomer that we could potentially use to improve the 
solubility of the trimer as well. 
As PKHB1 intends to mimic a beta strand, we thought that insolubility could be a 
result of beta strand stabilization and sheet nucleation, then, disrupting beta sheet 
stabilization could improve solubility. In peptides, it has been described that backbone 
amine methylations can improve solubility in this way. Thus, to improve PKHB1 
solubility, variants containing N-methylated residues were generated and assessed in 
terms of affinity and cytotoxicity. Affinity was measured by bio-layer interferometry 
(BLI) assays, using cell membranes obtained from MEC-1 cells, a CLL cell line. The 
cytotoxic activity of the N-methylated peptides was measured in MEC-1 cells by flow 
cytometry, using Ann-V/PI staining. From the N-methylation scan we observed that the 
only residue in which N-methylation did not significantly affect the activity of the peptide 
was arginine (NMeR-PKHB1), and this was also accompanied by a slight but significant 
improvement in its affinity. Double N-methylation did not improve PKHB1 nor NMeR-
PKHB1. And based on the previous work in the lab that led to the discovery of PKHB1, 
it was hypothesized that methionine or terminal end replacement could potentially 
improve the properties of NmeR-PKHB1. Thus, methionine was substituted by different 
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branched amino acids, including norleucine, an amino acid that is structurally very similar 
to methionine, but without the sulfur atom that is susceptible to oxidation. Norleucine 
replacement in this NmeR-PKHB1 gave rise to a peptide that was termed PKT16, with an 
improved affinity to its target compared to PKHB1, and as active as this last, but with 
improved solubility properties. 
Using this non-aggregating peptide, PKT16, homotrimerization was achieved as 
planned for PKHB1, and the resulting [PKT16]3 was soluble. Using biolayer 
interferometry, slower dissociation rates were observed for [PKT16]3 compared to their 
monomeric predecessors, PKT16 and PKHB1, resulting a KD in the nanomolar range. In 
terms of cell death induction, [PKT16]3 at concentrations ten times lower than those of 
the monomeric predecessors kill the same amount of CLL cells. Thus, this peptide is more 
potent to bind to and kill CLL cells. 
However, after substantial structural modifications, the mechanism of action of these 
new peptides had to be evaluated. To assess whether this was similar to PKHB1, cell death 
induction was measured, as in the previous chapters, in presence of pharmacological 
inhibitors of caspases (QVD), calcium  (BAPTA), PLCG1 (U73122), or calcium channels 
in the endoplasmic reticulum (dantrolene and 2-APB), using PKHB1 as positive control. 
As expected, QVD did not prevent PKHB1-induced cell death, but BAPTA, U73122, 
dantrolene and 2-APB used alone or in combination, significantly inhibited cell death. 
Simultaneous experiments with PKT16 and [PKT16]3, showed a very a similar pattern, 
suggesting that [PKT16]3, PKT16 and PKHB1 trigger a similar type of regulated cell death 
in CLL. 
Finally, to evaluate whether this more potent peptide was also efficient in other types 
of cancer, its effects were evaluated in a lung cancer cell line, A549. And similar to MEC-
1, cell death induced by [PKT16]3, evaluated by Ann-V/PI staining, was ten times more 
potent than PKHB1 or the monomeric PKT16. A characteristic morphological feature of 
[PKT16]3 was that it enhanced the attachment of dead cells to the plate, making harvesting 
difficult and potentially compromising the results observed by flow cytometry.  To 
overcome this technical limitation, real-time cell analysis of cultures’ electric impedance, 
which correlates to culture viability, was quantified. Impedance increased within the first 
hour of treatment but decreased with time, confirming the results obtained by flow 
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cytometry. Furthermore, the cell death induced by the trimer, PKT16 or PKHB1, was not 
inhibited by QVD, but BAPTA did prevent cell death. In the case of PKHB1 and PKT16, 
pharmacological inhibitors of PLC-regulated calcium signaling prevented cell death as in 
CLL. However, in the case of [PKT16]3 only the simultaneous inhibition of the pathway 
reduced cell death significantly, suggesting that this pathway is only partially involved in 
the cell death induced by the trimer in these cells. We can conclude that [PKT16]3, PKT16 
and PKHB1 induce calcium-regulated cell death in lung cancer cells, as well as PKHB1 
does in other types of cancer.
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Résumé de l’article 4 
 
Afin d'optimiser la puissance du premier peptide agoniste de CD47 stable dans le sérum 
(PKHB1) pour déclencher la mort cellulaire régulée des cellules cancéreuses, nous avons 
conçu un processus de maturation de l'affinité du peptide pour son ligand en imitant la 
structure trimérique de la thrombospondine-1. Tout d'abord, afin d'améliorer sa solubilité, 
nous avons évalué les effets de la méthylation des amides (N-méthylation) sur le squelette 
peptidique PKHB1. Des analyses structurales et pharmacologiques ont été réalisées pour 
évaluer l'impact conformationnel desdites modifications chimiques et l'activité biologique 
du peptide. Cette étude de relation structure-activité a conduit à la découverte d'un peptide 
N-méthylé hautement soluble que nous avons nommé PKT16. Ce monomère a été utilisé 
pour concevoir un peptide homotrimérique, [PKT16]3, qui s'est avéré être dix fois plus 
puissant que son homologue monomère. L'évaluation pharmacologique de la mort induite 
par [PKT16]3 montre que ce peptide induit un type de mort cellulaire régulée par 
l'augmentation du calcium intracellulaire dans les cellules de leucémie lymphoïde 
chronique, similaire à celle précédemment rapportée avec PKHB1, mais aussi en cellules 
cancéreuses du poumon. 
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I. Resumen del artículo 4 
 
Con el fin optimizar la potencia del primer péptido agonista de CD47 estable en suero 
(PKHB1) para desencadenar la muerte celular regulada de células cancerosas, diseñamos 
un proceso de maduración de la afinidad del péptido por su ligando imitando la estructura 
trimérica de la trombospondina-1. Primero, con el fin de mejorar su solubilidad, 
evaluamos los efectos de la metilación de las amidas (N-metilaciones) en el esqueleto del 
péptido PKHB1. Se realizaron análisis estructurales y farmacológicos para evaluar el 
impacto conformacional de las modificaciones químicas mencionadas y la actividad 
biológica del péptido. Dicho estudio de relación estructura-actividad condujo al 
descubrimiento de un péptido N- metilado, altamente soluble que nombramos PKT16. 
Este monómero se utilizó para el diseño de un péptido homotrimérico, [PKT16]3, que 
resultó ser diez veces mas potente que su homólogo monomérico. La evaluación 
farmacológica de la muerte inducida por el [PKT16]3 en líneas celulares adherentes 
(A549) y no adherentes (MEC-1) demuestra que este péptido induce un tipo de muerte 
celular regulada por el aumento de calcio intracelular, similar a lo reportado anteriormente 
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ABSTRACT: In order to optimize the potency of the first serum-stable
peptide agonist of CD47 (PKHB1) in triggering regulated cell death of
cancer cells, we designed a maturation process aimed to mimic the trimeric
structure of the thrombospondin-1/CD47 binding epitope. For that
purpose, an N-methylation scan of the PKHB1 sequence was realized to
prevent peptide aggregation. Structural and pharmacological analyses were
conducted in order to assess the conformational impact of these chemical
modifications on the backbone structure and the biological activity. This
structure−activity relationship study led to the discovery of a highly soluble
N-methylated peptide that we termed PKT16. Afterward, this monomer
was used for the design of a homotrimeric peptide mimic that we termed
[PKT16]3, which proved to be 10-fold more potent than its monomeric
counterpart. A pharmacological evaluation of [PKT16]3 in inducing cell
death of adherent (A549) and nonadherent (MEC-1) cancer cell lines was
also performed.
■ INTRODUCTION
A potential goal in the therapy of cancer disease is the selective
triggering of cancer cell death. With this aim, the CD47
receptor is attracting considerable attention. This membrane
glycoprotein is involved in many biological functions that are
sometimes antagonistic, depending on the spatiotemporal
expression of the receptor and its identified ligands (at least
thrombospondin-1 (TSP-1) and SIRPα) together with lateral
interactions of CD47 with other membrane receptors.1 On one
hand, its binding to SIRPα on phagocytes serves as an inhibitor
of phagocytosis.2 As a result, cancer therapies using agents that
disrupt the CD47:SIRPα interaction have been developed, and
some of them are currently under clinical investigation.3 On
the other hand, some studies have focused on targeting the
TSP-1:CD47 interaction, identified as a key signaling
integrator of tumor progression.4 With this aim, TAX2, a
peptide mimic of CD47 that targets TSP-1, was proven to
display promising antiangiogenic, antitumor, and antimeta-
static properties in vivo in preclinical mouse models of
childhood neuroblastoma.5
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We focused our attention on the reported ability of the TSP-
1:CD47 ligation to induce regulated cell death (RCD)6 and
recently described PKHB1,7,8 the first serum-stable agonist
peptide mimicking the CD47 binding epitope (i.e.,
RFYVVMWK) of TSP-1. This peptide was proven to be
efficient in triggering selective RCD of many adherent and
nonadherent cancer cell lines while sparing normal cells. The
molecular mechanism triggered by PKHB1 in chronic
lymphocytic leukemia (CLL) cells (i.e., caspase-independent
cell death mediated by sustained activation of PLCγ1 leading
to intracellular Ca2+ overload) was highlighted, and stimulation
of CD47 appeared to be key to the cytotoxicity induced by this
peptide since the disruption of the peptide:CD47 interaction
by a fusion protein designed to specifically bind to CD47 led to
inhibition of the cytotoxicity.7 The direct interaction between
our peptide and CD47 in its native environment was studied
using an active-site-directed covalent probe approach.8a We
also demonstrated its capacity to induce tumor regression in a
xenografted immunodeficient NSG mice CLL model7 together
with its ability to induce complete tumor remission in a BALB/
c immunocompetent mice model, activating in the latter case
immunogenic cell death.9 It was concluded from these
experiments that PKHB1 treatment of tumors prolonged the
life of the animals without affecting the vital and lymphoid
organs. Collectively, these results highlight the potential of
using peptide strategies to target the ubiquitous CD47 receptor
and may appear as complementary to the use of monoclonal
antibodies.3 However, even though PKHB1 appears to be a
promising tool, we remain aware that optimization of its
effectiveness could be an asset in order to reach the
standardized requirements in terms of nanomolar potency in
peptide-based drug development.10 Therefore, an affinity
maturation process capable of increasing the potency of the
peptide for its target would be invaluable. Since the X-ray
structure of the TSP-1/CD47 complex has not been solved to
date, the lead optimization of medicinal peptides remains a
fastidious task involving a long and iterative strategy.11
Nevertheless, the homotrimeric structure of TSP-1,12 the
multifunctional extracellular protein that we endeavor to
mimic, prompted us to evaluate a homotrimerization strategy
of our lead peptide, namely, PKHB1. The implication of
polyvalent interactions for the design and use of multivalent
ligands and inhibitors has been nicely reviewed and
demonstrated elsewhere.13 Typically, a peptide homomultime-
rization approach may be relevant since multivalent
interactions are much stronger than monovalent interactions.14
To this aim, the click chemistry cycloaddition15 of an azido
derivative of PKHB1 was considered.16 This strategy was
recently validated by Saludes and co-workers in the design of a
bradykinin-derived peptide.17
Herein we first describe the structure−activity relationship
(SAR) study that led to the discovery of a new monomeric
peptide as potent as PKHB1 but with better solubility
properties. Second, we discuss how we engaged this monomer
through the homotrimerization process to yield a new, highly
potent trimeric peptide. With regard to the efficacy of our
peptides to trigger cell death, two techniques were used in
parallel and correlated (in combination with microscopic
observations), i.e., (1) classical flow cytometry (FCM), which
combines the detection of phosphatidylserine (PS) exposure
on early apoptotic cells using allophycocyanin-labeled annexin
V (AnnV) and propidium iodide (PI) to distinguish dying cells
from dead cells,18 and (2) a real-time cell analyzer (RTCA), a
technique using noninvasive electrical impedance monitoring
that has been reported to quantify cancer cell proliferation,
viability, invasion, and drug cytotoxicity in a label-free and real-
time manner.19 The latter one was chosen to evaluate the
efficacy of our compounds on an adherent cancer cell line
(A549) because of its easy implementation, avoiding the cell-
harvesting methods required in FCM that are known to affect
the membrane integrity of adherent cancer cells and thus the
proportion of apoptotic cells during detection.20 Nevertheless,
both techniques were used and showed good correlation in cell
death detection. Although the design of our new peptide was
based on PKHB1, we assumed that the homotrimeric nature of
the peptide could trigger RCD that does not involve the same
pathway. Thus, to get further information on the type of cell
death triggered by our new peptides, experiments were realized
in the presence of QVD.Oph (a broad-spectrum caspase
inhibitor), BAPTA (an external calcium chelator), U73122 (a
PLCγ1 inhibitor), and 2-aminoethoxydiphenyl borate (2-APB)
and dantrolene (intracellular calcium channel inhibitors). We
report the results of these experiments that led to the discovery
of two new and potent peptides, the monomer, which we
termed PKT16, and its homotrimer [PKT16]3.
■ RESULTS
We recently described the first serum-stable TSP-1:CD47
binding epitope peptide mimic, i.e., PKHB1, and its ability to
trigger a caspase-independent Ca2+-mediated form of RCD on
CLL cells from patients and MEC-1 cells, a nonadherent CLL
cancer cell line, while sparing normal cells.7,8 The double
AnnV/PI copositive staining and the swelling of the
endoplasmic reticulum observed during the cell death induced
by this peptide7,8 led us to classify it as a “programmed
necrotic” cell death pathway.8,21 Although effective in inducing
rapid and selective RCD of malignant cells, the potency of
PKHB1 in terms of affinity and activity remained to be
improved. To this end, a homotrimerization strategy was
considered using a click chemistry approach, a tertiary amine
as a matrix, and an aminopentanoic acid derivative as spacer.
Unfortunately, because of aggregation propensities observed
with PKHB1 in some buffers, this peptide was not suitable for
the design of the homotrimer. This phenomenon was
attributed to the chaotropic effect of the buffer used to
solubilize the peptide22 together with its β-strand structure,
two parameters favoring the β-sheet nucleation. Thus, in order
to limit this phenomenon, we went back to the PKHB1
sequence to first design a monomer devoid of aggregation
properties. This goal was realized with the help of an N-methyl
scan of the peptide backbone and SAR studies combining
structural studies by NMR and circular dichroism (CD)
spectroscopy, affinity measurement on MEC-1 cell membrane
preparation using an Octet RED instrument as previously
described,8 and AnnV/PI cytotoxicity assays henceforth
coupled to RTCA investigations. N-Methylation of the
backbone amides was chosen for its renowned ability to
disrupt peptide:peptide interactions that promote aggrega-
tion.23 Indeed, the replacement of the amide proton by a
methyl group prevents the hydrogen-bonding interactions that
normally stabilize β-sheet formation. In addition, N-methyl-
amino acids prevent the close approach of β-strands because of
steric hindrance and favor β-strand structure in the peptide
itself by locally restricting the backbone conformation to
extended structures.24 Of importance, backbone methylations
also contribute to enhanced resistance against proteolytic
Journal of Medicinal Chemistry Article
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degradation.25 N-Methylated amino acids have been used in
several systems to control protein and peptide aggrega-
tion.26−28 A number of N-methylated peptides are currently
being evaluated in clinical trials, displaying the promise of this
chemical modification in delivering the next generation of
peptide-based drugs.29−32 We based the setup of our N-Me
sequence scan on the straightforward site-selective approach
developed by Kessler and colleagues,33 thus allowing fast
access to iterative N-methylation of the backbone through the
Fmoc/tBu solid-phase peptide synthesis (SPPS) technique.
The complete methylation process was performed through a
three-step methodology involving activation of the primary
amine via sulfonylation followed by the so-called methylation
using dimethyl sulfate and then elimination of the sulfonyl
moiety with the help of β-mercaptoethanol (Figure 1).
Next, we carried out a SAR study by systematic biological
evaluations of each methylated sequence (peptides 1 to 9) in
terms of affinity and activity. As described in our earlier work,8
such rational design was enabled by the development of a
binding assay using an MEC-1 cell membrane preparation in
order to maintain the essential integrity of the targeted CD47
receptor.34 Thus, the affinities reported as apparent Kd
estimations and shown in Table 1 correspond to the measures
of the peptide interactions with the membrane preparation
containing CD47 under the described conditions. We assumed
that all of our peptides were derived from PKHB1 and that any
variations in their pharmacological profiles were due to
variations in their interaction efficiency with the CD47
receptor since we had previously demonstrated that the
disruption of this interaction by a fusion protein that
specifically binds to CD47 led to inhibition of the cytotoxicity
induced by PKHB1.7 In parallel to binding assay investigations,
the ability of every peptide to selectively induce cell death was
measured by AnnV/PI colabeling on the MEC-1 cancer cell
line. The cytotoxicity activities are given as the mean ± SD of
the percentage of tumor cell death and refer to AnnV-positive
cells (Table 1). Other modifications were also evaluated
(peptides 10−16) to probe the potency of branched or
aromatic side chains by substitution with Ile and Val or Tyr
(Table 1). Both terminal ends were also modified to explore
the impact of the extremities in terms of activity and affinity.
To this end, C-terminal amino acids were replaced by a
carboxamide moiety and N-terminal amines were capped
through acetylation. Furthermore, additional terminal D-Lys
residues were removed to evaluate their biological impact.
Among all of the peptides designed and evaluated, peptide
10 not only appeared to be the most soluble peptide but also
presented a pharmacological profile very similar to that of
PKHB1 with a slight (3-fold) improvement of its affinity. The
conformational effects induced by N-methylation might
explain this improvement. Thus, the secondary structure of
peptide 10 was investigated, first by CD spectroscopy. Figure
2A shows the CD spectra of peptide 10 and the parent peptide
PKHB1. The spectrum of PKHB1 is characteristic of a
random-coil conformation with a negative minimum at 195
nm. The spectrum of peptide 10 exhibits a similar minimum
Figure 1. On-resin synthesis of backbone-N-methylated amino acids for the conception of an N-methyl library of PKHB1 analogues.
Table 1. Sequences, Affinities, and Activities of the Peptides
Designed from the N-Me Scan and Optimization
peptide sequencea Kd (μM)
b
MEC-1 cell death (%),
200 μM, 6 hc
PKHB1 kRFYVVMWKk 43 ± 21 67 ± 8
SPd KWVKYRVMFK NPD NPD
1 k(NMeR)FYVVMWKk 21 ± 1 54 ± 1
2 kR(NMeF)YVVMWKk NPD NPD
3 kRF(NMeY)VVMWKk NPD NPD
4 kRFY(NMeV)VMWKk 36 ± 4 11 ± 0
5 kRFYV(NMeV)MWKk NPD NPD
6 kRFYVV(NMeM)WKk NPD 11 ± 1
7 kRFYVVM(NMeW)Kk NPD NPD
8 kRFYVVMW(NMeK)k 48 ± 12 20 ± 1
9 k(NMeR)
FYVVMW(NMeK)k
38 ± 20 19 ± 1
10 k(NMeR)FYVVXWKk 8.6 ± 2 59 ± 5
11 k(NMeR)FYVVLWKk 15 ± 4 26 ± 8
12 k(NMeR)FYVVIWKk 17 ± 5 25 ± 3
13 k(NMeR)FYVVYWKk 13 ± 2 19 ± 1
14 k(NMeR)FYVVVWKk 9.5 ± 3 23 ± 0
15 Ac-(NMeR)
FYVVXWK-NH2
20 ± 4 51 ± 3
a
D-Amino acids are written in lower-case letters. X is the one-letter
code for the norleucine residue. bBinding affinities were evaluated by
biolayer interferometry using an Octet RED instrument. The reported
apparent Kd values are averages of at least three independent
experiments (standard deviations are indicated). NPD denotes
nonpertinent data. cCell death induction was evaluated through
cytotoxicity assays using AnV/PI colabeling on MEC-1 cancer cells.
The reported data are averages of at least three independent
experiments (standard deviations are indicated). The sum of AnnV
+/PI− and AnnV+/PI+ events were considered for cell death. dThe
scrambled peptide (SP)35 (see the Supporting Information) was
evaluated at 300 μM.
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near 198 nm and another minimum around 215 nm. This
additional contribution may be due to the presence of β-sheet
conformers. Indeed, deconvolution of the CD spectrum
allowed the estimation of a 14% population of β-sheet content
in peptide 10.
We next carried out NMR conformational studies to analyze
the structural effects of N-methylation at the residue level. 1H,
13C, and 15N resonances of peptide 10 were assigned and
revealed the presence of two sets of chemical shifts. The main
chemical shift differences involved the N-Me and CHα
resonances of N-methyl-Arg2 (NMeArg2) and also the HN
resonances of residues Phe3 up to Val6. This chemical shift
heterogeneity was ascribed to cis−trans isomerism of the
tertiary amide group between Lys1 and NMeArg2. The major
form, whose population was estimated to be 91% on the basis
of intensity ratios, corresponds to the trans isomer, as
evidenced by a strong rotating-frame Overhauser effect
(ROE) between the N-Me protons and Hα of Lys1. The
conformation of the major trans form was compared to that of
PKHB1 by examining chemical shifts, J coupling constants, and
ROEs. The structure of PKHB1 was previously shown to be
highly flexible with some propensity to adopt extended
backbone conformations for the FYVV segment containing
aromatic and β-branched residues.8 The comparison of peptide
10 and PKHB1 showed that most of the residues have very
similar chemical shifts, except for positions 2 and 7,
corresponding to the N-methylation and Met-to-Nle sub-
stitution, respectively. The 1Hα and 13Cα chemical shifts
marginally differ from random-coil values, indicating that
peptide 10 does not adopt a stable regular secondary structure
(Figure 2B). The four central residues FYVV exhibit 3JHN−Hα
values that tend to be higher than coil values36 (Figure 2C)
and also have strong sequential Hα−HN ROEs (data not
shown), suggesting that extended conformations are signifi-
cantly populated in this segment. The C-terminal part is
characterized by lower-intensity sequential Hα-HN ROEs and
the presence of sequential HN−HN ROEs (residues 7/8 and
9/10), indicating that it explores less-extended conformations.
Altogether, these NMR parameters show that the conforma-
tional space of residues 3−10 is very similar in peptide 10 and
PKHB1, a result that was somehow not inferred from the CD
study. The differences observed in the CD spectra must
therefore be related to local structural perturbations induced
by N-methylation and possibly changes in the CD spectro-
scopic properties of the tertiary amide bond.37 We conclude
that N-methylation restricts the backbone conformational
space only locally around residues 1−2 and has no major effect
on the global conformation of peptide 10 in segment 3−10.
Overall, we observed that backbone N-methylation conferred
very good solubility, and the peptide did not aggregate in water
or in biological liquids (pure water, phosphate buffers, and
human serum), thereby leading to promising physicochemical
features.
Consequently, with this new peptide 10, which we termed
PKT16, we considered the homotrimerization approach in
order to improve its pharmacological efficacy. The design and
synthesis of the analogue were considered using a click
chemistry strategy with a tertiary amine as a matrix and an
aminopentanoic acid derivative as a spacer (Figure 3). On the
basis of copper-catalyzed azide−alkyne cycloaddition
(CuAAC) processes that have been smartly applied in the
field of peptide therapeutics,44 various reaction conditions
were tested to implement a convenient trimerization strategy
onto scaffold. Surprisingly, the only way to achieve this one-pot
reaction was to use a methanol/acetonitrile mixture as the
solvent and the tetrakis(acetonitrile) complex as the copper I
source. In addition, the incorporation of tris[(1-benzyl-1H-
1,2,3-triazol-4-yl)methyl]amine (TBTA) for copper(I) stabili-
zation was crucial to properly conduct the homotrimer
formation. For this purpose, the monomeric PKT16 (k-
(NMeR)FYVVXWKk) sequence was synthesized on a solid
support using standard Fmoc chemistry (see the Supporting
Information) and coupled to the 5-azidopentanoic acid,45
which was used as a spacer bearing the azido group for click
chemistry (Figure 3. After cleavage and purification, the
unprotected PKT16-N3 peptide was used to perform the
chemoselective click chemistry attachment onto the tripro-
pargylamine matrix (see the Experimental Section for further
explanations regarding detailed reaction conditions). Success-
fully, the homotrimer built around PKT16 was soluble in water
and did not form insoluble aggregates over time, thus
confirming the enhanced physicochemical features. We thereby
started evaluation of the activity of this new trimeric peptide
object, termed [PKT16]3.
We first determined the affinity of [PKT16]3 (on an MEC-1
cell membrane preparation containing CD47 receptor), which
Figure 2. CD- and NMR-based conformational study of peptide 10 and PKHB1. (A) CD spectra of peptide 10 and PKHB1. (B) Chemical shift
deviations (CSDs) from random coil values of 13Cα resonances.38 The same reference random coil values were used for the noncanonical amino
acids of PKT16 (i.e., Arg and Met in place of NMeArg and Nle), explaining the larger CSDs observed for positions 2 and 7. (C) Comparison of
3JHN−Hα coupling constants with corresponding coil values.
36 The coil value for Met was used in place of that for Nle for peptide 10. Nle is the
three-letter code for the norleucine residue.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.9b00024
J. Med. Chem. 2019, 62, 7656−7668
7659
 177  
proved to be about 40-fold stronger than that of its monomeric
precursor (Kd([PKT16]3) = 190 ± 90 nM vs Kd(PKT16) = 8.6
± 2 μM; see the Supporting Information). Its potency to
induce cell death was evaluated on two different cancer cell
lines: (i) the MEC-1 cell line, an established TP53 dysfunc-
tional CLL cell line, and (ii) the adherent A549 nonsmall cell
lung cancer cell line. Cell death was evaluated using classical
FCM for MEC-1 cells (Figure 4) and A549 cells (Figure 5A−
C). The RTCA technique was also used for the A549 cells
(Figure 5D,E). The latter technique was chosen as a control
because of its easy implementation for adherent cells that
avoids the cell-harvesting methods required in FCM, which are
known to affect the membrane integrity of adherent cancer
cells and thus the proportion of apoptotic cells during
detection.20
In a first experiment, the efficiency of [PKT16]3 was
evaluated in a dose-dependent manner and compared with
those of PKHB1 and PKT16 on MEC-1 cells, and the data are
reported in Figure 4A. Moreover, although the design of this
new peptide was based on PKHB1, for which we reported a
caspase-independent Ca2+-mediated form of RCD,7,8 we
assume that the homotrimeric nature of the peptide could
trigger a different RCD pathway. Indeed, microscopy
observations of cells treated with the different peptides (Figure
4B) highlighted the ability of this new homotrimeric peptide to
induce cell aggregation. This might be explained by its
multivalency, which can promote simultaneous interactions
with receptors of different cells. Thus, in order to highlight the
cell death mechanism, in a second experiment cells were
pretreated with Q-VD-OPH (a broad-spectrum caspase
inhibitor), BAPTA (an extracellular calcium chelator),
U73122 (a PLCγ1 inhibitor), and 2-APB and dantrolene
(intracellular calcium channel inhibitors) before incubation
with the peptides (Figure 4C and Table S4).
[PKT16]3 was a much more potent RCD inducer than its
monomeric counterpart PKT16 and PKHB1 in MEC-1 cells.
Thus, its potency was also evaluated and compared to that of
PKHB1 and PKT16 on the adherent human pulmonary
alveolar epithelial cell line A549, and the data are reported in
Figure 5A. Contrary to caspase inhibition, which had no effect
on cell death induced by any of the three peptides, impairing
Ca2+ signaling significantly decreased PKHB1-, PKT16- and
[PKT16]3-induced cell death in A549 cells as well (Figure
5B,C and Table S5).
Enhanced cell adhesion was also a relevant feature of
[PKT16]3-induced RCD in A549 cells, which strongly stuck to
the well surface after treatment. In fact, cell collection from the
well prior to cell death analysis was a highly challenging task,
since trypsin was not very efficient at removing a
subpopulation of cells with morphological features character-
istic of [PKT16]3-induced RCD (Figure S2). Therefore, the
RTCA technique was used as a control to evaluate the cell
death induced by our new peptide because of its easy
implementation that avoids cell-harvesting methods, which
are known to affect the membrane integrity of adherent cells
and thus the proportion of dead and dying cells during
detection.20 In this way, the [PKT16]3 efficacy was also
characterized using RTCA with increasing peptide concen-
trations for up to 24 h (Figure 5D) together with measurement
of the release of AK (Figure S5) and compared with those of
known cytotoxic concentrations of PKHB1 and PKT16
(Figure 5E).
■ DISCUSSION AND CONCLUSIONS
The TSP-1:CD47 ligation was reported to induce RCD at least
in CLL cells,6 and for the past few years we have focused our
attention on the design of peptide mimics of the TSP-1:CD47
binding epitope. For that purpose, we implemented a SAR
study aimed first to highlight the pharmacophores involved in
this interaction. We reported that the crucial pharmacophores
were not only restricted to the VVM motif but involved mainly
the FYVV sequence.8 These studies led to the design of
PKHB1, the first serum-stable agonist peptide7,8 mimicking the
CD47 binding epitope (i.e., RFYVVMWK) of thrombospon-
din-1 (TSP-1). The PKHB1 sequence appeared to be key for
its activity since a scrambled peptide (SP) (i.e.,
KWVKYRVMFK; see Table 1)35 had no affinity for membrane
preparation or cell death activity under the same conditions.
PKHB1 was proven to be efficient in triggering cell death
selectively in many adherent and nonadherent cancer cell lines
while sparing normal cells. The molecular mechanism triggered
by PKHB1 (caspase-independent cell death mediated by
sustained activation of PLCγ1 leading to intracellular Ca2+
overload) was highlighted, and stimulation of CD47 appeared
to be key in the cytotoxicity induced by this peptide since
disruption of the peptide:CD47 interaction by a fusion protein
designed to specifically bind CD47 led to inhibition of the
cytotoxicity.7 Its potency was also demonstrated in vivo in
mice models at a dose of 10 mg/kg.7,9 However, even though
PKHB1 appeared to be a promising tool, its high in vitro LC50
(200 μM), which might be considered as a drawback in drug
development, led us to design and explore an optimization
process. Since the X-ray structure of the TSP-1/CD47 complex
has not been solved to date, a multimerization approach was
investigated, considering that the homotrimeric structure of
Figure 3. General scheme for the preparation of [PKT16]3.
Incorporation of the azido moiety was achieved via SPPS. Synthesis
of the trimer was performed through a click chemistry reaction for
attachment onto the trialkyne scaffold.
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TSP-1 did not happen by accident but rather is linked to
evolution enabling TSP-1 to interact simultaneously with
multiple receptors.
The design of the homotrimer was first based on the PKHB1
structure (see the Supporting Information)m but because of
the aggregation propensities observed with PKHB1 and its
trimer in some buffers, we concluded that this peptide was not
suitable for our purpose. Thus, in order to limit this
phenomenon, we went back to the PKHB1 structure and
performed an N-methyl scan of its sequence since N-
methylation of the backbone is known to disrupt peptide:pep-
tide interactions that promote aggregation. The implementa-
tion of the N-Me scan enabled the identification of key
positions for amide backbone modification (Table 1). First, we
observed that some of the residues do not have the capacity to
accept N-methylation. Notably, with regard to the FYVV
segment, previously identified as the peptide pharmacophore,8
methylation of the backbone ultimately yielded a complete
drop in activity, as observed with peptides 2, 3, 4, and 5, thus
confirming that structural information included in this four-
residue motif is crucial for CD47 engagement. Furthermore,
we observed here that the only residue that can be methylated
without a dramatic decrease in efficacy is Arg2, since peptide 1
retains full affinity and a range of activity similar to that of
PKHB1. To evaluate the impact of multiple backbone
methylations, the data observed with peptides 1 and 8 led us
to design the doubly N-methylated peptide 9. This peptide,
which resulted from two successive N-methylations at Arg2
and Lys9, presented a pharmacological profile similar to that of
peptide 8. This confirmed that unlike the suitable Arg2
position, N-methylation of Lys9 is deleterious, as observed
with peptide 8. These data indicated that a single methylation
might be sufficient to prevent peptide aggregation while
maintaining efficiency. Actually, like the Pro residue, N-
methylation is known to favor turn secondary structures in
peptide sequences, thereby leading to disruption of the desired
extended conformation.39 According to the N-Me scan results,
Arg2 was identified as the key amino acid to suitably accept
backbone N-methylation. In addition, we also introduced
chemical modifications into the sequence of peptide 1, for
instance, replacement of Met7 with all-hydrocarbon counter-
part Nle, as Met had previously been shown to be readily
replaceable by Nle.8 This modification was proposed to avoid
possible oxidation of the sulfur atom of the Met side chain,
which might lead to decreased potency, as observed in the case
of tachykinins.40 This was demonstrated by the synthesis and
biological evaluation of the sulfoxide and sulfone derivatives of
PKHB1, which proved to be totally inactive (see the data
related to PKHB1-SO and PKHB1-SO2 given in the
Supporting Information).
Figure 4. Low concentrations of [PKT16]3 induce caspase-independent cell death regulated by Ca
2+ in MEC-1 cells. (A) Comparison of cell death
induction by different TSP-1-mimetic peptides. Cells were treated with the indicated peptide concentrations in complete medium, and cell death
was analyzed by AnnV/PI staining. Histograms represent the mean ± SD of two independent experiments. (B) Microscopy observations (20×) of
cells treated with vehicle, PKHB1 (200 μM), PKT16 (200 μM), or [PKT16]3 (20 μM). (C) Effect of pharmacological inhibition of caspases or
calcium signaling in [PKT16]3-induced cell death. Cells were preincubated with vehicle (Control), Q-VD-OPH (10 μM), BAPTA (3 mM),
U73122 (400 nM), 2-APB (60 μM), dantrolene (80 μM), or a 1/3 combination of the last three (133 nM U73122, 20 μM 2-APB, 27 μM
dantrolene) 1 h before treatment with [PKT16]3 (5 μM), PKT16 (50 μM), or PKHB1 (50 μM) in serum-free medium to limit peptide interactions
with albumin (see Figure S3). Cell death was analyzed by flow cytometry using AnnV/PI staining, and the cell death index was obtained by
normalizing to 1.0 the cell death induced by each peptide with its corresponding control (see the Supporting Information). Histograms represent
the mean ± SD of at least two independent experiments. Two-way ANOVA: ***, P ≤ 0.0001; **, P ≤ 0.001; *, P ≤ 0.05.
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With regard to the SAR study performed (i) to probe the
potency of branched or aromatic side chains by substitution
with Ile, Val, and Tyr and (ii) to explore the impact of the
extremities in terms of activity and affinity (Table 1), the
results showed that only amino acids presenting linear side
chains are suitable to mimic Met7. Indeed, branched (Ile and
Val) and aromatic (Tyr) residues are deleterious for peptide
efficacy, as observed with peptides 11, 12, 13, and 14,
suggesting that the CD47 binding pocket interacting with these
side chains is rather small since it accepts only linear moieties.
Nevertheless, these data have to be interpreted carefully since
these modified peptides were prone to aggregation, as
suggested by their more hydrophobic profiles. Chemical
modifications of the extremities yielded the potent peptide
15, but this peptide was not suitable for the design of the
homotrimer, which required a free amine function at the N-
terminus.
Finally, peptide 10, in which Arg2 is N-methylated and Met7
is replaced by Nle, was chosen for further investigation because
of (i) its structure suitable for further development, (ii) its
potency similar to that of PKHB1, and (iii) its higher solubility
in all of the buffers tested. This crucial point was confirmed
during the structural analyses of peptide 10 realized by NMR
and CD spectroscopy. Indeed, we observed by NMR
spectroscopy that backbone N-methylation conferred very
good solubility and that the peptide did not aggregate in either
water or biological liquids (pure water, phosphate buffers, and
human serum), thereby leading to promising physicochemical
features.
Consequently, with peptide 10, which we termed PKT16,
the homotrimerization was investigated using a click chemistry
strategy with a tertiary amine as a matrix and an amino-
pentanoic acid derivative as a spacer (Figure 3). The synthesis
was realized in a one-pot reaction for which the use of a
Figure 5. [PKT16]3 induces caspase-independent cell death regulated by Ca
2+ in A549 cells. (A) Comparison of cell death induction by different
TSP-1-mimetic peptides. Cells were treated with the indicated peptide concentrations in complete medium, and cell death was analyzed by AnnV/
PI staining. Histograms represent the mean ± SD of two independent experiments. (B) Effect of pharmacological inhibition of caspases or calcium
signaling in [PKT16]3-induced cell death. Cells were preincubated with vehicle (Control), Q-VD-OPH (10 μM), BAPTA (3 mM), U73122 (400
nM), 2-APB (60 μM), dantrolene (80 μM), or a 1/3 combination of the last three (133 nM U73122, 20 μM 2-APB, 27 μM dantrolene) 1 h before
treatment with [PKT16]3 (10 μM), PKT16 (100 μM), or PKHB1 (100 μM) in serum-free medium to limit peptide interactions with albumin (see
Figure S3). Cell death was quantified by AnnV/PI and trypan blue staining, and the cell death index was calculated as in Figure 4C. Histograms
represent the mean ± SD of two independent experiments. Two-way ANOVA: ***, P ≤ 0.0001; **, P ≤ 0.001; *, P ≤ 0.05. (C) Microscopy
observations (20×) of cells treated with the corresponding inhibitors alone (Control) or with TSP-1-mimetic peptides. *Similar morphology was
observed irrespective of the peptide used ([PKT16]3, PKT16, or PKHB1). (D) Full kinetics with cell index parameter on the A549 cell line with
20 000 cells/well and n = 4 repetitions in a single experiment (two independent experiments were performed). Shown are [PKT16]3 dose−
response curves from 5 to 40 μM with the control (0.4% DMSO) in red. (E) Comparison of the impedance signals of DMSO, 4NGG (negative
control),7,8 PKHB1, PKT16, and [PKT16]3 after incubation for 24 h at their respective LC50 values.
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methanol/acetonitrile mixture as the solvent, the tetrakis-
(acetonitrile) complex as the copper(I) source, and incorpo-
ration of TBTA for copper(I) stabilization were revealed to be
crucial to properly conduct the formation of the homotrimer,
which we termed [PKT16]3. Successfully, the homotrimer
built using PKT16 was soluble in water and did not form
insoluble aggregates over time, thus confirming the enhanced
physicochemical features. We therefore started its pharmaco-
logical evaluation by first determining its affinity on an MEC-1
cell membrane preparation containing the CD47 receptor.
Remarkably, we observed a significant synergistic effect that
was not simply additive as a result of the 3-fold increased local
concentration of PKT16 stretches. Indeed, the binding affinity
of the [PKT16]3 homotrimer (190 ± 90 nM) was about 40-
fold stronger compared with its monomeric precursor (8.6 ± 2
μM). Its potency in triggering cell death was evaluated first on
MEC-1 cells and compared with those of monomeric PKHB1
and PKT16 in a dose-dependent manner (Figure 4A). The
LC50 was 20 μM for the homotrimer, while a concentration of
200 μM was required with the monomers to reach the same
efficacy (see Table 1). Thus, the novel N-methylated trimer
produces 10-fold higher induction of cell death, thereby
confirming the synergistic effect allowed by multivalency. It
should be noted that the observed discrepancy between
activity and affinity is linked to the experimental conditions,
which are different in the binding experiments and cell death
experiments. The binding experiments were performed with a
cell membrane preparation in simple phosphate-buffered saline
(PBS), whereas the cell death experiments were performed
with cells incubated in advanced RPMI medium containing
albumin. Albumin binds low-molecular-weight molecules,
including proteins and peptides, and thus affects the free
peptide concentration required for cell death experiments (see
Figure S3).41 The potency of the homotrimer to induce cell
death was also evaluated on the adherent A549 cancer cell line
(Figure 5). First, the potency was evaluated in a dose-
dependent manner and compared with those of PKHB1 and
PKT16 as for the MEC-1 cells, and the data are reported in
Figure 5A. From these experiments, we can conclude that the
homotrimer is much more potent than the monomers, with an
LC50 between 10 and 20 μM. Furthermore, microscopy
observations highlighted a peculiar behavior of the homotri-
meric peptide (Figures 4B and S2). Indeed, compared with
PKHB1 and PKT16 at 200 μM, for which dead cells were
observed without cell aggregation, the homotrimer peptide led
to cell aggregates, which might be explained by its ability to
establish multivalent interactions with receptors from different
cells. Since this peculiar behavior might result in a different cell
death mechanism than the one described for PKHB1,7 cells
were preincubated with Q-VD-OPH, BAPTA (an external
calcium chelator), U73122 (a PLCγ1 inhibitor), and 2-APB
and dantrolene (intracellular calcium channel inhibitors)
before incubation with each of the three peptides PKHB1,
PKT16, and [PKT16]3 (Figures 4C and 5B). Together with
Ca2+ chelation, inhibition of PLCγ1 or the IP3R or ryanodine
receptors significantly diminished PKHB1- and PKT16-
induced cell death in both cell lines. However, with
[PKT16]3, inhibition of PLCγ1 or the calcium channels
alone caused a significant decrease in cell death of MEC-1 cells
but only a slight decrease that was not significant in A549 cells.
However, combined inhibition of PLCγ1-mediated calcium
signaling significantly decreased cell death in all cases. These
results suggest that PLCγ1-mediated calcium overload is
crucial for [PKT16]3 and its monomeric counterpart PKT16
to trigger RCD in the nonadherent MEC-1 cells, as already
described for PKHB1. However, in the adherent lung cancer
cells, this may also be true for the monomeric peptides PKHB1
and PKT16, but it is not the case for [PKT16]3, in which
PLCγ1-mediated calcium signaling is only a partial modulator
of RCD. Together with morphological observations, the
double AnnV/PI copositive staining observed during MEC-1
cell death induced by [PKT16]3 led us to classify it as a
programmed necrotic cell death pathway similar to that
reported for PKHB1.7,8,21 To go further, in the case of A549
cells, a type of RCD sharing some biochemical and
morphological features of [PKT16]3-induced RCD, such as
caspase independence, ion-exchange dependence, enhanced
cell−substrate adhesion, and focal ballooning of the
perinuclear space, was recently reported under the name of
autosis.42Among other similar cellular stimuli, autotic cell
death can be triggered by a cell-penetrating autophagy-
inducing peptide (Tat-Beclin 1). Moreover, it has been
recently demonstrated that targeting CD47 with a fusion
protein approach (SIRPαD1-Fc) induces autophagy in non-
small cell lung cancer cells, including the A549 cell line.43
However, autosis is defined by autophagy triggering, and it is
an autophagy-dependent cell death mechanism regulated by
the Na+/K+-ATPase pump, which was not assessed in the
present work. Thus, further analysis is needed to know whether
[PKT16]3 induces autosis in A549 cells. Altogether, our results
showing pharmacological inhibition of TSP-1-mimetic pep-
tides in MEC-1 and A549 cells highlight the molecular
disparities among the two cell types, which come from two
different diseases, and demonstrate that TSP-1-mimetic
peptides can restore programmed cell death in both cases.
Since it was reported that the cell-harvesting methods
required in FCM affect the membrane integrity of adherent
cancer cells and thus the proportion of apoptotic cells during
detection,20 cell death induced by [PKT16]3 was also
evaluated using the RTCA technique in a dose-dependent
manner (Figure 5D), and its cell index was compared with
those of PKHB1 and PKT16 at their respective LC50 values
(Figure 5E). The cell index was continuously recorded every
minute for 24 h, and treatments were realized 1 h after the
beginning of the cell index recording (see the arrows in Figure
5D,E). For all of these experiments, the addition of peptide
provoked first a large increase in the impedance signal that was
attributed to the calcium burst we already observed through
CD47 receptor activation with PKHB1 in CLL cells. In Figure
5D, the experiment realized in a dose-dependent manner
(from 5 to 40 μM) highlighted a rapid and profound
diminution of the cell index upon 2 h treatments at peptide
concentrations of 20 and 40 μM. These observations correlate
with those realized by FCM. Indeed, the maximum diminution
of the cell index was observed from 20 μM, corresponding to
the approximate LC50 estimated for this cell line using FCM.
This ability of our peptide to induce profound diminution of
the cell index was correlated to the loss of cell membrane
integrity identified by measurement of the release of adenylate
kinase (AK) (see Figure S5D). The loss of cell membrane
integrity is also reflected by the double AnnV/PI staining in
FCM. Finally, the impedance signals in cells treated with
PKHB1, PKT16, or its trimer [PKT16]3 were similar when the
cells were treated with their respective LC50’s (Figure 5E).
Again, even for the PKHB1 and PKT16 monomers, the
profound diminution of the cell index was correlated to the
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loss of cell membrane integrity identified by measurement of
the release of AK (see Figure S5E). This technique is therefore
effective and powerful to quickly and simply evaluate the
potency of our compounds on adherent cancer cell lines.
In conclusion, in this work we designed a new series of
soluble peptides mimicking the action of the TSP-1 C-terminal
binding domain, namely, the selective induction of RCD in
tumors. We initiated rational SAR studies that led to the
discovery of mimetic peptides, the monomer termed PKT16
and its trimeric analogue [PKT16]3, both with improved
pharmacological features, increased solubility, fitter structural
properties, and higher efficacy. Such refinements were
unlocked by scanning the entire sequence through amide
backbone N-methylation and the judicious substitution of key
amino acids. In order to further ameliorate our lead properties,
we set up a multivalency strategy through homotrimerization
of active peptide stretches mounted onto a rigid small-
molecule scaffold. Preparation of the trimer object via click
chemistry yielded a soluble biopolymer that presented deeply
improved pharmacological parameters in terms of activity and
affinity. To our knowledge, this trimeric peptide is the
strongest-affinity and most active TSP-1 C-terminal binding
domain-mimetic peptide in triggering RCD through CD47
engagement in tumors. Many pieces of evidence urge us to
propose programmed necrotic cell death as the cell death
mechanism triggered by our peptide. However, the behavior of
our homotrimer led us to propose a death mechanism
comparable to autosis, which, however, remains to be
characterized here. Overall, this work provides several insights
of major importance for identifying potent therapeutic
strategies in the design of new TSP-1 C-terminal binding
domain-mimetic peptides triggering RCD of cancer cells.
■ EXPERIMENTAL SECTION
1. General Chemistry. 1.1. Peptide Synthesis. All of the peptides
were manually synthesized from Fmoc-protected amino acids utilizing
standard SPPS methods. SPPS was performed in polypropylene
Torviq syringes (10 or 20 mL) fitted with a polyethylene porous disk
at the bottom and closed with an appropriate piston. Solvent and
soluble reagents were removed through back-and-forth movements.
The appropriate protected amino acids were sequentially coupled
using PyOxim/Oxyma as coupling reagents. The peptides were
cleaved from the chlorotrityl or Rink amide resin with a classical
cleavage cocktail (95:2.5:2.5 TFA/TIS/H2O). The crude products
were purified using preparative-scale HPLC. The final products were
characterized by analytical LC−MS and NMR spectroscopy. All of the
tested compounds were TFA salts and were at least 95% pure.
Detailed NMR studies were performed for the relevant peptides, and
assignment tables are provided in the Supporting Information.
1.2. Site-Selective N-Methylation of the Amide Backbone.
Residues were N-methylated on the solid phase through Kessler’s
methodology.33 First, the free amino functionality was protected and
activated with the o-nitrobenzenesulfonyl (o-NBS) group, then N-
methylated using 1,8-diazabicyclo[5,4,0]undec-7-ene (DBU) and
dimethyl sulfate (DMS), and finally deprotected (removal of o-
NBS) by treating the resin with β-mercaptoethanol and DBU. For o-
NBS activation, a solution of o-NBS-Cl (4 equiv) and collidine (10
equiv) in N-methylpyrrolidone (NMP) was added to the resin-bound
free-amine peptides and shaken for 15 min at room temperature. The
resin was washed with NMP (5×). For N-methylation with DBU and
DMS, a solution of DBU (3 equiv) in NMP was added to the resin
bound o-NBS-protected peptides, and the resulting mixture was
shaken for 3 min. A solution of DMS (10 equiv) in NMP was added
to the reaction mixture, which was then shaken for 2 min. The resin
was filtered off and washed once with NMP, and the N-methylation
procedure was repeated once more. The resin was washed with NMP
(5×). For o-NBS removal, the resin bound N-methyl-N-o-NBS
peptides were treated with a solution of β-mercaptoethanol (10
equiv) and DBU (5 equiv) in NMP for 5 min. The deprotection
procedure was repeated once more, and the resin was washed with
NMP (5×).
1.3. Homotrimerization by Solution-Phase Click Chemistry.
Typically, pure azido peptide derivative (36 mg, 19 μmol, 3.6
equiv) was taken up in 750 μL of MeOH that had previously been
frozen, put on a vacuum pump to remove gas molecules, and then
purged with N2 for at least 30 min. To this mixture was added
tripropargylamine (0.94 μL, 6.7 μmol, 1 equiv) in 250 μL of MeOH,
followed by the addition of TBTA (21 mg, 40 μmol, 6 equiv) and
t e t r a k i s ( a c e ton i t r i l e ) coppe r ( I ) h ex afluo ropho spha t e ,
[(CH3CN)4Cu]PF6 (78 mg, 203 μmol, 30 equiv). To this mixture
was added MeCN dropwise (around 20 drops) to bring everything
into solution, and the reaction was allowed to proceed in a round-
bottom flask at room temperature under a flow of nitrogen with
constant stirring for a maximum of 72 h. The sample was quenched
with 5 mL of H2O, frozen, and then lyophilized. The dried crude
product was resuspended in 0.1 M EDTA (3 × 5 mL to rinse the
tube), loaded on a 1.6 g Zeoprep 90 C18 cartridge (particle size 40−
63 μm), and sequentially eluted with 15 mL of H2O, 1:1 H2O/
MeCN, and MeCN. Each fraction was collected in a round-bottom
flask and analyzed by LC−MS (method A). The EDTA, H2O, and
H2O/MeCN fractions were concentrated to dryness, resuspended in
H2O, filtered with a 0.22 μm filter, and purified as described earlier to
isolate the peptide homotrimer.
1.4. Analytics. All of the analytical data are given in the Supporting
Information. Two methods were conducted for LC−MS analysis.
Method A: Analytical HPLC was conducted on an X-Select CSH
C18 XP column (30 mm × 4.6 mm i.d., 2.5 μm), eluting with 0.1%
formic acid in water (solvent A) and 0.1% formic acid in acetonitrile
(solvent B) using the following elution gradient: 0−3.2 min, 0−50%
B; 3.2−4 min, 100% B. The flow rate was 1.8 mL/min at 40 °C. The
mass spectra were recorded on a Waters ZQ mass spectrometer using
electrospray positive ionization (ES+) mode to give [M + H]+
molecular ions or electrospray negative ionization (ES−) mode to
give [M − H]− molecular ions. The cone voltage was 20 V.
Method B. Analytical HPLC was conducted on an X-Select CSH
C18 XP column (30 mm × 4.6 mm i.d., 2.5 μm), eluting with 0.1%
formic acid in water (solvent A) and 0.1% formic acid in acetonitrile
(solvent B) using the following elution gradient: 0−3.2 min, 5−100%
B; 3.2−4 min, 100% B. The flow rate was 1.8 mL/min at 40 °C. The
mass spectra were recorded on a Waters ZQ mass spectrometer in ES
+ or ES− mode. The cone voltage was 20 V.
1.5. Purification. Preparative-scale purification of peptides was
performed by reversed-phase HPLC on a Waters system consisting of
a quaternary gradient module (Waters 2535) and a dual-wavelength
UV/vis absorbance detector (Waters 2489), piloted by Empower Pro
3 software using the following columns: a preparative Macherey-Nagel
column (Nucleodur HTec, C18, 250 mm × 16 mm i.d., 5 μm, 110 Å)
and a preparative Higgins analytical column (Proto 200, C18, 150
mm × 20 mm i.d., 5 μm, 200 Å) at flow rates of 14 and 20 mL/min,
respectively. Small-scale crudes (<30 mg) were purified using a
semipreparative Ace column (Ace 5, C18, 250 mm × 10 mm i.d., 5
μm, 300 Å) at a flow rate of 5 mL/min. Purification gradients were
chosen to get a ramp of approximately 1% solution B min−1 in the
interest area, and UV detection was done at 220 and 280 nm. Peptide
fractions from purification were analyzed by LC−MS (method A or B
depending on the retention time) or by analytical HPLC on a Dionex
system consisting of an automated LC system (Ultimate 3000)
equipped with an autosampler, a pump block composed of two
ternary gradient pumps, and a dual-wavelength detector, piloted by
Chromeleon software. All of the LC−MS and HPLC analyses were
performed on C18 columns. The pure fractions were gathered
according to their purities and then freeze-dried using an Alpha 2/4
freeze-dryer (Bioblock Scientific) to get the expected peptide as a
white powder. The final peptide purity of the corresponding pooled
fractions (>95%) was checked by LC−MS using method A.
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2. Peptide Stability Studies. 2.1. Degradation Assays in
Human Serum and Mouse Plasma. To a mixture of 250 μL of
human serum or mouse plasma and 750 μL of RPMI 1640 medium
was added 20 μL of the peptide DMSO stock solution at 10 mM. The
mixture was incubated at 37 °C, and 100 μL aliquots were removed
from the medium at different times, mixed with 100 μL of TCA
solution (6%), and incubated at 4 °C for at least 15 min to precipitate
all of the serum proteins. After centrifugation at 12 000 rpm for 2 min,
50 μL of the supernatant was transferred to an injection vial and
analyzed by HPLC with a linear gradient of MeCN in water (5 to 95%
+ 0.1% TFA). The relative concentrations of the remaining soluble
peptides were calculated by integration of the absorbance at 220 nm
as a function of the retention time (peak area).
2.2. Stability under Chymotrypsin and Trypsin Incubation. A 0.6
mL microcentrifuge tube was charged with 180 μL of phosphate
buffer (pH 7.4), 10 μL of enzyme (0.05 mg/mL stock solution in pH
7.4 phosphate buffer), and 10 μL of peptide (10 mM stock solution in
DMSO). The resulting reaction mixture was capped and incubated at
room temperature for 3 h. A 20 μL aliquot of the crude reaction
mixture was quenched by addition of 180 μL of 1:1 water/
acetonitrile, and the resulting mixture was subjected to LC−MS
analysis.
3. Structural Analyses. 3.1. CD Spectroscopy. CD experiments
were performed on a Jasco J-815 CD spectropolarimeter with a Peltier
temperature-controlled cell holder (30 °C) over the wavelength range
190−270 nm. Peptide samples were prepared at a concentration of 50
μM in 10 mM sodium phosphate buffer (pH 7.4) using a quartz cell
with a path length of 1 mm. Measurements were taken every 0.2 nm
at a scan rate of 10 nm/min.
3.2. NMR Spectroscopy. Lyophilized PKT16 peptide was dissolved
at 1 mM concentration in 550 μL of H2O/D2O (90:10 v/v). Sodium
4,4-dimethyl-4-silapentane-1-sulfonate-d6 (DSS) (Sigma-Aldrich) was
added at a final concentration of 0.11 mM for chemical shift
calibration. NMR experiments were recorded on a Bruker Avance III
500 MHz spectrometer equipped with a TCI 1H/13C/15N cryoprobe
with Z-axis gradient. NMR spectra were processed with TopSpin 3.2
software (Bruker) and analyzed with the NMRFAM-SPARKY
program.38 1H, 13C, and 15N resonances were assigned using 1D 1H
WATERGATE, 2D 1H−1H TOCSY (DIPSI-2 isotropic scheme of 80
ms duration), 2D 1H−1H ROESY (300 ms mixing time), 2D 1H−13C
HSQC, 2D 1H−15N HSQC, and 2D 1H−13C HMBC spectra
recorded at 25 °C. 1H chemical shifts were referenced against the
DSS 1H signal, and 13C and 15N chemical shifts were referenced
indirectly. The chemical shift deviations were calculated as the
differences between the observed 1H and 13C chemical shifts and
random coil values.46 3JHN−Hα coupling constants were measured by
1D 1H WATERGATE experiments recorded at 5 or 25 °C or 1D
rows extracted from 2D TOCSY spectra acquired with high
resolution.
4. Biological Assays. 4.1. Binding Affinity Measurements by
Biolayer Interferometry. The binding affinities of peptides for a
membrane preparation from MEC-1 cells were measured by biolayer
interferometry on an Octet RED96 System (Pall ForteB́io Corp.,
Menlo Park, CA). This system monitors interference of light reflected
from two sources (an internal reflection surface and the liquid−solid
interface of a fiber optic sensor) to measure the rate of binding of
molecules to the biosensor surface. MEC-1 cell membrane
preparations were biotinylated with an EZ-Link NHS-PEG4-Biotin
kit from Thermo Scientific. Biotinylated membranes were then loaded
onto SuperStreptavidin (SSA) biosensors (Pall ForteB́io Corp.) at
empirically determined concentrations. All of the affinity measure-
ments were carried out in assay buffer (PBS with 0.2% bovine serum
albumin (BSA) and 1% DMSO) at 30 °C. The assay protocols are
further detailed in the Supporting Information.
4.2. Cell Death Induction and Pharmacological Inhibition.
MEC-1 cells (an established CLL cell line with dysfunctional TP53)
and A549 cells (human alveolar basal epithelial adenocarcinoma cells)
were maintained in complete medium (Advanced RPMI 1640
supplemented with 10% fetal calf serum, 2 mM L-glutamine, and
100 units/mL penicillin−streptomycin). Cell death was induced by
treating MEC-1 cells for 2 h or A549 cells for 6 h with the indicated
peptide concentrations. Etoposide (200 μM, 24 h) was used as a
positive control for p53- and caspase-dependent apoptosis. Cell death
was measured by flow cytometry using AnnV-APC (0.1 μg/mL; BD
Biosciences) and PI (0.5 μg/mL; Sigma-Aldrich) staining or by the
automated counting of trypan-blue-stained cells (Beckman Vi-CELL
XR cell viability analyzer). Q-VD-OPH (BioVision, Milpitas, CA,
USA), BAPTA (CalbioChem; Merck, Billerica, MA, USA), U73122
(Sigma-Aldrich), 2-APB (Sigma-Aldrich), and dantrolene (Sigma-
Aldrich) were used as indicated in the figure legends. Two-way
ANOVA was performed using GraphPad Prism 8.0 software for
statistical analysis.
4.3. Cell Viability Evaluation by Impedance Measurement. The
xCELLigence system (ACEA Biosciences Inc.) monitors cellular
events in real time without the incorporation of labels. The system
measures the electrical impedance across interdigitated micro-
electrodes integrated on the bottom of tissue culture E-Plates (16-
well). The impedance measurement provides quantitative information
about the biological status of the cells, including cell number, viability,
and morphology. With regard to cell culture, A549 cells were grown in
RPMI 1640 medium supplemented with 10% fetal bovine serum and
2 mM L-glutamine. The peptide incubations were perfomed in RPMI-
1640 medium supplemented with 2 mM L-glutamine and 0.2% BSA
(incubation medium). For our experiments, 50 μL of growth medium
was added to each well of the 16-well E-plate to measure background
levels of impedance. Then 150 μL of cell suspension was added to
reach a cell density of 20 000 cells/well. Cells were allowed to seed at
room temperature for 30 min and then placed in the reader at 37 °C
and 5% CO2 for real-time recording of the cell index. The following
day, the growth medium was removed and replaced with 100 μL of
the incubation medium. After stabilization of the impedance signal for
2 h, 100 μL of incubation medium containing 2-fold peptide
concentrations was added to the cells in order to reach the desired
concentration in the well (direct addition of DMSO caused stress and
damaged the cells). Negative controls were treated with the vehicle
(DMSO at 0.4% final concentration). Each condition was tested in
triplicate or quadruplicate and in two independent experiments. The
cells were monitored every minute until 24 h after treatment.
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1. Synthesis and characterization of the peptides 
 
General methods:  
 
Chemicals: All commercial chemicals and solvents were reagent grade and were 
used without further purification unless otherwise specified. All reactions except those in 
aqueous media were carried out with the use of standard techniques for the exclusion of 
moisture. All reactions were performed under argon or nitrogen in oven-dried glassware 
using anhydrous solvents and standard syringe techniques. Peptide synthesis 
transformations and washes were performed at room temperature. All Fmoc carbamate 
protected amino acid derivatives, coupling reagents (PyOxim/Oxyma Pure), Fmoc-Rink 
Amide (200-400 mesh, loading 0.62 mmol/g) and 2-CTC resin (100-200 mesh, loading 
1.6 mmol/g) were purchased from Iris Biotech (Marktredwitz, Germany). Reagents such 
as DIEA, piperidine, DMF, IPA, Ac2O, MeOH, TFA and TIS were obtained from Sigma-
Aldrich (Saint Louis, USA). Compounds molecular weights were calculated using 
ChemBioDraw® Ultra 12. All final products were of > 95% purity unless otherwise 
indicated (determined by analytical reverse phase LC-MS). Analytical data are given in 
Table S1.  
  
Analytics: Two methods were conducted for LC-MS analysis. Method A: analytical 
HPLC was conducted on a X-Select CSH C18 XP column (30 × 4.6 mm id, 2.5 μm) 
eluting with 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile 
(solvent B), using the following elution gradient 0 - 3.2 min: 0% to 50% B, 3.2 - 4 min 
100% B, at a flow rate of 1.8 mL/min at 40 °C. The mass spectra (MS) were recorded on 
a Waters ZQ mass spectrometer using electrospray positive ionisation [ES+ to give (MH)+ 
molecular ions] or electrospray negative ionisation [ES- to give (MH)- molecular ions] 
modes. The cone voltage was 20 V. Method B: analytical HPLC was conducted on a X-
Select CSH C18 XP column (30 × 4.6 mm id, 2.5 μm) eluting with 0.1% formic acid in 
water (solvent A) and 0.1% formic acid in acetonitrile (solvent B), using the following 
elution gradient 0 - 3.2 min: 5% to 100% B, 3.2 - 4 min: 100% B, at a flow rate of 1.8 
mL/min at 40 °C. The mass spectra (MS) were recorded on a Waters ZQ mass 
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spectrometer using electrospray positive ionisation [ES+ to give (MH)+ molecular ions] 
or electrospray negative ionisation [ES- to give (MH)- molecular ions] modes. The cone 
voltage was 20 V.  
 
Purification: Preparative scale purification of peptides was performed by reverse 
phase HPLC on a Waters system consisted of a quaternary gradient module (Water 2535) 
and a dual wavelength UV/Visible Absorbance detector (Waters 2489), piloted by 
Empower Pro 3 software using the following columns: preparative Macherey-Nagel 
column (Nucleodur HTec, C18, 250 × 16 mm id, 5 μm, 110 Å) and preparative Higgins 
Analytical column (Proto 200, C18, 150 × 20 mm id, 5 μm, 200 Å) at a flow rate of 14 
mL/min and 20 mL/min respectively. Small- scale crudes (< 30 mg) were purified using 
semi-preparative Ace column (Ace 5, C18, 250 × 10 mm id, 5 μm, 300 Å) at a flow rate 
of 5 mL/min. Purification gradients were chosen to get a ramp of approximately 1% 
solution B per minute in the interest area and UV detection was done at 220 nm and 280 
nm. Peptide fractions from purification were analyzed by LC-MS (method A or B 
depending of retention time) or by analytical HPLC on a Dionex system consisted of an 
automated LC system (Ultimate 3000) equipped with an auto sampler, a pump block 
composed of two ternary gradient pumps and a dual wave-length detector, piloted by 
Chromeleon software. All LC-MS or HPLC analyses were performed on C18 columns. 
The pure fractions were gathered according to their purity and then freeze-dried using an 
Alpha 2/4 freeze dryer from Bioblock Scientific to get the expected peptide as a white 
powder. Final peptide purity (> 95%) of the corresponding pooled fractions was checked 
by LC-MS using method A.  
 
Manual loading of the first amino acid: 
Solid-phase peptide syntheses were performed in polypropylene Torviq syringes (10 
or 20 mL) fitted with a polyethylene porous disc at the bottom and closed with an 
appropriate piston. Solvent and soluble reagents were removed through back and forth 
movements. The 2-CTC resin was previously swelled in strictly anhydrous DCM 
(distilled) for 2 h. Side-chain protected Fmoc-Aa-OH (0.30 mmol, 1eq.) was coupled to 
2-CTC resin (400 mg, loading 1.6 mmol/g) in the presence of DIEA (1.2 mmol, 4 eq.) in 
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DCM (4 mL). The unreacted sites on the resin were capped by washing with a mixture of 
DCM/MeOH/DIEA (17:2:1) repeated 3 times. Thus loading was reduced to 0.80 mmol/g 
for optimal peptide growth. In the case of Rink Amide resin, swollen in DCM was done 
similarly in 2 h (500 mg, loading 0.62 mmol/g). However, first coupling was directly 
performed with protected Fmoc-Aa-OH (1.2 mmol, 4 eq.), PyOxim (1.2 mmol, 4 eq.), 
Oxyma Pure (1.2 mmol, 4 eq.) and DIEA (2.4 mmol, 8 eq.) without loading decreasing.  
 
Manual solid phase peptide synthesis:  
In all syntheses the scale was 0.30 mmol. Fmoc group was split off by treatment 
with piperidine/DMF (1:4) (1 × 1 min, 1 × 10 min). Washing steps between deprotection 
and coupling were carried out with DMF (3 × 1 min), IPA (3 × 1 min) and DMF (3 × 1 
min). Activation step was carried out with Fmoc-Aa-OH (1.2 mmol, 4 eq.), PyOxim (1.2 
mmol, 4 eq.) as coupling agent, Oxyma Pure (1.2 mmol, 4 eq.) as auxiliary nucleophile, 
and DIEA (2.4 mmol, 8 eq.) as base. The activated amino acid is then transferred to the 
resin where the coupling was performed for 1 to 18 h. Supported coupling reactions were 
monitored by classical Kaiser test (solution kit from Sigma-Aldrich). When elongation of 
the peptide chain was completed, a MeOH washing step was added after final N-terminal 
Fmoc removal for complete shrinkage of the resin under vacuum. 
 
Site-selective N-Methylation of peptide backbone:  
Residue was N-methylated on solid-phase through Kessler’s methodology: first, the 
free amino functionality was protected and activated with the o-nitrobenzenesulfonyl (o-
NBS) group, then N-methylated using 1,8-diazabicyclo[5,4,0]undec-7-ene (DBU) and 
dimethylsulfate (DMS), and finally deprotected (removal of o-NBS) by treating the resin 
with ß-mercaptoethanol and DBU. 
• o-NBS Activation: A solution of o-NBS-Cl (4 eq.) and collidine (10 eq.) in NMP was 
added to the resin-bound free amine peptides and shaken for 15 min at room 
temperature. The resin was washed with NMP (5×).  
• N-Methylation with DBU and DMS: A solution of DBU (3 eq.) in NMP was added to 
the resin bound o-NBS-protected peptides and shaken for 3 min. A solution of 
dimethylsulfate (10 eq.) in NMP was then added to the reaction mixture and shaken for 
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2 min. The resin was filtered off, washed once with NMP and the N-methylation 
procedure repeated once more. The resin was washed with NMP (5×).  
• o-NBS Deprotection: The resin bound Nα-methyl-Nα-o-NBS-peptides was treated 
with a solution of ß-mercaptoethanol (10 eq) and DBU (5 eq) in NMP for 5 min. The 
deprotection procedure was repeated once more and the resin was washed with NMP 
(5×). 
 
Homotrimerization by solution phase click chemistry (CuAAC):  
Typically, pure PKT16-N3 TFA salts (47,1 mg, 24 μmol, 3.6 eq.) was taken up in 
750 μL MeOH that was frozen and put on a vacuum pump to remove gas molecules and 
then purged with N2 for at least 30 min. To this mixture was added tripropargylamine 
(0.94 μL, 6.7 μmol, 1 eq.) in 250 μL MeOH, followed by the addition of Tris[(1-benzyl-
1H-1,2,3-triazol-4-yl)methyl]amine (TBTA, 21 mg, 40 μmol, 6 eq.) and Tetrakis 
(acetonitrile)copper(I) hexafluorophosphate ([(CH3CN)4Cu]PF6, 78 mg, 203 μmol, 30 
eq.). To this mixture was added MeCN dropwise (around 20 drops) to bring everything 
into solution, and the reaction was allowed to proceed in a round-bottom flask at room 
temperature under nitrogen flow with constant stirring for 72 h. The sample was quenched 
with 5 mL H2O, frozen, and then lyophilized. The dried crude product was re-suspended 
in 0.1 M EDTA (3×5 mL to rinse the tube), loaded on a 1.6 g zeo prep 90 C18 (part. size 
40-63 μm) cartridge, and sequentially eluted with 25 mL H2O, 1:1 H2O/MeCN, and 
MeCN. Each fraction was collected in a round-bottom flask and analyzed by LCMS 
(method A). The EDTA, H2O and H2O/MeCN fractions were concentrated to dryness, 
re- suspended in H2O, filtered with 0.22 μm filter and purified as described earlier to 
obtain [PKT16]3 as a white powder (depending on experiments: 5 – 15% yield).  
 
Final side-chain deprotection and cleavage from the resin:  
The crude peptides were treated with the following cleavage cocktail: 
TFA/H2O/TIS (95/2.5/2.5, 10 mL). The syringes were shaken for 3 h and then precipitated 
3 times using cooled Et2O (3 × 30 mL), recovered after centrifugations (3 × 5 min, 7800 
rpm), diethyl ether was removed (3 times), and then the peptide pellets were dried (under 
nitrogen flow). The resulting crude peptide was dissolved in aqueous 0.1% (v/v) TFA. 
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Purification was conducted on reversed-phase HPLC Prep C18 column, eluting with 0.1% 
TFA in water (solvent A) and 0.1% TFA in acetonitrile (solvent B) as described earlier. 
 
Analytical data of synthesized peptides 
 
Table S1. Analytical data for the all synthesized peptides. 
peptide Mw (g·mol-1) m/z (ESI) tR (min) 




































































15 1165.5 1165.6 [M+H]+ 
583.9 [M+2H]2+ 
2.42 
































Retention times are indicated for LCMS method A. Masses determined by LC-MS 



















Peptide 5:  
 
 




Peptide 7:  
 
 










































Determination of peptide concentrations in stock solutions 
 
The concentration of peptide was determined by absorption spectrometry at 280 nm 
or by weighing the lyophilized peptide before dissolving in water, or both. For 
determining the concentration of peptides by absorption spectrometry, theoretical 
extinction coefficients (ε280) were calculated based on the presence of tryptophan (ε = 
5500 M-1cm-1) and tyrosine (ε = 1490 M-1cm-1). For determining the concentration of 
peptides by weighing, it was assumed that one trifluoroacetic acid molecule is bound per 
positive charge of the peptide. The concentration of peptides that contain unnatural amino 
acids absorbing UV light at 280 nm with unknown ε280, or that lack tryptophan or tyrosine, 
was determined by weighing. 
 
2. Stability studies 
 
2.1. Degradation assays in human serum & mouse plasma  
To a mixture of 250 μL of human serum (or mouse plasma) and 750 μL of RPMI 
1640 were added 20 μL of the peptide DMSO stock solution at 10 mM. The mixture was 
incubated at 37 °C. Aliquots of 100 μL were removed from the medium at different time, 
mixed with 100 μL of TCA solution (6%) and incubated at 4 °C for at least 15 min to 
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precipitate all the serum proteins. After centrifugation at 12000 rpm for 2 min, 50 μL of 
the supernatant were transferred to an injection vial and analyzed by HPLC with a linear 
gradient of MeCN in water (5 to 95% + 0.1% TFA). The relative concentrations of the 
remaining soluble peptides were calculated by integration of the absorbance at 220 nm as 
a function of the retention time (peak area).  
 
2.2. Stability under Chymotrypsin and Trypsin incubation  
A 0.6 mL tube was charged with 180 μL of phosphate buffer pH 7.4, 10 μL of 
enzyme (0.05 mg/mL stock solution in phosphate buffer pH 7.4), 10 μL of peptide (10 
mM stock solution in DMSO). The resulting reaction mixture was capped and incubated 
at room temperature for 3 hours. 20 μL of the crude reaction was quenched by addition of 








3. Structural analyses 
 
3.1 CD spectroscopy 
CD experiments were acquired on a Jasco J-815 CD spectropolarimeter with a 
Peltier temperature-controlled cell holder (30 °C) over the wavelength range 190-270 nm. 
Peptide samples were prepared at a concentration of 50 μM in 10 mM sodium phosphate 
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buffer, pH 7.4, using a quartz cell of 1 mm path length. Measurements were taken every 
0.2 nm at a scan rate of 10 nm/min. 
 
3.2. NMR conformational analysis 
Lyophilized PKT16 peptide was dissolved at 1 mM concentration in 550 μL of 
H2O/D2O (90:10 v/v). Sodium 4,4-dimethyl-4-silapentane-1-sulfonate-d6 (DSS, from 
Sigma Aldrich) was added at a final concentration of 0.11 mM for chemical shift 
calibration. NMR experiments were recorded on a Bruker Avance III 500 MHz 
spectrometer equipped with a TCI 1H/13C/15N cryoprobe with Z-axis gradient. NMR 
spectra were processed with TopSpin 3.2 software (Bruker) and analysed with NMRFAM-
SPARKY program.i 1H, 13C, and 15N resonances were assigned using 1D 1H 
WATERGATE, 2D 1H-1H TOCSY (DIPSI-2 isotropic scheme of 80 ms duration), 2D 
1H-1H ROESY (300 ms mixing time), 2D 1H-13C HSQC, 2D 1H-15N HSQC, and 2D 
1H- 13C HMBC recorded at 25 °C. 1H chemical shift was referenced against DSS 1H 
signal and 13C, 15N chemical shifts were referenced indirectly. The chemical shift 
deviations were calculated as the differences between observed 1H, 13C chemical shifts 
and random coil values.ii 3JHN-H! coupling constants were measured on 1D 1H 
WATERGATE experiments recorded at 5 or 25 °C, or on 1D rows extracted from 2D 









4. Binding affinity measurements  
 
The binding affinities of peptides for a MEC-1 cancer cells membrane preparation were 
measured by biolayer interferometry on an Octet RED96 System (Pall FortéBio Corp., 
Menlo Park, CA). This system monitors interference of light reflected from two sources 
(an internal reflection surface and the liquid/solid interface of a fiber optic sensor) to 
measure the rate of binding of molecules to the biosensor surface.  
MEC-1 cells membrane preparation is biotinylated with the EZ-Link NHS-PEG4-Biotin 
kit from Thermo-Scientific and excess biotin is removed using desalting column from 
Thermo- Scientific. Biotinylated membranes are then loaded onto SuperStreptavidin 
(SSA) biosensors (Pall FortéBio Corp.) at empirically determined concentrations. All 
affinity measurements were carried out in assay buffer (PBS with 0.05% Tween 20 and 
1% DMSO) at 30 °C.  
Typically, the biosensors were pre-equilibrated in PBS containing either 
biotinylated membranes or biocytine 100 μg/mL. Biosensors are then equilibrated in assay 
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buffer for 10min, brought to baseline in assay buffer for 60 sec. and transferred to wells 
containing peptide in dose-response (association for 120 sec. and dissociation for 300 
sec.). The double reference with either membrane-loaded biosensors without any peptide 
dose-response or biocytine-loaded biosensors with each peptide dose-response were run 
in parallel for background signal double subtractions. Binding kinetics were calculated 
using the FortéBio Data Analysis v8.2 software. 
 
Table S3. Apparent Kd values 
Peptide Kd 
1 (MeR2) 21 ± 1 μM 
2 (MeF3) NPD 
3 (MeY4) NPD 
4 (MeV5) 36 ± 4 μM 
5 (MeV6) NPD 
6 (MeM7) NPD 
7 (MeW8) NPD 
8 (MeK9) 48 ± 12 μM 
9 (MeR2K9) 38 ± 20 μM 
10 (PKT16) 8.6 ± 2 μM 
11 15 ± 4 μM 
12 17 ± 5 μM 
13 13 ± 2 μM 
14 9.5 ± 3 μM 
15 20 ± 4 μM 
[PKHB1]3 ND 
[PKT16]3 0.19 ± 0.09 μM 
n > 2 independent measurements 
NPD: Non Pertinent Data. 



















5. Cell culture  
 
Human chronic lymphocytic leukemia cells (MEC-1) and lung adenocarcinoma 
cells (A549) were grown in Advanced RPMI-1640 medium supplemented with 10% fetal 
bovine serum (FBS), 100 units/mL penicillin, and 100 μg/mL streptomycin, and 
maintained following the standard procedures proposed by the American Type Culture 
Collection. 
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6. Cell death induction and inhibition  
 
Peptides were solubilized in water or DMSO and stock concentrations were 
measured by protein absorbance at 280 nm using NanoDropTM 8000. Only freshly 
prepared solutions were used for each experiment. Cell death was induced by treating 
MEC-1 cells for two hours or A549 for six hours with the indicated peptide 
concentrations. Etoposide (200 μM, 24 h) was used as positive control for p53- and 
caspase-dependent apoptosis. For the inhibition assays, MEC-1 cells were seeded in non-
supplemented medium prior to treatment with inhibitors to limit Ca2+ concentration in 
the medium, while complete medium was used to let A549 cells adhere overnight but was 
replaced with serum free medium prior to treatment. Calcium chelator, BAPTA (3 mM, 
CalbioChem; Merck, Billerica, MA, USA) or the pan-caspase inhibitor Q-VD-OPh (10 
μM; BioVision, Milpitas, CA, USA) were added 30 minutes before cell death induction, 
while the PLCγ1 inhibitor U73122 (Sigma-Aldrich), the IP3R inhibitor 2-APB (Sigma- 
Aldrich), and the ryanodine receptor inhibitor dantrolene (Sigma-Aldrich) were added one 
hour before. Cell death was analyzed in first instance by microscopic observations 
(Axiovert 40 CFL Zeiss microscope) and comparison of representative photographs (Sony 
Power HAD 3CCD colour video camera coupled to microscope, 20X). Annexin-V-
allophycocyanin (Ann-V-APC 0.1 μg/mL; BD Pharmingen, San Jose CA, USA) and 
propidium iodide (PI, 0.5 μg/mL; Sigma-Aldrich) in annexin binding buffer (ABB, 10 
mM Hepes [pH 7.4], 140 mM NaCl, and 2.5 mM CaCl2) were used to evaluate 
phosphatidylserine exposure and plasma membrane permeability, respectively. Samples 
were sorted in a BD FACSCalibur Flow Cytometer (total population 10 000 cells) and 
data was analysed using FlowJo software (LLC, Ashland, OR, USA). Since peptides-
induced cell death consistently presented a double copositive Ann/PI staining, to evaluate 
cell death in samples where calcium had been chelated, PI staining was used alone in 
Ca2+[-]/Mg2+[-] DPBS (Gibco) to avoid Ca2+ provision by the ABB. For similar 
reasons, a simpler method as it is trypan blue staining, analysed with an automated counter 
(Beckman Vi-CELL XR), was used as well to study A549 cell death in the context of 
PLCγ1-related calcium signalling inhibition. In all cases, the wells were washed twice 
with Ca2+[-]/Mg2+[-] DPBS (Gibco) after supernatant recovering. A549 cells were 
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generally detached using trypsin-EDTA 0.05% (Gibco), but in some cases chymotrypsin 
0.05% (Sigma-Aldrich) was also used to assist [PKT16]3-treated cells detachment. Cell 
death index was calculated by normalizing peptide-specific cell death (% Cell death - % 
Cell death in control) in each condition with peptide-specific cell death induced by the 
peptide alone (Mateo, et al. 2002, doi: https://doi.org/10.1182/blood-2001- 12-0217). 
Two-way ANOVA were performed in GraphPad Prism 8.0 Software for statistical 
analysis. 
 
Table S4. Effect of caspase and Ca2+ signaling inhibition on MEC-1 cell death. 
 Treatment Cell death index SD Difference from control (p ≤ )* 
[PKT16]3 
Control  1.00   
Q-VD-OPH  1.04 0.07 NS 
BAPTA  0.38 0.00 0.0001 
U73122  0.77 0.03 0.0001 
2-APB  0.69 0.04 0.0001 
Dantrolene  0.75 0.08 0.0001 
D+U+2 0.42 0.01 0.0001 
PKT16 
Control  1.00   
Q-VD-OPH  0.95 0.02 NS 
BAPTA  0.00 0.02 0.0001 
U73122  0.60 0.08 0.0001 
2-APB  0.67 0.01 0.0001 
Dantrolene  0.56 0.14 0.0001 
D+U+2 0.39 0.05 0.0001 
PKHB1 
Control  1   
Q-VD-OPH  0.97 0.02 NS 
BAPTA  0.01 0.07 0.0001 
U73122  0.78 0.04 0.001 
2-APB  0.88 0.03 0.05 
Dantrolene  0.79 0.09 0.0001 
D+U+2 0.64 0.17 0.0001 
Etoposide§ 
Control  0.14 0.07  
Q-VD-OPH  0.07 0.02 NS 
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MEC-1 cells were pre incubated with vehicle (control), Q-VD-OPH (10 μM), BAPTA (3 mM) U73122 
(400 nM), 2-APB (60 μM), dantrolene (80 μM), or a 1/3 combination of the last three (U73122 133 nM, 
2-APB 20 μM, dantrolene 27 μM), one hour before treatment with [PKT16]3 (5μM), PKT16 (50μM) or 
PKHB1 (50μM) in serum free medium. Cell death was analysed by flow cytometry using Ann-V/PI 
staining and cell death index was obtained by normalizing to 1.00 the cell death induced by each peptide 
with its corresponding control. The values represent the means (±SD) of at least two independent 
experiments. §Total cell death induced by etoposide is shown instead of cell death in serum free medium 
index. *Two-way ANOVA were used to compare problem vs control data populations. 
 
 
Table S4. Effect of caspase and Ca2+ signaling inhibition on MEC-1 cell death. 
 Treatment Cell death index SD Difference from control (p ≤ )* 
[PKT16]3 
Control  1.00   
Q-VD-OPH  0.99 0.00 NS 
BAPTA  0.52 0.02 0.0001 
U73122  0.84 0.02 NS 
2-APB  0.77 0.08 NS 
Dantrolene  0.86 0.08 NS 
D+U+2 0.73 0.04 0.05 
PKT16 
Control  1.00   
Q-VD-OPH  1.03 0.14 NS 
BAPTA  0.14 0.14 0.0001 
U73122  0.32 0.15 0.0001 
2-APB  0.72 0.04 0.001 
Dantrolene  0.59 0.23 0.0001 
D+U+2 0.51 0.22 0.0001 
PKHB1 
Control  1.00   
Q-VD-OPH  1.03 0.01 NS 
BAPTA  0.29 0.06 0.0001 
U73122  0.34 0.31 0.0001 
2-APB  0.67 0.09 0.001 
Dantrolene  0.52 0.19 0.0001 
D+U+2 0.40 0.26 0.0001 
Etoposide§ 
Control  0.59 0.03  
Q-VD-OPH  0.05 0.04 0.0001 
A549 cells were pre incubated with vehicle (control), Q-VD-OPH (10 μM), BAPTA (3 mM) U73122 
(400 nM), 2-APB (60 μM), dantrolene (80 μM), or a 1/3 combination of the last three (U73122 133 nM, 
2-APB 20 μM, dantrolene 27 μM), one hour before treatment with [PKT16]3 (5μM), PKT16 (50μM) or 
PKHB1 (50μM) in serum free medium. Cell death was analysed by flow cytometry using Ann-V/PI 
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staining and cell death index was obtained by normalizing to 1.00 the cell death induced by each peptide 
with its corresponding control. The values represent the means (±SD) of at least two independent 
experiments. §Total cell death induced by etoposide is shown instead of cell death in serum free medium 





Figure S2. Peptide-induced cell death induces enhanced cell-substrate adhesion: [PKT16]3-treated A549 
cells before and after trypsin-EDTA addition. 
 
 





7. Cell viability evaluation through impedance  
 
7.1. Brief insights about impedance technology  
Label-free detection has emerged as a new approach in the development of 
technologies for cell-based screening assays. Unlike the classic detection methods that use 
fluorescence, radioisotope, luminescence, or light absorption, label-free detection directly 
measures the cell function without using a labeled molecule. The advantages of label-free 
detection include a simple homogeneous assay format, noninvasive measurement, less 
interference with normal cell function, kinetic measurement, and reduced time for assay 
development. Cell-based assays have an important role in drug discovery. Designed 
appropriately, these in vitro tests can help predict the effect of chemical agents in vivo and 
can provide relevant biochemical and pharmacological insight that is not possible in a 
whole animal study. Label-free technologies with the potential to substantially change 
some aspects of whole-cell assays have emerged within the past few years. These 
technologies detect changes in cellular features including adhesion and morphology, 
complex endpoints that are modulated by many different receptors, ion channels and 
signal transduction pathway. Currently available label-free instruments use either an 
impedance-based biosensor or an optical-based biosensor to detect changes in cell 
behavior.  
Here, we have applied the electrical impedance detection method in a real-time cell 
analyzer (RTCA) system for cell viability assays. The use of impedance to measure 
cellular processes was first reported by Giaever and Keese at the GE Corporation Research 
and Development Center. Biosensors measure the impedance to current flow across two 
electrodes mounted in the base of the microtiter well. Cells that adhere to the surface of 









labels.	 The	 system	 measures	 electrical	 impedance	 across	 interdigitated	
microelectrodes	integrated	on	the	bottom	of	tissue	culture	E-Plates	(96-well).	The	
impedance	 measurement	 provides	 quantitative	 information	 about	 the	 biological	
status	 of	 the	 cells,	 including	 cell	 number,	 viability,	 and	 morphology.	 Using	 the	
xCELLigence	system,	we	continuously	monitored	the	“Cell	Index”	which	is	derived	






The	 ToxiLightTM	 bioassay	 is	 a	 non-destructive	 bioluminescent	 cytotoxicity	
assay	designed	to	measure	toxicity	in	mammalian	cells	and	cell	lines	in	culture.	The	
kit	quantitatively	measures	the	release	of	adenylate	kinase	(AK)	from	damaged	cells.	
It	 is	 a	 safe,	 convenient,	 and	highly	 sensitive	method	 for	measuring	 cytolysis.	 The	
assay	can	be	conducted	directly	cells	cultured	in	a	microtiter	plate.	The	kit	is	based	
on	the	bioluminescent	measurement	of	AK	which	is	present	in	all	cells.	A	loss	of	cell	
integrity,	 through	 damage	 to	 the	 plasma	 membrane,	 results	 in	 the	 leakage	 of	 a	


















Figure S5. The profound diminution of cell index is correlated to the loss of cell membrane integrity 
traced by measurement of the adenylate kinase (AK) release after treatment with PKHB1, PKT16 and 










































Conclusions and perspectives 
_____________________________________________________ 
 
Cell death mechanism and immunogenicity of cell death induced by PKHB1 
 
Overall toxicity 
In the present work it was demonstrated that PKHB1 is cytotoxic against T-ALL, 
breast cancer, and lung cancer cell lines, but not to freshly isolated PBMCs or cells from 
mice’s bone marrow, spleen, thymus, or lymph nodes at similar concentrations. On the 
other hand, in immunocompetent tumor-bearing mice, PKHB1 treatment reduces tumor 
growth and ameliorates immune cell count. Altogether, this highlights the specificity of 
PKHB1’s cytotoxicity. However, PKHB1 toxicity in healthy mice was only partially 
assessed, therefore, PKHB1 in vivo-dosage toxicity should be evaluated using adequate 
models. Biodistribution, pharmacokinetics and pharmacodynamics studies using different 
concentrations of formulated peptide via intra-venous and intra-peritoneal injections have 
already begun to be assessed in mice. 
Ca2+ regulation of cell death 
As it was previously demonstrated for CLL, where PKHB1 induced an intracellular 
Ca2+ overload, result of a sustained PLC activation and subsequently of ER Ca2+ channels 
(Martinez-Torres et al., 2015), in the present study we observed that PKHB1 induced 
Ca2+-dependent cell death in T-ALL, breast cancer and lung cancer. In breast cancer cells, 
PKHB1 increased intracellular Ca2+, and Ca2+ chelation or pharmacological inhibition of 
PLC (by U73122) or ER Ca2+ channels (using dantrolene and 2-APB) significantly 
inhibited cell death. In lung cancer cells, cell death induced by PKHB1 was also inhibited 
by Ca2+ chelation or inhibition of PLC or ER Ca2+ channels; and in T-ALL, Ca2+ chelation 
inhibited PKHB1-induced cell death. Inhibition of PLC or ER Ca2+ channels were not 
assessed in T-ALL, and Ca2+ concentration was not measured neither in T-ALL nor in 
lung cancer, leaving opened questions about their molecular mechanisms that would need 
to be answered with similar experiments as in breast and lung cancer cells. It should be 
also considered that the Ca2+ chelator BAPTA is negatively charged and used at high 
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concentrations (3-5 mM), thus, it could potentially interfere directly with PKHB1, which 
holds a net positive charge. Complexation of these molecules could be measured using 
physical techniques (e.g., changes in UV absorbance) to evaluate the relevance of using 
BAPTA as a cell death inhibitor. Additionally, to confirm ER Ca2+ release, 
pharmacological inhibition of the PLC and ER Ca2+ channels should be also assessed in 
T-ALL, as the mechanism by which PKHB1 induces cell death is largely unknown. On 
this subject, deeper studies are needed to characterize the molecular pathway activated by 
PKHB1 in all the models used in the present work. Activation of PLC should be assessed, 
as it was done for CLL (Martinez-Torres et al., 2015), at different time points after PKHB1 
treatment. In addition, knowing the potential implication of this signaling pathway and the 
potential binding partners of CD47, assessing the differences in expression of mRNA and 
protein levels of CD47, ubiquilin-1, Gi proteins, protein kinase A, PLCs (and 
phosphorylated PLCs), IP3 and ryanodine receptors, STIM, and Orai proteins in untreated 
versus PKHB1-treated cells, this, followed by pharmacologic and genetic modulation of 
proteins with differential expression, to assess their involvement in cell death. 
Immunogenicity of cell death  
Another important effect induced by PKHB1 treatment was the exposure of DAMPs 
in T-ALL and in breast cancer cells. However, the molecular mechanisms relating 
PKHB1-induced cell death and DAMPs exposure remain unknown. Participation of PLC 
and ER Ca2+ channels hint that ER stress could be implicated. Therefore, evaluation of 
ER stress markers involved Ca2+ dynamics, such as PERK, IRE1!, ATF6, GRP78, and 
EIF2!, activation after PKHB1 treatment should be assessed. Moreover, although 
inhibition of autophagy did not prevent cell death, its implication in cell death 
immunogenicity was not assessed; thus, autophagy should be adequately monitored after 
PKHB1 treatment. This could also be useful to understand the origin of ATP released after 
treatment. 
Besides exposure of DAMPs in vitro, ex vivo experiments in T-ALL and in breast 
cancer, tumor cells killed by PKHB1 (i.e., PKHB1-TCL) induced the maturation of DC, 
which in turn were able to prime T cells to induce tumor cell cytotoxicity. In vivo, PKHB1 
treatment induced lymphocyte infiltration; prophylactic vaccination with PKHB1-TCL 
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prevented tumor growth; therapeutic treatment with PKHB1-TCL reduced tumor growth; 
and these treatments prevented tumor growth after rechallenging. Together, this indicates 
that PKHB1 can be an ICD inductor. The ability of PKHB1-TCL to induce ex vivo DC 
maturation capable to prime T cells was not compared to that of a known ICD inductor; 
therefore, the efficacy of PKHB1-TCL with respect to other therapies to induce DC 
maturation remains unclear. Similar experiments in the future that include the parallel 
analysis of a known ICD inducer could answer this interrogation. Moreover, although 
PKHB1-TCL protected mice from tumor rechallenging, the characteristics that leads to 
this potential immune memory are largely unknown; hence, evaluation of memory T cell 
populations as well as memory B cells and humoral responses after prophylactic 
vaccination with PKHB1-TCL would be of interest. In this sense, it would also be 
important to assess whether PKHB1 or PKHB1-TCL treatment induces the infiltration of 
subpopulations of NK cells and DC to the tumor site. 
 
Relevance of optimizing TSP1 peptide mimics 
Homotrimeric peptides and cell death triggering mechanism 
The main limitation of using PKHB1 as an anticancer agent is the high concentration 
(micromolar range) needed to induce its effects in vitro, which is distant for the standard 
requirements for drug development (nanomolar range). However, optimization of the 
potency of this kind of peptide-mimics is possible, as exposed by the development of 
PKT16 and [PKT16]3. Nevertheless, this homotrimeric peptide was obtained in a 
significantly lower yield (~10%) than PKHB1 (>90%), leaving important opportunities 
for synthesis optimization. Moreover, the cell death mechanism induced by [PKT16]3 in 
A549 cells seemed to differ to that induced by its monomeric predecessors PKHB1 and 
PKT16. This suggests that whether a) [PKT16]3 triggers the same receptor in a way that 
is different to that of the monomers, leading to differential signaling; or that b) it triggers 
a different receptor and, therefore, a different molecular signaling pathway. In this way, 
deciphering whether the triggering mechanism of [PKT16]3 utilizes the same molecular 
components as PKHB1 and PKT16 deserves special attention considering that these 
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monomeric peptides keep substantial structural and chemical similarities with 4N1K, 
which has been shown to mimic several TSP1 functions. 
To date, the design of drugs targeting the CD47-TSP1 axis has only relied on peptide 
screening, molecular modeling, and structure-activity relationship studies. However, the 
absence of descriptive evidence of this interaction, such as crystallization, limit a 
substantial improvement of drug development. Therefore, crystallization of the TSP1 C-
terminal domain with CD47 remains a crucial aspect that needs to be answered to generate 
more potent peptide-mimics targeting this interaction. Nevertheless, considering the 
multi-ligand nature of TSP1, the consistent association of CD47 with lateral partners, and 
the post-translational modifications in both proteins necessary for their interaction, it is 
expected that additional mechanisms, absent during the simple binding experiments with 
soluble recombinant TSP1 and CD47 proteins, stabilize adequate conformations suitable 
for interaction, such as what happens in certain scenarios involving alpha and beta 
integrins interaction with RGD-containing proteins. With this, the use of a potent peptide 
binder could be of valuable interest to understand TSP1-CD47 interaction, such as the 
RGD peptide was to understand the complexity of RGD-dependent integrin signaling. 
One should keep in mind that it was thanks to a synthetic peptide that alpha-beta integrin 
interaction with the RGD motif, present in different matricellular proteins, including 
TSPs, was crystalized. 
Indeed, TSP1 includes an RGD motif at its signature domain. And in the present 
work RGD improved PKHB1 activity, different variants of RGD-linked peptides were 
also designed in the present work in an unsuccessful attempt to improve PKHB1 efficacy. 
However, keeping a developmental perspective in mind, only short linkers were selected, 
even when the RGD motif stands far away from PKHB1’s pharmacophore in the three-
dimensional structure of the thrombospondin. Thus, trying linkers of varying length might 
help to understand the role of integrins in PKHB1-induced cell death. A Ca2+-interacting 
DDD motif is close in distance from the PKHB1 pharmacophore in the three-dimensional 
structure of the globular domain of thrombospondins and is necessary for homotrimeric 
TSP1 C-terminal domain retention by the cell. A recombinant protein with a mutant 4N1 
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β-strand, or a calcium-binding peptide-mimic containing the PKHB1 pharmacophore and 
the DDD motif might be useful to study this. 
Potential of TSP-C-terminus peptide-mimics to induce cell death in cancer and non-
resolving inflammatory cells 
Overall, the results of the present thesis work support the therapeutic potential and 
further development of peptide-mimics of the TSP-C-terminus against cancer. However, 
the TSP1-CD47 axis is also involved in the induction of RCD of certain populations of 
immune cells during resolution of inflammation (e.g., CD47low-status effector memory T 
cells, and recruited monocyte-derived inflammatory macrophages). In some of them, the 
4N1 and 4N1K peptides have been shown to have a potential therapeutic use. The 
structural similarity of PKHB1 with 4N1K suggests that PKHB1-induced cell death could 
render similar results in specific subtypes of immune cells where the TSP1-CD47 axis has 
potential therapeutic applications. In that sense, studying the use of PKHB1 to treat 
inflammatory diseases where the TSP1-CD47 axis has shown to be implicated in 
resolution of inflammation is pertinent. An example of such a use has been demonstrated 
for macular degeneration and acute sterile peritonitis (Calippe et al., 2017). However, this 
could be extended to other nonresolving inflammatory diseases such as the Sjögren's 
syndrome (Contreras Ruiz et al., 2017) or psoriasis (Rodríguez-Jiménez et al., 2019), for 
which treatment options are limited. 
The future of therapeutic peptides 
Finally, among the options to target immune checkpoints such as CD47, or mimic 
protein-protein interactions, such as the TSP1-CD47 axis, the major strategies rely 
whether on small molecules or big recombinant proteins and antibodies. Due their ease of 
production and minimal cost, small molecules are largely preferred over proteins for 
pharmaceutic exploitation, however, they largely account for secondary effects related to 
their unspecificity. On the other hand, therapeutic proteins (e.g., humanized antibodies 
and soluble recombinant proteins) are by nature, more specific to their targets, however 
their size represents high production costs compared to small molecules synthesized 
chemically. Peptides place in a middle point, between low-cost and target specificity. If 
peptides have several drawbacks (e.g., poor metabolic stability, and high flexibility 
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leading to poor target selectivity compared to bigger proteins), many strategies have been 
developed to optimize their properties (e.g., the use of non-natural amino acids, and the 
design of peptidomimetics or foldamers). Such strategies, however, add technical 
complications that impact their ease of production at large scale. Therefore, the philosophy 
of the DRUG Lab is to use only natural amino acids to optimize the properties of potential 
therapeutic peptides, making a balance with appropriate rational designs. Indeed, more 
than 700 amino acids exist in nature that help to improve peptide properties, such as, for 
example, N-Methyl amino acids or D-amino acids present in cyclosporin A. This has been 
applied in other research subjects, such as in one concerning the recent COVID-19 
pandemic, where peptides consisting of only natural amino acids were designed to interact 
with the spike RBD. Although this aspect is not discussed in the present manuscript, I had 
the opportunity to contribute within the project (see annex), and beyond my thesis, in 
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In light of the recent accumulated knowledge on SARS-CoV-2 and its mode of human cells
invasion, the binding of viral spike glycoprotein to human Angiotensin Converting Enzyme 2
(hACE2) receptor plays a central role in cell entry. We designed a series of peptides
mimicking the N-terminal helix of hACE2 protein which contains most of the contacting
residues at the binding site, exhibiting a high helical folding propensity in aqueous solution.
Our best peptide-mimics are able to block SARS-CoV-2 human pulmonary cell infection with
an inhibitory concentration (IC50) in the nanomolar range upon binding to the virus spike
protein with high affinity. These first-in-class blocking peptide mimics represent powerful
tools that might be used in prophylactic and therapeutic approaches to fight the coronavirus
disease 2019 (COVID-19).
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he coronavirus disease 2019 (COVID-19), caused by the
severe acute respiratory syndrome-coronavirus 2 (SARS-
CoV-2) has emerged as a pandemic, claiming at the time
of writing more than 1.3 million deaths and over 57 millions
confirmed cases world-wide between December 2019 and
November 20201. Since the SARS-CoV-2 discovery2,3 and
identification, the energy deployed by the scientific community
has made it possible to generate an extraordinary wealth of
information. However, to date, efficient therapeutics or
drugs are lacking and prevention of the disease relies only
on non-specific barrier measures4. Indeed, no specific drugs
targeting the virus are available5 yet, many clinical trials have
been engaged with SARS-CoV-2 non-specific treatments4.
The structural and biochemical basis of the mechanism of
infection has been investigated, highlighting that the virus cell-
surface spike protein of SARS-CoV-2 targets human
receptors6,7. Human angiotensin converting enzyme 2
(hACE2) and the cellular transmembrane protease serine 2
(TMPRSS2) have been identified as major actors of the virus
entry into human cells8.
With the goal of preventing the SARS-CoV-2 from infecting
human cells, blocking the interaction between hACE2 and the
virus spike protein has been validated. Indeed, inhibition of
SARS-CoV-2 infections in engineered human tissues using
clinical-grade soluble ACE2 was recently demonstrated9. Like-
wise, an engineered stable mini-protein mimicking three helices
of hACE2 to plug SARS-CoV-2 spikes10 was described, but its
capacity to block viral infection was not demonstrated. Although
several in silico designed peptides were proposed to prevent
formation of the fusion core11,12, first attempts to design a pep-
tide binder derived from hACE2 proved to be a difficult task,
leading to mitigated results13.
Thus, starting from the published crystal structure of SARS-
CoV-2 spike receptor-binding domain (RBD) bound to hACE214,
we designed peptide-mimics of the N-terminal hACE2 helix
which interact with the spike protein. We report here the strategy
implemented to optimize the design of our peptide mimics, their
high helical folding propensity in water, their ability to block
SARS-CoV-2 human pulmonary cell infection with an IC50 in the
nanomolar range and their binding to spike RBD with strong
affinity. We also demonstrated the non-toxicity of our mimics at
concentrations 150 times higher than the IC50 on pulmonary
cell lines.
Results
Design of peptides mimicking the helix H1 of hACE2. We first
examined the complex between hACE2 and the surface spike
protein of SARS-CoV-2 (PDB 6m0j)14 in order to highlight the
important contacts and some relevant characteristics of the
interacting hACE2 sequence (Fig. 1).
Twenty residues from hACE2 were identified14 as to be in close
contacts with the Spike protein, using a distance cut-off of 4 Å.
These interactions occur mainly through the N-terminal α-helix
H1 of hACE2 (Fig. 1a). This α-helix (Fig. 1b), composed of 27
residues (from S19 to L45, Fig. 1c) contains 12 residues
(highlighted in magenta in Fig. 1c) involved in hydrogen bonds,
salt bridges, and van der Waals interactions (see Supplementary
Table 1 for details)14.
A Clustal multiple sequence alignment of viruses isolated in
China, United States and France was performed (See Supple-
mentary Fig. 1). From these analyses, we observed that all the
randomly selected sequences were 100% identical at least in the
ACE2 interacting interface. This highlights a highly conserved
sequence for the portion of spike interacting with the α-helix H1
of hACE2, possibly because deleterious mutations at this interface
would limit viral infectivity.
Our strategy was designing a peptide with a high helical folding
propensity and retaining most of the binding affinity of hACE2 to
the spike RBD of SARS-CoV-2, using natural amino acids15.
Indeed, we preferred not to use complex chemical tools known to
stabilize α-helix16,17 in order to limit developability constraints.
Our mimics were designed and optimized for binding, high
helical content and low antigenicity, to avoid triggering a
neutralizing immune response that would compromise the
peptide therapeutic potential. A combination of the Agadir
program18,19, an algorithm developed to predict the helical
content of peptides and the semi-empirical method reported by
Kolaskar20 to highlight the number of antigenic determinants,
was iteratively used.
We observed that the N-terminal sequence of the H1 helix,
composed of four residues (S19TIE22), corresponds to a consensus
N-capping box motif (SXXE)21. A capping box features reciprocal
backbone-side-chain hydrogen-bonds favoring a helix initiation.
Although this sequence does not adopt the H-bonded capping
conformation in the crystal structure of the full protein, it could
constitute a stabilizing element in the isolated helix when
extracted from the protein context. These observations led us to
Fig. 1 Structure of the complex between hACE2 and the spike protein of SARS-CoV-2 (pdb 6m0j)14. a Contact residues of the hACE2 / SARS-CoV-2
spike interface. hACE2 protein is colored in green, apart from N-terminal helix H1 which is highlighted in salmon. SARS-CoV-2 spike protein is shown in
cyan. b Residues of hACE2 H1 helix interacting with spike. c Sequence of hACE2 H1 helix showing the 12 interacting residues in magenta. Residue positions
in green were considered as possible substitution sites for the helical peptide design.
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keep 14 residues from the native H1 helix of hACE2 as contact
residues or putative stabilizing capping box. The 13 remaining
residues that are not essential for the interaction were considered
as possible sites for amino acid substitutions (Fig. 1c). We thus
substituted non-essential positions by Ala and/or Leu residues
which display higher helical folding propensities, and we
calculated the peptide helical content after each substitution
(Supplementary Table 2).
A peptide sequence optimization was then carried out to lower
the antigenicity while keeping the helical propensity thanks to an
iterative residue scanning and calculation of the helical content
variation upon new substitutions (Supplementary Table 3). This
strategy highlighted the influence of the residue N33 in the native
sequence. Indeed, if the N33/L33 substitution systematically
improved the helical content, it was always at the expense of
antigenicity. Conversely, the L33/N33 substitution reduced the
antigenicity at the expense of helical content. The solution was
found by L33/M33 substitution which decreased the
number of AD.
The H1 helix of ACE2 adopts a kinked conformation in the
crystal structure, leading to a distorted CO/HN hydrogen bond
network between H34/D38 and E35/L39 residues. Therefore, we
considered introducing a proline, as this residue is known to
induce local kinks or distortions in natural helices22,23. D38 was
classed as a contact residue, while L39 side chain is not involved
in any direct interaction. Consequently, L39 position was selected
for substitution by proline (peptide P5, Table 1).
In order to increase the helical content to a maximum level,
this iterative study was also applied to longer peptide sequences
starting from the 29-residue native one, albeit at the expense of
antigenicity. Diverse combinations of N- and C-terminus capping
groups were also considered (free extremities or N-acetyl, C-
carboxamide groups).
Finally, we examined the possibility of promoting additional
side chain contacts provided by ACE2 residues that do not belong
to H1 helix. Y83 residue in H2 helix appeared as a good candidate
as it lies very close in space to A25 in H1 helix (Fig. 1a).
Molecular modeling was carried out on H1 helix analogs in which
A25 was replaced by tyrosine or homotyrosine (hTyr) residues
(Supplementary Fig. 2). Calculations showed that hTyr residue
was able to project the phenol ring in an adequate orientation to
mimic Y83 position. Of note, hTyr is a natural amino acid24.
Three peptides were selected as controls in our optimization
process, P1 (native sequence), P1scr (scrambled peptide from
P1), and Ppen (described by Pentelute and colleagues in a longer
biotinylated and pegylated construct and termed SBP1 as a
putative spike binder13).
The results highlighting the progression in helical content and
number of antigenic determinants are reported in Table 1 for the
most relevant peptide mimics (see Supplementary Tables 2–4 for
all the peptide-mimics that were designed and/or synthesized).
These peptides were synthesized on a 5-mg to 20-mg scale from
Fmoc-protected amino acids utilizing standard solid-phase
peptide synthesis methods on rink amide resin (see Methods
section).
The designed peptides highlight an excellent correlation
between calculated and experimentally determined helical
content by circular dichroism in aqueous media. The con-
formation of synthesized peptides in aqueous solution was
investigated by circular dichroism (CD) spectroscopy25. Figure 2
shows the superimposed CD spectra of 12 peptides, including
control ones, i.e., P1 (native sequence), P1scr (Scramble), and
Ppen. The CD spectra of peptides P1 (native), P1scr (scrambled)
are characteristic of a predominant random coil structure with a
negative minimum near 200 nm, as expected. Similarly, Ppen
described as a helical peptide sequence13 also adopted a random
coil conformation in solution. For all other peptides, the CD
spectra exhibit a canonical α-helix signature, featuring a double
minimum around 208 nm and 222 nm, with the exception of the
proline-containing P5 peptide. The deconvolution of the CD
spectra using DichroWeb25 allowed us to estimate the helical
population for each peptide, which is reported in Table 1. Overall,
an excellent agreement was observed between the Agadir-
computed values and the experimental helical population infer-
red from CD data. The native hACE2 H1 helix sequence (pep-
tides P1, Ppen) has a weak propensity to fold into an α-helix in
aqueous solution (below 10%). In contrast, the sequence opti-
mization led to H1 analogs exhibiting a high helical propensity
(between 50 and 80%). The introduction of a proline residue in
peptide P5 has a strong destabilizing effect on helical con-
formation (17%) whereas Leu/hTyr substitution only led to a
slight decrease of the helical content (P7 versus P6 and P10
versus P8).
Peptide mimics of hACE2 show high anti-infective efficacy and
are devoid of cell toxicity. To determine whether our peptide
mimics of hACE2 H1 helix block SARS-CoV-2 cell infection,
antiviral assays26 were performed (Fig. 3) with a SARS-CoV-2
clinical isolate obtained from bronchoalveolar lavage (BAL) of a
symptomatic infected patient (#SARS-CoV-2/PSL2020) at Pitié-
Salpêtrière hospital, Paris (France) (see Methods section). We first
measured the inhibition of viral replication in Vero-E6 cell cul-
tures exposed to 10 µM of the first set of peptide-mimics (P2 to
P8, P1, P1scr, and Ppen being used as controls), for 48 h
(Fig. 3a). These preliminary assays helped us to identify two
peptide-mimics that stand out (P7 and P8) for their ability to
block the viral infection, highlighting a potential role of hTyr.
This observation helped us in the peptide-mimics structure
optimization process. Two new peptides were designed, P9 and
P10 incorporating the hTyr residue and evaluated with P8 for
their ability to block viral infection on Vero-E6 cells through the
measurement of infectious virus production and viral genome
(Fig. 3b and Supplementary Fig. 3)27. These peptides proved to be
devoid of toxicity in Vero-E6 (Fig. 3c). In order to get insight on
their ability to block viral infection on human pulmonary cells,
Calu-3 cell line (ATCC HTB55) was chosen. This pulmonary
epithelial cell line is commonly used as a respiratory models in
preclinical applications28 and SARS-CoV-2 has been shown to
replicate efficiently in this cell line29.
We first observed a dose-dependent reduction in virus titer
(Fig. 3d) and then, using ELISA assays we evaluated the average
median inhibitory concentration (IC50) on Calu-3 cells for P8,
P9, and P10 to be 46 nM, 53 nM, and 42 nM respectively
(Fig. 3e). Importantly, no cytotoxicity was observed in similarly
treated uninfected culture cells at 10 μM, a concentration 150
times higher than the IC50 (Fig. 3f). Collectively, these data
demonstrate the high antiviral potency of peptide analogs P8, P9,
and P10.
The designed peptides bind to SARS-CoV-2 spike RBD with
high affinity. Finally, the peptides that were able to block cell
infection with an IC50 in the sub-µM range (P8, P9, and P10)
were evaluated for their ability to bind to SARS-CoV-2 spike RBD
(Fig. 4) using biolayer Interferometry (BLI) with an Octet
RED96e system (ForteB́io)30. hACE2 was used as a positive
control (Fig. 4a).
Even though this technique presents some drawbacks31
offering narrow signal windows with low molecular weight
analytes32 such as peptides, it remained useful to identify and
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rank our binding mimics. In the conditions tested here, peptide
P1 does not bind to RBD when using 100 nM nor 10 µM peptide
solutions (Fig. 4b). For peptides P8, P9, and P10, multiple
concentrations experiments were performed and dose-dependent
associations were observed (Fig. 4c–e). Of note, only association
rates could be quantified accurately, the dissociation ones being
very slow, highlighting strong binding properties for these mimics
(Supplementary Table 6).
Discussion
The current pandemic originated by SARS-CoV-2 causes an
unprecedented health crisis. The medical world has found itself
helpless in the face of this virus, having to deal with the absence of
specific effective treatment. At the time of writing, preventive
vaccines are not yet clinically approved, other antiviral drugs have
been shown ineffective, and specific drugs addressing SARS-CoV-
2 targets are lacking4. Among all possible viral targets, the virus
spike protein/hACE2 interaction has been validated and the
design of compounds able to block this interaction upon binding
to spike protein is a promising approach. However, developing a
specific drug at a pandemic speed is a hard task especially in the
design of a small molecule. Indeed, beyond the time required for
the identification and validation of a lead compound after a
library screening, followed by structure-activity relationship stu-
dies and clinical development, small molecule drugs are asso-
ciated with a high attrition rate partly due to their off-target
toxicity observed during pharmacological studies.
Peptides appear here as a possible solution for design and
development at pandemic speed. Peptides are widely recognized
as promising therapeutic agents for the treatment of various
diseases such as cancer, and metabolic, infectious, or cardiovas-
cular diseases33–35. To date, ~70 peptide drugs have reached the
market and 150 are currently under clinical development33,36.
Special advantages that peptides show over small drugs include
their high versatility, target-specificity, lower toxicity, and ability
to act on a wide variety of targets35 which are directly responsible
for a greater success rate than small molecules (approval rate of
around 20% versus 10%)36,37. The synthesis and the development
of long therapeutic peptides (over 30 residues) are no longer a
challenge, as highlighted by the success story of many GLP-1
analogs38. Their possible antigenicity can be evaluated using
prediction tools in the design20.
Of course, even for peptides, the development of a drug at a
pandemic speed requires some considerations. Our aim was to
design a peptide with reasonable helical folding propensity in water
in order to mimic the H1 helix of hACE2 in the protein context,
considering that this helical folding is a prerequisite to compete
with hACE2 upon interaction with viral spike protein. The design
was realized using only natural amino acids15 and avoided complex
tools that are known and validated to stabilize α-helix16. Stabilizing
α-helical structure of medium-sized peptide sequences (up to 15
residues) using only natural amino acids is a hard but achievable
task39. Our choice was guided by the desire to build a simple
peptide that can be upscaled quickly and easily, without technical
constraints that may require laborious development. We also
assumed that the use of mostly natural amino acids can facilitate the
essential stages of the development of therapeutic tools in the event
of success, particularly concerning pharmacokinetics, preclinical,
and clinical toxicity aspects. We thought it would be a fair com-
promise between designing α-helix peptides with optimized binding
affinity and developing an effective tool within short deadlines while
integrating the constraints of developability to move a prophylactic
device and/or a therapeutic peptide drug quickly in the clinic.
Using a combination of validated methods, we improved the
helical folding propensity of the native α-helix extracted from the
protein context. Thanks to leucine and alanine scanning (Table 1
and Supplementary Tables 2 and 3) a first set of peptides (P1 to
P8) were designed and synthesized. These peptides demonstrated
to have a high helical content (up to 80% for P6). However,
increasing this helical content to a maximum level led to
increasing mean hydrophobicity and a hydrophobic moment
(Supplementary Table 4) that proved to be detrimental to solu-
bility and efficacy. The substitution of a leucine residue by the
homotyrosine residue led to the peptide analog P7 with a slight
increase in solubility and a weak efficiency to block SARS-CoV-2
cell infection. In this first generation of peptides, the 27-residue
P8 peptide appeared to be highly soluble with a high helical
folding propensity (70%), and an ability to block SARS-CoV-2
cell infection at 10 μM on Vero-E6 cells (Fig. 3a).
In order to improve the potency of our peptides, we designed a
second set of mimics combining the properties of peptides P7 and
P8, i.e., P9 and P10. If the Leu/hTyr substitution led to a slight
decrease in helicity, this was at the advantage of the mean hydro-
phobicity (Supplementary Table 4) also highlighted by lower HPLC
retention times (Supplementary Table 5 and Supplementary
Data 1). These peptides proved to be highly efficient in reducing
SARS-CoV-2 viral titers (100% efficacy at 1 µM) on pulmonary cells
with an IC50 in the nanomolar range. This blocking property is
related to their ability to bind to SARS-CoV-2 spike RBD with
affinity estimated in the sub-nanomolar range (Table 1 and Sup-
plementary Table 6). Finally, these peptides proved to be devoid of
cell toxicity at 150 times the IC50 concentration (Fig. 3c, f) high-
lighting their therapeutic potential.
In conclusion, we demonstrated here the feasibility of design-
ing hACE2 peptide-mimics with high helical folding propensity
in water. The folding propensity promotes interaction with spike
RBD and blocks SARS-CoV-2 pulmonary cell infection. Devoid
of cell toxicity even at high doses, these mimics could be con-
sidered for prophylactic or therapeutic purposes upon adequate
formulation. Targeting prophylaxis first might shorten the drug
development time scale. Delivered through a medical device such
as a nasal or oral spray or as a sublingual tablet, these peptides
could be aimed at blocking the infectivity of the virus in a pre-
ventive manner. Their biodistribution would be limited to the
upper airways (nasal and oral cavity) before they are degraded in
the digestive tracks without toxic residues. Their therapeutic use
might also be considered formulated in that case as an inhaler to
reach pulmonary cells.
Fig. 2 Far-UV CD spectra of synthesized peptides. Samples of peptides
P1-P10, P1Scr, and Ppen were prepared at a concentration of 60 µM in
50 mM sodium phosphate buffer at pH 7.4. CD measurements are reported
as molar ellipticity per residue.
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Peptides syntheses. Peptides were produced manually, synthesized from Fmoc-
protected amino acids utilizing standard solid-phase peptide synthesis methods.
Solid-phase peptide syntheses were performed in polypropylene Torviq syringes
(10 or 20 mL) fitted with a polyethylene porous disk at the bottom and closed with
an appropriate piston. Solvent and soluble reagents were removed through back-
and-forth movements. The appropriate protected amino acids were sequentially
coupled using PyOxim/Oxyma as coupling reagents. The peptides were cleaved
from the rink amide resin with classical cleavage cocktail trifluoroacetic acid/
Fig. 3 Peptide-mimics of hACE2 show high anti-infective efficacy and are devoid of cell toxicity. a Percent inhibition of SARS-Cov-2 replication. Vero-E6
cells were infected with SARS-CoV-2/PSL2020 P#2 stock at a multiplicity of infection (MOI) of 0.1 in the presence of 10 peptides (P1 to P8, P1scr, and
Ppen as controls) at 10 µM for 2 h. Then, the virus was removed, and cultures were washed, incubated for 48 h, before supernatant was collected to
measure virus replication by ELISA. Data are combined from 3 to 6 independent experiments and expressed as compared to untreated SARS CoV-2-
infected Vero-E6 cells. b SARS-CoV-2 titer reduction in Vero-E6. Cells were infected with SARS-CoV-2/PSL2020 P#2 stock in triplicate at a multiplicity of
infection (MOI) of 0.1 in the presence of different concentrations (from 0.01 to 10 µM) of peptides P8, P9, and P10 for 2 h. Then the virus was removed,
and cultures were washed and incubated for 72 h to measure virus production by plaque assay. c Cell cytotoxicity in Vero-E6 cells. Cell viability was
measured by MTT assays after treatment with vehicle 0, 0.1, 1, or 10 µM of P8, P9, or P10 for 24, 48, or 72 h. Cell death was measured by flow cytometry
using annexin-V-APC and PI staining in cells treated with vehicle or 10 µM P8, P9, or P10 for 24, 48, or 72 h. The plots represent the means (±SD) of three
independent experiments. d SARS-CoV-2 titer reduction in Calu-3. Cells were infected with SARS-CoV-2/PSL2020 P#2 stock in triplicate at a multiplicity
of infection (MOI) of 0.3 in the presence of different concentrations (from 0.01 to 10 µM) of peptides P8, P9, and P10 for 2 h, after which the virus was
removed, and cultures were washed in, incubated for 72 h to measure virus production by plaque assay. e Dose-inhibition curve in Calu-3. Cells were
infected with SARS-CoV-2/PSL2020 P#2 stock at respectively a multiplicity of infection (MOI) of 0.3 in the presence of six different concentrations (from
0.01 to 10 µM) of peptides P1, P1 scr, P7, P8, P9, P10, for 2 h. Then the virus was removed, and cultures were washed in, incubated for 48 h, before
supernatant was collected to measure virus replication by ELISA. Data are combined from 3 to 6 independent experiments and expressed as percent of
inhibition compared to untreated SARS CoV-2-infected Vero-E6 cells. Data fitted in the sigmoidal dose-response curve represent the means (±SD) of at
least three independent experiments and are expressed as percent of inhibition compared to untreated SARS CoV-2-infected Vero-E6 cells. f Cell
cytotoxicity in Calu-3 cells. Cell viability was measured by MTT assays after treatment with vehicle 0, 0.1, 1, or 10 µM of P8, P9, or P10 for 24, 48, or 72 h.
Cell death was measured by flow cytometry using annexin-V-APC and PI staining in cells treated with vehicle or 10 µM P8, P9, or P10 for 24, 48, or 72 h.
The plots represent the means (±SD) of three independent experiments.
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triisopropyl silane/water (95:2.5:2.5). The crude products were purified using
preparative scale high-performance liquid chromatography (HPLC). The final
products were characterized by analytical liquid chromatography (LC)–mass
spectrometry (MS). All tested compounds were trifluoroacetic acid salts and were
at least 95% pure. The relevant peptides after CD spectra analyses were selected and
produced by Genecust France on 20 mg scale.
Purification. Preparative scale purification of peptides was performed by reverse
phase HPLC on a Waters system consisting of a quaternary gradient module
(Water 2535) and a dual wavelength UV/visible absorbance detector (Waters
2489), piloted by Empower Pro 3 software using the following columns: pre-
parative Macherey-Nagel column (Nucleodur HTec, C18, 250 mm × 16 mm
internal diameter, 5 μm, 110 Å) and preparative Higgins analytical column (Proto
200, C18, 150 mm × 20 mm i.d., 5 μm, 200 Å) at a flow rate of 14 mL min−1 and
20 mLmin−1, respectively. Small-scale crudes (<30 mg) were purified using
semipreparative Ace column (Ace 5, C18, 250 mm × 10 mm i.d., 5 μm, 300 Å) at a
flow rate of 5 mLmin−1. Purification gradients were chosen to get a ramp of ~1%
solution B per minute in the interest area, and UV detection was done at 220 and
280 nm. Peptide fractions from purification were analyzed by LC−MS (method A
or B depending on retention time) or by analytical HPLC on a Dionex system
consisting of an automated LC system (Ultimate 3000) equipped with an auto-
sampler, a pump block composed of two ternary gradient pumps, and a dual
wavelength detector, piloted by Chromeleon software. All LC−MS or HPLC
analyses were performed on C18 columns. The pure fractions were gathered
according to their purity and then freeze-dried using an Alpha 2/4 freeze-dryer
from Bioblock Scientific to get the expected peptide as a white powder. Final
peptide purity (>95%) of the corresponding pooled fractions was checked by
LC−MS using method A (outlined below).
Analytics. Two methods were conducted for LC−MS analysis. Method A. Analy-
tical HPLC was conducted on a X-Select CSH C18 XP column (30 mm × 4.6 mm i.
d., 2.5 μm), eluting with 0.1% formic acid in water (solvent A) and 0.1% formic
acid in acetonitrile (solvent B), using the following elution gradient: 0−3.2 min,
0−50% B; 3.2− 4 min, 100% B. Flow rate was 1.8 mLmin−1 at 40 °C. The mass
spectra were recorded on a Waters ZQ mass spectrometer using electrospray
positive ionization [ES+ to give (MH)+molecular ions] or electrospray negative
ionization [ES−to give (MH)−molecular ions] modes. The cone voltage was 20V.
Method B. Analytical HPLC was conducted on a X-Select CSH C18 XP column
(30 mm × 4.6 mm i.d., 2.5 μm), eluting with 0.1% formic acid in water (solvent A)
and 0.1% formic acid in acetonitrile (solvent B), using the following elution gra-
dient: 0−3.2 min, 5−100% B; 3.2−4 min, 100% B. Flow rate was 1.8 mLmin−1 at
40 °C. The mass spectra were recorded on a Waters ZQ mass spectrometer using
electrospray positive ionization [ES+ to give (MH)+molecular ions] or electro-
spray negative ionization [ES− to give (MH)−molecular ions] modes. The cone
voltage was 20 V.
CD spectroscopy. CD spectra were recorded on a Jasco J-815 CD spectro-
polarimeter equipped with a Peltier temperature controller. Data were obtained at
25 °C over a wavelength range between 185 nm and 270 nm, using a wavelength
interval of 0.2 nm and a scan rate of 20 nmmin−1. Peptide samples were prepared
at a concentration of 60 µM in 50 mM sodium phosphate buffer, pH 7.4, in a quartz
cell of 1 mm path length. CD experiments were processed and plotted with R
program. CD spectra were analyzed using DICHROWEB web server and CDSSTR
deconvolution algorithm24.
Anti-infectivity study on Calu-3 and Vero-E6 cells
Cells and virus preparation. Calu-3 (ATCC HTB55) and Vero-E6 (ATCC CRL-
1586) cells were purchased from the American Type Culture Collection and rou-
tinely checked for mycoplasma contamination26. Cells were cultured in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with non-essential amino acids,
penicillin-streptomycin, and 10% v/v fetal bovine serum.
The SARS-CoV-2 clinical isolate was obtained from BAL of a symptomatic
infected patient (#SARS-CoV-2/PSL2020, available at Pitié-Salpêtrière hospital,
Paris (France)). The patient recruited for virus isolation and culture was in
intensive care unit in the Pitié Salpêtrière hospital. The patient underwent a
bronchoalveolar lavage for clinical purpose (seeking for a bacterial pulmonary
infection). The protocol was approved by our institution’s ethics committee
(Immuno-COVID-REA, CER-Sorbonne Université, no. CER-SU-2020-31). BAL
(0.5 mL) was mixed with an equal volume of DMEM without FBS, supplemented
with 25 mM Hepes, double concentration of penicillin–streptomycin and
miconazole (Sigma), and added to 80% confluent Vero-E6 cells monolayer seeded
into a 25-cm2 tissue culture flask. After 1 h adsorption at 37 °C, 3 mL of infectious
media (DMEM supplemented with 2% FBS, penicillin-streptomycin and
miconazole) were added. Twenty-four hours post-infection another 2 mL of
infectious media were added. Five days post-infection, supernatants were collected,
aliquoted, and stored at −80 °C (P#1). For secondary virus stock, Vero-E6 cells
seeded into 25 cm2 tissue culture flasks were infected with 0.5 mL of P#1 stored
aliquot, and cell-culture supernatant were collected 48 h post-infection and stored
at −80 °C (P#2). Infectious viral particles were measured by a standard plaque
assay previously described25 with fixation of cells 72 h post infection. Accordingly,
the viral titer of SARS-CoV-2/PSL2020 P#2 stock was about 5.3 105 PFU mL−1.
Viral neutralization. Vero-E6 or Calu-3 (1 × 105 cells mL−1) were seeded into 24
wells plates in infectious media and treated with different concentrations of the
peptides (from 0.1 to 10 μM). After 30 min at room temperature, cells were infected
with 0.1 multiplicity of infection (MOI) (Vero-E6) or 0.3 MOI (Calu-3) of SRAS-
CoV-2 (SARS-CoV-2/PSL2020 P#2 stock) in infectious media. Cell supernatants
were collected at 48 h post-infection for enzyme-linked immunosorbent assay
(ELISA) assay using a SARS-CoV-2 (2019-nCoV) nucleoprotein ELISA kit (Sino
biological), according the manufacturer’s instructions, and standard plaque assay26.
Fig. 4 Helical peptide-mimics of hACE2 strongly bind to the spike RBD. The Fc-tagged 2019-nCoV RBD-SD1 (Sanyou Biopharmaceuticals Co. Ltd) was
immobilized to an anti-human capture (AHC) sensortip (ForteB́io) using an Octet RED96e system (ForteB́io). The sensortip was then dipped into a 0.1 µM
solution of hACE2 (Sanyou Biopharmaceuticals Co. Ltd, His Tag), b 0.1 or 10 µM solution of P1, or a range of concentrations (1 in 3 dilutions starting from
10 µM, i.e., 41 nM, 123 nM, 370 nM, 1.1 µM, 3.3 µM, and 10 µM) for c P8, d P9, and e P10 to measure association rates before being dipped into a well
containing only running buffer to measure dissociation rates. Data were reference subtracted and fitted to a 1:1 binding model using Octet Data Analysis
Software v10.0 (ForteB́io). All figures are representative of at least two independent experiments. KD values were calculated from Supplementary Table 6.
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Inhibition of infection was calculated comparing viral concentration in each case
with that of untreated SARS- CoV-2-infected cells.
Toxicity study on Calu-3 and Vero-E6 cells. Cell cytotoxicity was measured
using MTT assays and fluorescent activated cell sorting (FACS). Calu-3 and Vero-
E6 were seeded in 96-well (for MTT assays) or 24-well (for FACS) plates and let
adhere. When ~40% confluence was reached, the wells were washed, and new
medium containing vehicle (water, 5% final volume) or different concentrations of
the indicated peptide was added. MTT (2 mM) was added to each well after 24 h,
48 h, or 72 h of treatment and incubated 4 h at 37 °C. Supernatants were then
discarded and formazan salts were dissolved in DMSO to read plate absorbance at
570 nM. Absorbance in each well was normalized with those treated with vehicle.
For FACS analyses, cells were harvested from the wells with the help of accutase,
pelleted, and stained with Annexin-V-APC (0.1 μg mL−1) and propidium iodide
(0.5 µg mL−1) in annexin binding buffer (10 mM Hepes pH 7.4, 140 mM NaCl,
and 2.5 mM CaCl2). Cells were sorted in a FACScalibur flow cytometer and
data was analyzed using FlowJo 10.0 software, considering cell death as the sum
of Ann-V+/PI− and Ann-V+/PI+ events.
Biolayer Interferometry experiments. Fc-tagged 2019-nCoV RBD-SD1 (Sanyou
Biopharmaceuticals Co. Ltd) was immobilized to an anti-human capture sensortip
(ForteB́io) using an Octet RED96e (ForteB́io). The sensortip was then dipped into
100 nM hACE2 (Sanyou Biopharmaceuticals Co. Ltd, His Tag) or 1 µM of any
tested peptide to measure association before being dipped into a well containing
only running buffer composed of DPBS (Potassium Chloride 2.6 mM, Potassium
Phosphate monobasic 1.5 mM, Sodium Chloride 138 mM, Sodium Phosphate
dibasic 8 mM), 0.05% Tween 20 and 0.5% bovine serum albumin to measure
dissociation. (Extended conditions, and suppliers in Supplementary Note 1).
Statistics and reproducibility. All conditions in the viral neutralization and cell
cytotoxicity experiments were tested in triplicate. Data from viral neutralization
assays was analyzed using nonlinear regression, fitting sigmoidal curves used
to calculate the IC50 values with Graphpad Prism 8.0.1. For BLI experiments,
data were reference subtracted and fit to a 1:1 binding model using Octet Data
Analysis Software v10.0 (ForteB́io). KD values were extracted from 3 independent
determinations (P9 and P10) validated by a statistical coefficient determination
(R2) > 0.95.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The complex between hACE2 and the surface spike protein of SARS-CoV-2 data used for
peptide design is available in RCSB PDB with the identifier doi: 10.2210/pdb6M0J/pdb14.
The randomly selected RBD amino-acid sequences from China (QOH25833, QIG55857,
QHR63290, QHR63250, QJG65957, QJG65956, and QJG65951), USA (QIV65044,
QJD23847, QJU11481, QJD24531, QJD25193, QJD25529, and QJA17180), and France
(QJT73034, QJT73010, QJT72902, QJT72806, QJT72794, QJT72722, QJT72710,
QJT72626, QJT72614, and QJT72554), used for sequence alignment are available in the
Genebank database at ncbi.nlm.nih.gov. The amino acid sequence of the Fc-tagged 2019-
nCoV RBD-SD1 was provided by Sanyou bio with purchase (sanyoubio.com/EN/2019-
nCoV.php) and is depicted in Supplementary Fig. 1a. The datasets generated and/or
analyzed during the current study are in the manuscript and the raw data are available
from the corresponding author on reasonable and justified request.
Code availability
The predictive data supporting our work was generated using publicly available software.
For sequence alignment, the Weblogo software (available at https://weblogo.berkeley.
edu) and Clustal Omega (available at https://ebi.ac.uk/Tools/msa/clustalo/) were used.
The Agadir helical content predictor is available at https://agadir.crg.es. Peptide
antigenicity can be determined at https://imed.med.ucm.es/Tools/antigenic.pl. Online
analysis for peptide CD spectra and using DichroWeb server and the CDSSTR algorithm
is available at https://dichroweb.cryst.bbk.ac.uk. The HELIQUEST web server used to
calculate peptide hydrophobicity and hydrophobic moment is available at https://
heliquest.ipmc.cnrs.fr.
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